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G E N E R A L  I N  T R O D U C T I O N
1
Adenoviruses (AdV) were first isolated in 1953 by Rowe et 
al from the adenoids of children. The group name 
Adenoviruses, indicating the occurrence in adenoid tissue, 
was created in 1956 and the group was given a family 
status Adenoviridae in 1976 with two genera Mastadenovirus 
and Aviadenovirus. They encompass AdV occurring in 
mammals and birds respectively (Doerfler, 1986 and
references therein). The viruses are widely distributed 
in nature in many mammalian and avian species.
AdV are non-enveloped particles, that replicate and
assemble their virions in the nucleus of infected cells, 
with a linear double-stranded DNA, molecular weight (m.w.) 
20-30 Megadaltons (MegaD) corresponding to 30-45.5 
kilobase pairs (kb) and with at least 10 structural 
polypeptides ranging from 5-120 kilodaltons (kD). The
isometric particles, 70-90 nanometres (nm) in diameter, 
have an icosahedral symmetry with 252 capsomers. The 12 
penton bases (vertex capsomeres) carry one or two
filamentous projections (fibres) for the genus 
mastadenovirus or aviadenovirus respectively (figure 1).
The Canine Adenoviruses
Two distinct but related adenoviruses, canine adenovirus 
type 1 (CAV-1) and canine adenovirus type 2 (CAV-2) , have 
been isolated from the dog. They differ in structure, 
pathogenicity and antigenicity. CAV-1, formerly known as 
infectious canine hepatitis virus (ICHV), was first
2
F I G U R E  1 
Structure of the Adenovirus Virion
Polypeptide SOS-gel Structural Unit
n —
in —
nr a
—  Hexon
—  Pentonbase
  Penton associated protein
Fiber
  —  Core protein
Hexon associated protein 
Core protein
Hexon associated protein 
Protein specific for 
groups of nine hexons
Schematic representation of an adenovirus. The mobilities 
and relative amounts of each protein after electrophoresis 
of the dissociated virus on a sodium dodecyl sulphate- 
containing polyacrylamide gel are shown on the right. The 
position of each polypeptide in the virion is designated; 
however, the configuration of the DNA does not imply the 
actual structure within the core. The roman numerals 
refer to a polypeptide designation described by Maizel et 
al (1968). The hexon (II), penton base (III), fibre (IV) 
and hexon-associated proteins (Ilia, VI, VIII and IX) are 
subunits of the capsid. The core contains proteins V, VII 
and the 55kD terminal protein (TP) covalently linked at 
each of the 5'ends of the DNA. The two molecules of TP 
per virion are too few to be demonstrated by the coomassie 
stain of the viral polypeptides. Adapted from Persson and 
Philipson (1982).
isolated by Cabasso et al (1954) from a dog with hepatitis 
and has since been associated with a range of clinical 
syndromes, the best known being a systemic disease with 
hepatitis (Rubarth's disease), reviewed by Koptopoulos and 
Cornwell (1981).
CAV-1 infection is known to be widespread in the canine 
population and most infections are probably subclinical 
(Ablet and Baker, 1960). The virus replicates in vascular 
endothelial tissue and can affect many organs (Appel et 
al, 1973). As well as the classical hepatitis described by 
Rubarth (1947), CAV-1 is also associated with focal 
intestinal nephritis (Wright, 1976), glomerulonephritis 
(Wright et al, 1974), chronic hepatitis (Gocke et al, 
1970) and respiratory tract infections.
The route of infection plays a significant role in the 
type of disease produced by the virus. Intravenous or 
intraperitoneal inoculation leads to hepatitis with focal 
nephritis and anterior uveitis (the blue eye syndrome) in 
recovering animals. Aerosol infection however causes 
severe pneumonia but hepatitis is rarely seen (Koptopoulos 
and Cornwell, 1981). ■
CAV-2 (formerly called canine laryngotracheitis virus) was 
first isolated by Ditchfield and co-workers (1962) from 
kennelled dogs during an outbreak of respiratory tract 
disease. This virus was designated Toronto A26/61 and is 
one of the prototypic isolates of CAV-2. CAV-2 has been
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isolated from throat swabs or from the lungs of dogs with 
pneumonia, bronchitis, tonsillitis and pharyngitis in 
North America where it is recognised as one of the 
aetiological agents of "kennel cough". Unlike CAV-1, when 
CAV-2 is inoculated by the IM, SC or IV routes, clinical 
signs are rarely seen except for the occasional mild fever 
and nasal discharge. Inoculation by the oro-respiratory 
route results in a mild fever with discharge in the 
majority of cases. By contrast, aerosol infection of dogs 
with CAV-2 leads to severe respiratory disease. Hepatitis 
has not been associated with CAV-2.
There are only two reports of the isolation of CAV-2 from 
dogs in Britain (Danskin, 1973; Macartney et al, 1988).
Danskin (1973) isolated both CAV-1 and CAV-2 from dogs 
with respiratory disease although no dogs were found to be 
co-infected with both viruses. Hamelin et al (1986) 
recently isolated CAV-2 from the faeces of dogs suffering 
from haemorrhagic diarrhoea and it may therefore be 
implicated as an enteric as well as a respiratory 
pathogen. The molecular basis of the pathogenicity of 
the canine adenoviruses has not yet been established.
Cornwell et al (1970) were the first to propagate CAVs in 
the Madin and Darby canine kidney (MDCK) continuous cell 
line. The sensitivity of these cells was comparable to 
that of secondary dog kidney cultures but the yields of 
virus obtainable from them were greater by 0.5 to 0.8
4
log TCID /ml. The cytopathic effect (CPE) is
10 50
essentially the same in all types of susceptible cells, 
with infected cells rounding up, becoming refractile and 
clumping together to form characteristic "bunches of 
grapes" before detaching from the glass (Cabasso et al, 
1954).
Moulton and Frazier (1965) reported that viral DNA 
synthesis occurred 8-10 hours post infection (pi) and 
preceded the production of protein by approximately two 
hours. CAV-1 release occurs by degeneration of the 
nuclear membrane whereas release of CAV-2 into the 
cytoplasm occurs by the formation of protrusions of the 
nuclear membrane which, when pinched off, release a 
membrane-bound aggregate of virions. Although the 
formation of intracellular spheres has been described for 
CAV-1 infection, the production of crystalline aggregates 
and their release by protrusion of the nuclear membrane 
seems to be peculiar to CAV-2 infection (Koptopolous and 
Cornwell, 1981). The relevance of this difference in the 
"release" mechanism of the two strains is not yet apparent 
nor is its role, if any, in the pathogenicity of the 
viruses.
Electron microscopy has shown that the virions of both 
CAVs are characteristic of the adenoviridae, i.e. are 
icosahedral structures made up of 252 capsomeres (Yamamoto 
and Marusyk, 1968). However, the fibres of CAV-2 (35- 
37nm long) are approximately lOnm longer than those of
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CAV-1. This difference in fibres may account for the fact 
that, although both viruses agglutinate human and rat 
erythrocytes (RBC), they use different receptors on the 
RBC surface. The CAV-2 receptor complex is sensitive to 
trypsinisation whereas that of CAV-1 is not (Marusyk and 
Yamamoto, 1971). Ditchfield et al (1962) showed that
antisera to CAV-1 and CAV-2 prevented haemagglutination 
with the homologous viruses but completely failed to
inhibit the heterologous viruses whereas levels of 
neutralising and complement fixing antibodies (Ab) to the 
heterologous viruses were found in both types of 
antiserum. Using the haemagglutination-inhibition (HI) 
test, Swango et al (1969) compared seven CAV isolates and 
confirmed that they formed two distinct but related
serological groups. In 1970, Marusyk et al reported that 
the hexons carried a common.group specific, complement- 
fixing antigen (Ag); the penton oligomers acted as a 
complete soluble haemagglutinin while the penton and fibre 
monomers were able to haemagglutinate only when bound by 
selected antisera against human AdV soluble Ags
(haemagglutination enhancement). CAV-1 and CAV-2 were 
also found to have a distinct polypeptide pattern when 
compared to human, simian and equine AdV (Marusyk and 
Cummings, 1978).
The first modified live CAV vaccine was described by 
Fieldsteel and Emery (1954) and consisted of the 51t 
serial passage of CAV-1 in dog kidney tissue cultures.
Although this proved safe for the inoculated animals, it 
was later shown to be excreted in the urine and, after 
four serial passages in dogs, could revert to virulence 
(Cabasso et al, 1958). Fortunately it was found that this 
problem could be overcome by growing the virus in pig 
kidney cells (PKC) and these are now used to produce the 
CAV-1 vaccines.
Provided that maternal Ab is absent, a single dose of the 
live vaccine produces good immunity in dogs of any age 
(Cabasso, 1962). However, several side-effects of CAV-1 
vaccines became apparent, notably nephritis and a 
characteristic ocular reaction consisting of corneal 
oedema and inflammation of the anterior uveal tract, often 
known as "blue eye". The isolation of CAV-2 in 1962 and 
the discovery that it does not produce an acute 
generalised disease, is not excreted in urine and does not 
produce renal and ocular lesions, led several groups to 
show that both CAVs can protect against each other through 
heterotypic Ab production (Appel et al f 1970; Wright et 
al, 1974) . Appel et al (1973) reported that dogs 
inoculated intranasally or intramuscularly with attenuated 
CAV-2 did not become ill and were completely immune to 
intravenous challenge inoculation with virulent CAV-1. 
Koptopolous (1979) compared the efficacy of two live 
attenuated vaccines, one CAV-1 and one CAV-2, in 
protecting dogs against an aerosol of virulent CAV-2. The 
CAV-2 vaccine was found to give better protection. It is 
believed that CAV-2 vaccines confer greater protection
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than CAV-1 vaccines as the CAV-1 vaccines produce systemic 
immunity only (cell and humoral mediated) whereas CAV-2 
vaccines produce both systemic and local immunity
(Koptopolous and Cornwell, 1981). Killed virus vaccines 
were found to be much less efficient than live viral 
vaccines (Cornwell et__al, 1982). No immunological
relationship to human AdVs has been detected (Willimzik et 
al, 1981).
The advent of molecular biology enabled a direct 
comparison of CAV-1 and CAV-2 genomes using restriction 
enzyme analysis. The difference between the restriction 
enzyme cleavage patterns of CAV-1 and CAV-2 confirms the 
distinctiveness of the two species (Assaf et al, 1983;
Shinagawa et alf 1983; Hamelin et alf 1984; Darai et al, 
1985; Hamelin et al, 1986; Jouvenne and Hamelin, 1986). 
All strains and isolates examined thus far appear to have 
virtually identical restriction enzyme cleavage patterns
to their respective prototypic strains; i.e. all CAV-1 
isolates appear virtually identical to the prototypic 
strain Lederle 255; all CAV-2 isolates to the prototypic 
strain Toronto A26/61. However, small variations have 
been observed. Hamelin et al (1986) reported enteric 
isolates of CAV-2 which revealed variation in the Hpall 
cleavage patterns of different isolates but all other 
restriction enzyme cleavage patterns examined appear to be 
identical to the prototypic Toronto A26/61.
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The BamHI, Clal, SacI, Sail and Smal restriction maps of 
the CAV-1 strain Behring HCC 299 have been reported (Darai 
et al, 1985) but none of CAV-2. Marusyk and Hammarskjold 
(1972) reported the CAV-1 and CAV-2 genomes to be 70% 
homologous and Hamelin et al (1986) showed that CAV DNA 
was unmethylated as defined by Hpall/MspI digestion. A 
terminal protein was found to be covalently linked to the 
5' ends of the CAV genome (Darai et alf 1985). This was 
confirmed by the use of \ 5'-exonuclease and Escherichia 
coli (E.coli) 3'-exonuclease III. The CAV DNA was 
resistant only to X 5'-exonuclease and was degraded by 
E.coli 3'-exonuclease III. Terminal proteins have been 
described for all AdVs, irrespective of species of origin, 
so far examined (Ginsberg, 1984).
Adenovirus Subclassification
The first isolation of a human AdV was reported by Rowe et 
al (1953) from cultured, uninoculated explants of human 
tonsils and adenoids. Since then over 40 distinct 
antigenic types have been found to infect humans and 
numerous other types infect a wide variety of lower animal 
species including cattle, pigs, horses, monkeys, rodents, 
fowl and, of course, dogs. An AdV has even been isolated 
from the frog (for review of AdV isolations see Doerfler, 
1986). A further group of AdV of avian origin has been 
described. Egg-drop syndrome (EDS), a disease which 
causes infected birds, mainly ducks, to produce fewer 
eggs and eggs with defective shells has been isolated 
which has been found to be immunologically distinct from
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other avian AdV. Analysis to date has demonstrated the 
EDS virus to be similar in structure and organisation to 
the mammalian AdV (personal communication, Dr. N. Spibey) 
and possibly represents a species of avian AdV 
phylogenically less diverged from the mammalian AdV than 
other avian AdV?
The original subclassification of the human AdVs was based 
on the haemagglutination patterns of rat and rhesus monkey 
RBC. A different type of subclassification is based on 
the oncogenicity of the human AdV. The different 
serotypes have been subdivided into a highly oncogenic 
subgroup A (e.g. Adl2, Adl8, Ad31), a weakly oncogenic 
subgroup B (e.g. Ad3, Ad7) and a non-oncogenic subgroup C 
(e.g. Ad2, Ad5). It is interesting to note that there is 
a correlation between the guanine-cytosine (GC) content of 
the human AdVs and their oncogenicity. The GC content of 
the DNAs decreases with increasing oncogenicity (Doerfler, 
1986).
Subsequent grouping on the basis of DNA homology has 
agreed with the original classifications very well. 
Different human AdV serotypes were divided into six 
different subgroups, A-F (Green et al, 1979). In general, 
members of the same subgroup have genomes that are 
homologous for more than 90%. However, members of highly 
oncogenic subgroup A share only 50-70% of their DNA 
sequences. The homology between members of different
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subgroups is less than 20%. The poor homology between 
subgroups demonstrates that the DNA sequences of different 
serotypes have significantly diverged in the course of 
viral evolution but the complex organisation of the AdV 
genome has been rigidly conserved (Tibbets, 1977).
By analogy, the extensive homology between CAV-1 and CAV-2 
places them in the same group. In addition, the reported 
homology of 70% between CAV-1 and CAV-2 (Marusyk and 
Hammarskjold, 1972) is comparable to that displayed by 
members of the highly oncogenic (group A) human AdVs. It 
is therefore interesting that both CAV-1 and CAV-2 induce 
tumours in newborn hamsters (Sarma et_al, 1967; Dulac et 
al, 1969). Hoggan et al (1965) reported that CAV-1 and 
CAV-2 share a common T-Ag. The virus specific, non-virion 
T-Ag produced during acute infection of cell cultures with 
AdV have been shown to be essentially indistinguishable 
from tumour specific Ag in viral-induced tumours. Highly 
oncogenic AdV 12, 18 and 31 share a common T-Ag which does 
not cross-react with the common T-Ag shared by the 
moderately oncogenic Ad3, 7, 14, 16 and 21 (Heubner,
1967).
The pathogenesis and tissue tropism of each strain of 
human AdV also appears to be associated with its 
subclassification. Again the GC content appears 
significant with the highly oncogenic respiratory tract 
associated group A having a relatively low GC content, as 
previously defined by Smal digestion (CCC/GGG), with 4-5
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sites whereas the non-oncogenic enteric group F exhibits a 
high GC content with 9-11 Smal sites.
The greatest number of human AdV infections has always 
been associated with diseases of the respiratory tract 
(groups A-C) followed by those of the gastrointestinal 
tract (groups E and F) and finally as casual agents of 
opthalmic disease (group D). The pathological divisions 
between groups A-C and D are not strictly defined as 
certain members of group B have been associated with 
conjunctivitis, e.g. Ad3, although usually in conjunction 
with respiratory symptoms. In addition, members of group 
B have also been associated with urogenital infections, 
mainly haemorrhagic cystitis. The number of all 
respiratory infections associated with the human AdV is 
lower than that caused by the influenza and rhinoviruses 
but higher than all other respiratory viruses. Most 
severely infected are the young and immunologically 
compromised hosts and, although most infections are upper 
respiratory, lower respiratory tract infections can lead 
to severe, occasionally fatal, pneumonia. Of the diseases 
of the gastrointestinal tract, infantile gastroenteritis 
is the most common. Opthalmic infection most commonly 
takes the form of keratoconjunctivitis and is widespread 
in eye clinics, usually due to transmission from patient 
to patient by clinic staff. This tissue tropism is not 
well understood at the present time but is known to be 
associated with more than the ability of each strain to
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gain access to the relevant cell type.
Studies in animal models (e.g. cotton rats) show that type 
C AdV demonstrate a limited ability to replicate in rodent 
cells, a capacity not found in other subgroups.Conversely, 
subgroup F viruses, the causative agents of infantile 
gastroenteritis, are extremely difficult to grow in vitro 
although they are capable of entry into the majority of 
cell types commonly used for AdV replication, namely HeLa, 
KB and HEK cells. They appear to be blocked at an early 
step in the growth cycle when introduced into these cells 
(Ishino et alf 1988). A recent isolate of a group D AdV 
has been found to be capable of causing gastroenteritis. 
Its restriction enzyme pattern is unique compared to all 
other AdV but it is immunologically a member of group D. 
All variation within the genome of this new strain 
appears to be restricted to the right-hand 25% of the
genome (Gomes and Neil, 1987). Thus attachment and entry 
of the virus into various cell types is not the only
limiting factor in "tissue tropism", a fact which may have
direct significance on the isolation of a canine
adenovirus from the gastrointestinal tract when its genome 
is compared to the wild-type respiratory virus.
This tropism is found in other non-human AdV for example 
within the Bovine AdV (BAdV). The 10 serotypes of BAdV 
are subdivided into two groups, I and II, as determined by 
immunological tests and their tissue tropism. Both groups 
grow well in bovine testicle cells but only subgroup I can
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replicate in bovine kidney cells. Subgroup I appears to be 
a bovine specific respiratory disease whereas subgroup II, 
the causative agent of pneumoenteritis, has been routinely 
isolated from sheep as well as cattle but remains 
immunologically distinct from all ovine AdV species (Belak 
et al, 1986).
The relationship of the various areas of the AdV genome 
will be discussed with relevance to their effect on 
pathogenicity as each gene is described in the following 
pages.
Structure of the Adenovirus Genome
The genomes of the AdVs are linear, double-stranded 
molecules. Both ends of the viral genome function as 
origins for DNA replication and contain a terminal protein 
(TP) which is covalently linked to the 5'-end of each DNA 
strand via a serine residue (Ginsberg, 1984). The ends of 
the viral DNA contain an inverted terminal repetition 
(ITR). AdV gene expression is strictly regulated at 
multiple levels during a productive infection. The lytic 
cycle is traditionally divided into two distinct phases; 
an early phase precedes viral DNA replication and is 
triggered by gene products from early region Ela and a 
late phase which follows DNA replication and is 
characterised by the expression of structural proteins. A 
schematic diagram of the AdV genome is shown in fig. 2. 
It should be noted that the descriptions of the various
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components of the AdV genome are based on the extensive 
studies carried out on the human AdV type 2 unless 
otherwise stated.
Inverted Terminal Repetition
The existence of an ITR in AdV DNA was discovered when 
denatured DNA was reannealed at low concentrations and 
examined by EM. A high percentage of the single strands 
were present in a circular form indicating the presence of 
an ITR (Garon et al, 1975). ITRs have been detected in 
every serotype so far examined. The length of the ITR is 
very variable, ranging in size from 52bp in the avian AdV 
EDS-76, the smallest found so far, to 196bp in CAV-2. All 
other AdV ITRs range in size between these two.The ITR DNA 
sequences of CAV-1 (strain CC1-64) and CAV-2 (strain 
Toronto A26/61) were reported by Sira et al (1987) and 
Shinagawa et al (1987) respectively, the length of the 
CAV-1 ITR reported as being 160bp. The first nucleotide 
of the 5'-end of the ITR is always dC (deoxycytosine) with 
the exception of chick embryo lethal orphan AdV (CELO) 
which has a terminal dG (deoxyguanosine).
A striking property of the ITRs is the asymmetrical 
distribution of GC and AT (adenosine/thymidine) base 
pairs; a terminal AT rich region an internal GC rich 
region. DNA sequences within the AT rich region are 
highly conserved among all human AdV and partially 
conserved in the simian, murine, canine, equine and avian 
AdVs. Particularly notable are the 7bp sequence ATAATAT
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located from nucleotides 9-15, thought to be involved in 
the initiation of DNA replication, and the 8bp sequence 
AATTTGGG, thought to be essential for encapsidation. The 
GC rich region is not highly conserved although some short 
blocks of conserved sequences can be found. One such 
sequence, GGGCGG, appears in multiple copies in the GC 
rich region of all human AdVs. Interestingly, this 
sequence is similar to the sequence GGGXGGAG which is 
present in multiple copies at the origin of the BK, SV40 
and polyoma viruses (Ginsberg, 1984) The second sequence 
is TGACGT and this 6bp block is always present at or near 
the end of the ITR of human AdVs and the 5bp block TGACG 
in all other AdV ITRs. The function of the TGACG(T) block 
is at present unknown.
The phylogenetic relationships between AdVs as inferred 
from the nucleotide sequences of the ITRs, from a wide 
range of AdVs, has recently been examined by Shinagawa et 
al (1987). It was found that members belonging to the 
same AdV subgenus are closely related to each other 
whereas representatives of different human subgenera are 
distributed rather divergently among animal AdV. Thus the 
conclusion was that human AdV have not necessarily evolved 
from a common human AdV ancestor although it is almost 
certain that the two CAVs, CAV-1 and CAV-2, have arisen 
from a common CAV ancestor.
Terminal Protein
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Fig. 2 Organisation of the Ad2 genome. Arrows show the 
location of the major RNA species. Thick lines illustrate 
the mRNAs expressed early after infection and thin lines 
mRNAs expressed at intermediate times after infection. 
Open arrows show sequences present in late mRNA. 
Polypeptides that have been assigned to the different 
regions are indicated. Adapted from 'The Adenoviruses', 
Doerfler (ed.), 1984.
The terminal protein (TP) is a highly conserved, 
approximately 55kD, virus-coded protein which is 
synthesised as an 80kD precursor (pTP). The pTP is the 
active form of the TP in AdV DNA replication. Stillman et 
al (1981) showed that cell free translation of mRNA 
selected from a region between co-ordinates 11 and 31.5 on 
the Ad2 genome 1-strand (see fig.2) leads to synthesis of 
the three proteins, one of which is the 80kD pTP.
The TP is believed to play an essential role in the 
initiation of DNA replication. The protein is thought to 
recognise a specific sequence within the ITR, probably the 
conserved sequence ATAATAT (bp9-15), which might be 
involved in binding the pTP to the DNA, the first step in 
the replication of the AdV DNA. It has also been proposed 
that the TP protects the viral DNA against nucleolytic 
degradation. This function would explain the high 
infectivity of DNA-protein complexes. Deproteinised DNA 
is infectious when assayed by transfection into 
permissive cell lines but the infectivity of the DNA-TP 
complexes is 50-100 times higher (Sharp et al, 1976).
Thus perhaps the two functions, aid to replication and DNA 
protection, are inextricably linked.
Early Region 1 (El)
El is transcribed from the left-hand end of the viral r- 
strand (see fig.2) and contains the genes which are 
involved in the regulation of transcription and are 
responsible for cell transformation (Graham et al, 1974;
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Berk and Sharp, 1977). The overall organisation of this 
region appears to be very similar for all the different 
serotypes of AdV. The region, map units (m.u.) 1.3-11.2,
can be subdivided into three transcription units 
designated Ela (m.u. 1.4-4.5), Elb (m.u. 4.7-11.3) and
region pIX (m.u. 9.9-11.3). The pIX transcription unit 
overlaps completely with Elb, encodes the structural 
virion polypeptide IX and has the only AdV mRNA which does 
not have a spliced structure. pIX is a minor structural 
component of the virion located between the hexons in the 
AdV icosahedron. Mutants lacking this gene are viable 
although less heat stable than wild-type virions, 
suggesting that the protein plays a role in stabilising 
the capsid structure. The gene is translated throughout 
both early and late phases of replication, although with 
the highest efficiency at late times, and is often 
referred to as an "intermediate" gene (Doerfler, 1986). 
In addition, a number of unidentified reading frames (URF) 
have been detected; in particular, a 22S mRNA which spans 
the border between Ela and Elb and encodes an llkD 
polypeptide. However, the exact function of this 
transcription unit remains to be established.
E1A
The three mRNAs produced in region Ela: 13S, 12S and 9S: 
generated by differential splicing of a common nuclear 
precursor RNA, have common 5' and 3'-ends but differ from 
each other by the size of the intron which is removed
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during mRNA maturation. Analysis of the sequence of the 
Ela region, of all AdV serotypes so far examined, reveals 
the presence of a TATA box, e.g. TATTTATA in Ad2, and a 
polyadenylation site for all Ela mRNAs. The
polyadenylation site is always preceded by the 
polyadenylation signal, AATAAA, which is specifically 
required for the cleavage of the precursor RNA prior to 
its polyadenylation (Doerfler, 1986). The Ela mRNAs 
accumulate with different kinetics during the infectious 
cycle. The 12S and 13S being the most abundant species 
early after infection, the 9S becoming the most abundant 
at late times. The polypeptides encoded by the 13S, 12S
and 9S mRNAs are 289, 243 and 55 amino acid residues 
(a.a.) long with molecular weights of 31.9kD, 26.5kD and 
6.1kD respectively.
Region Ela is the first to be expressed during the 
infectious cycle, transcripts can be detected 45 minutes 
after infection, and the 289a.a. protein encoded by the 
13S mRNA is responsible for the stimulation of early viral 
transcription. This 289a.a. protein has been shown to be 
a nuclear antigen and stimulates transcription by RNA 
polymerases II and III from many promoters. The detailed 
mechanism of transcriptional activation (transactivation) 
by the Ela protein remains unclear but preliminary results 
suggest that the Ela product might act to stimulate the 
activity of cellular transcription factors (Kovesdi et al, 
1986; Wu et al,1987). This process of transactivation by 
Ela may, in part, contribute to oncogenesis and
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immortalisation which will be discussed later.
Studies in an animal model (cotton rats) revealed that a 
functional Ela was required for the onset of viral 
pneumonia (Ginsberg et alf1987). This was evinced by the 
use of AdV mutants. Mutants defective in all late 
functions were found to produce a pneumonia as extensive 
as that induced by wild-type virus. The pneumonia 
occurred even with mutants which were temperature 
sensitive (ts) at late times. These viruses do not 
replicate in the lungs because viral DNA cannot replicate 
at lung temperature and therefore viral structural 
proteins (i.e. late gene products) are not synthesised. 
Ela deletion mutants produced no pneumonia.
Recent studies have shown (Ishino et al, 1988) that the 
enteric AdV, Ad40, codes for only two Ela products unlike 
the respiratory AdV which produce those outlined above. 
In addition, the ability of Ad40 Ela to induce 
transformation is considerably reduced when compared to 
that of Ad5 and Adl2. The transactivation capability of 
the Ela gene is also much lower than that of other 
respiratory AdV to which it was compared by CAT 
(chloramphenicol acetyltransferase) assay. This variation 
is thought to be associated with the inability to 
propagate the virus in the standard cell lines in which it 
is blocked at an early stage in the replicative cycle. 
The relevance of these changes to the pathogenicity of the
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virus is not discussed however but it seems likely that, 
as a fully functional Ela, as defined by the Ad2/Ad5 Ela, 
is necessary for the onset of viral pneumonia, this
alteration in the coding capacity of the Ad40 Ela will
prove significant in the pathogenesis of the virus. It 
also raises the question as to whether the newly isolated 
"enteric" CAVs will differ in the structure of their Ela 
regions as compared to the wild-type respiratory CAVs. 
The effect of Ela on pathogenesis other than respiratory 
infections is not clear. A new strain of the group D 
viruses, previously associated with conjunctivitis, has 
been found to cause gastroenteritis but the Ela region, on 
preliminary examination, appears identical to other 
"normal" group D viruses and the only alteration appears 
to be in the right-hand 25% of the genome (Gomes and Neil, 
1987). This would indicate that other parts of the genome 
are responsible for/involved in gastrointestinal 
infections.
E1B
Region Elb is located immediately adjacent to region Ela, 
is also transcribed in a rightward direction and is 
stimulated by the Ela 289a.a. (fig.2). Ela is believed to 
mediate its effect on the Elb promoter through the TATA 
box transcription factor (Wu et al, 1987). Two major
mRNAs (22S and 13S) and two minor mRNAs (14.5S and 14S)
are generated by the splicing of a common precursor RNA.
The accumulation of the Elb mRNAs is subjected to post- 
transcriptional regulation. The stability of the Elb
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mRNAs is influenced by the E2A-72kD DNA binding protein 
(DBP) and at late times by a change in the specificity of 
the RNA splicing machinery (reviewed in Doerfler, 1986).
Region Elb contains three long open reading frames (ORF) 
which encode polypeptides with m.w. of 14.3kD, 21kD and 
55kD. The 14.3kD polypeptide corresponds to the virion 
polypeptide IX. Gosh-Choudhury et al (1987) revealed that 
protein IX is essential for the packaging of full length 
genomes and is dispensable only for virions containing DNA 
of less than genomic size. Edbauer et al (1987) revealed 
that, in Adl2 at least, this protein is not required for 
oncogenic transformation. The 21kD polypeptide is 
associated with both the nuclear and the plasma membrane 
fractions of both infected and transformed cells and its 
localisation on the cell surface makes it a likely 
candidate for the tumour specific transplantation antigen 
(TSTA) expressed by AdV-transformed cells (Rowe et al,
1983) . The 21kD polypeptide is also believed to function 
as a nuclease inhibitor as, in mutants defective for the 
21kD protein, its absence results in the degradation of 
both viral and cellular DNA during infection (Pilder et 
al, 1984).
The 55kD protein is reported to be essential for efficient 
shut-off of host protein synthesis, demonstrated by the 
use of engineered mutants (Babiss and Ginsberg, 1984) . The 
translation of late proteins and the synthesis of late
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cytoplasmic mRNAs are drastically reduced if an intact Elb 
region is not present. It therefore appears that the 55kD 
protein is required for the transition from the early to 
the late mode of gene expression. The 55kD protein also 
appears to be one of the products responsible for the 
production of AdV pneumonia (Ginsberg et alf 1987) which 
could be related, either directly or indirectly, to its 
association with the shut-off of host cell protein 
synthesis.
The role of Elb has also been investigated by Mautner and 
Mackay (1987) who demonstrated the effectiveness of Ad40, 
an enteric AdV, as compared to Ad2 and Ad5. Studies in a 
range of host cells and using complementation with Ad2 and 
Ad5 mutants showed that Ad40 had a functional Ela as 
defined by its ability to complement Ela defective Ad2 and 
Ad5. However the Ad40 Elb could not complement Elb 
defective Ad2 or Ad5. Ad40 growth in normal non- 
permissive cell lines, e.g. HeLa cells, was made possible 
in the presence of a functional El region from Ad2 or Ad5 
but not in the presence of Ela alone. It was suggested 
that this "dysfunction" of Ad40 Elb plays a role in the 
host range of the virus.
Early Region 2 (E2)
Region E2, which is transcribed from the viral 1-strand 
(fig.2), differs from other AdV transcription units by 
using alternative promoter sites for the initiation of 
transcription (Chow et al, 1979). An early promoter (E2-
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E) is activated at early times after infection, m.u. 75.4 
in Ad2, following which a promoter shift occurs at late 
times during infection to the E2 late promoter (E2-L), 
located at m.u. 72.2 in Ad2. The two E2 promoters are 
regulated differently; the E2-E promoter is Ela inducible 
whereas the E2-L promoter appears to be inhibited by Ela. 
The transactivation of E2-E by Ela appears to involve a 
cellular transcription factor, the concentration or 
binding activity of which increases as a result of the 
action of the Ela gene product (Kovesdi et al, 1986).
This regulation can occur even when the E2 promoter region 
is stably integrated into the cellular genome (Kingston 
et al, 1984).
Two major classes of transcripts are generated from E2. 
The first mRNA class, designated E2A, extends from the 
transcription initiation site to a polyadenylation site, 
at m.u. 62.4 in Ad2, and codes for the single-strand- 
specific DNA-binding protein (DBP). The DBP is a 
multifunctional protein, is phosphorylated and has an 
apparent m.w. of 72kD. It is involved in DNA replication, 
in regulation of early and late gene expression and in 
cell transformation. In the absence of a functional DBP 
the normal turn off of early mRNA expression does not 
occur (Carter and Blanton, 1978). The DBP also influences 
the host range of the virus; Brough et al (1985) reported 
that a very limited number of changes in the 5' portion of 
the DBP gene gives rise to Ad2 mutants which can replicate
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efficiently in monkey cells. Wild-type Ad2 fails to 
multiply in the same monkey cells due to a block to late 
viral gene expression. Additionally, they found that 
minor mutations in the 3' portion of the DBP gene gave 
rise to ts phenotypes. Conversely, mutations in the DBP 
appear to have no effect upon the pathogenicity of the 
virus in that DBP mutants produce viral pneumonia to the 
same extent as wild-type virus although the mutants are ts 
and could not replicate at lung temperature (Ginsberg et 
al, 1987) . A comparison of the DBP of animal AdVs 
demonstrated to replicate (altered host range) and cause 
disease (retained pathogenicity) in animals other than the 
host of origin, e.g. enteritis in sheep due to bovine AdV 
and Rubarth's disease due to CAV-1 in bears (Koptopolous 
and Cornwell, 1981: Kapp and Lehoczki, 1966), may
therefore prove valuable in the understanding of AdV 
pathogenicity and determination of host range.
The second major class of transcripts, designated E2B, by­
pass the polyadenylation signal used by the E2A mRNAs and 
extend to a second polyadenylation site, at m.u. 11.3 in 
Ad2. Three differentially spliced mRNAs have been 
identified from region E2B (Ginsberg, 1984) . The longest 
of the E2B mRNAs encodes the pTP which serves as a primer 
for DNA replication and which is later cleaved to its 
mature 55kD form by a viral encoded protease. The shortest 
of the E2B mRNAs encodes a 14 0kD polypeptide which is the 
DNA polymerase required to replicate the DNA. Mutations 
in the DNA polymerase gene had no effect upon the
pathogenicity of the virus as viruses defective in the 
production of the viral polymerase were capable of 
producing a wild-type pneumonia in infected animals 
(Ginsberg et al, 1987). The function of the intermediate­
sized E2B mRNA is at present unknown.
Early Region 3 (E3)
Region E3 is transcribed from the viral r-strand and is 
located completely within the major late transcription 
unit (fig.2). The E3 mRNAs are generated by differential 
processing of two major RNA precursors which have a common 
cap site but different 3'-termini. In Ad2 the major 
polyadenylation site is located at m.u. 85.9, and is 
preceded by the hexanucleotide sequence AAUAAA. A second 
polyadenylation site, at m.u. 82.9, is less frequently 
used.
At least nine E3 mRNAs are generated by differential 
splicing and most of the splice junctions have been 
characterised by sequence analysis of several human AdVs. 
Based on the DNA sequence, seven of the proteins encoded 
by this region are believed to be membrane proteins 
(Cladaras and Wold, 1985). Functional studies on proteins 
derived from E3 have been limited mainly because E3 can be 
deleted without apparent effect on virus growth in 
cultured cells (Kelly and Lewis, 1973). E3 is not 
required for replication of Ad5 in the lungs of acutely 
infected hamsters. However, the overall organisation of E3
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is highly conserved between even distantly related 
serotypes implying that E3 serves an important function 
when the virus infects its natural host.
Support for this theory is provided by Belak et al (1986) 
who compared the genomes of two bovine AdV, one bovine 
specific and one capable of producing, and routinely 
isolated from, enteritis in sheep as well as cattle. 
Ninety-five precent of the two genomes proved highly 
homologous but major differences occurred between their E3 
regions. It is also feasible that the human group D AdV 
(normally associated with ocular infections) isolate 
described by Gomes and Neil (1987) which was found to be 
the causative agent of an outbreak of gastroenteritis also 
contains variation within E3. All variation noted, by 
restriction enzyme analysis, between the enteric group D 
virus and other group D viruses was confined to the right- 
hand 25% of the genome which includes the E3 region. It 
seems apparent therefore that E3 must serve an important 
biological function.
Only three proteins have thus far been purified and mapped 
to E3; a 19kD glycoprotein, an 11.6kD polypeptide and a 
14.7kD polypeptide (Tollefson and Wold, 1988). The 
E3/19kD has been demonstrated to bind to human 
histocompatability class I antigens (HLA). The formation 
of an HLA-E3/19kD complex prevents the HLA antigens from 
being correctly processed by inhibiting their terminal 
glycosylation. This effect is specific for HLA antigens
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and does not generally involve the glycosyltransferases. 
In addition, the HLA-E3/19kD association dramatically
reduces the cell surface expression of the HLA antigens. 
This reduced level of antigens may influence the cytotoxic 
T-cell response and might show a possible molecular 
mechanism whereby AdV escape the cellular immune system of 
the host (Burgert and Kvist, 1985; Paabo et al, 1986). 
All serotypes so far examined have demonstrated this
capability. No functions have been ascribed to any other 
E3 products as yet although it has been proposed that 
several of them may be cell membrane proteins.
The findings of Belak et al (1986) support this
hypothesis. They observed differences between the E3 
regions of two bovine AdV, one of which was capable of 
replicating and causing disease in two distinct animal 
species (bovine and ovine). They propose that the virus 
in this specific case has been "placed under pressure to 
alter the genes that influence the interaction between the 
virus and its host, rather than the genes which determine 
the structure of epitopes that are exposed on the surface 
of the viral capsid (hexon and fibre)11. Other reports of 
natural transmission of AdV to an animal species different 
from the host of origin are rare and have not, as yet, 
been clearly associated with a specific area of the 
genome. It is interesting to note however that one such 
occurrence includes the transmission of CAV-1 which 
resulted in an outbreak of Rubarth's disease (canine
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hepatitis) in bears (Kapp and Lehoczki, 1966).
Deletions and/or mutations in the E3 region led to 
latency of the virus in lymphocytes when Ad5 mutants were 
inoculated into cotton rats. Latent infection was 
maintained indefinitely in vitro when excess neutralising 
antibodies were added to the culture. Virus became 
detectable and the amount of infectious virus rapidly 
increased after the antibodies were removed (Ginsberg et 
al, 1987). The cause and effect of these results are not 
clear at present.
Early Region 4 (E4)
Region E4 is transcribed from the 1-strand and is located 
at the extreme right end of the genome (Fig. 2). The Ela 
289 a. a. protein induces E4 transcription early after 
infection whereas the E2A 72kD-BP has been shown to down 
regulate E4 transcription at intermediate to late times ( 
Raychaudhuri et al. 1987a,b: Handa et al. 1983) . The
Ela-mediated induction of E4 , as with E2 transcription, 
involves the post-translational activation of previously 
limiting cellular factors. Two binding sites for the Ela 
induced cellular factors have been demonstrated upstream 
of the E4 TATA box both comprising multiple copies of 
hepatanucleotide sequences (Cortez et al. 1987; Leza and
Hearing, 1987). These cellular factors are independent of 
the cellular factors involved in Ela transactivation of 
other AdV promoters thereby confirming that Ela control 
involves an activation of multiple promoter specific
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binding proteins.
The primary transcript from E4 is spliced into a 
complicated set of cytoplasmic mRNAs (Tigges and Raskas, 
1984)? alternate splicing of the precursor RNA can 
generate as many as 25 mRNAs that encode at least 16 
polypeptides. Of particular interest among the E4 mRNAs is 
an extensively spliced class which includes multiple 
species with sizes ranging from 1.1 to 0.75kb which were 
found to specify at least 10 polypeptides in vitro.
Identification of E4 proteins produced in vivo has been 
difficult because E4 is not expressed at high levels 
during productive infections. The only viral protein 
conclusively identified as an in vivo product of E4, an 
llkD polypeptide, has been found to be tightly bound to 
the nuclear matrix. This protein is highly conserved in 
different AdV serotypes (Sarnow, et alf 1982). Expression 
of this product is not essential for virus yield in 
cultured cells.
In the absence of E4 AdV are defective in the synthesis of 
late mRNAs and proteins. Viral DNA replication appears 
normal but the shut off of host cell macromolecule 
synthesis seems to be incomplete. Since mutants in the 
Elb-55kD polypeptide are also defective in late mRNA 
synthesis and in the control of cellular gene expression 
it seems likely that the physical complex formed between
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the Elb-55kD and the E4 product ( possibly a 34kD 
polypeptide ) is of major significance for the switch from 
early to late AdV gene expression. The E4 region has been 
demonstrated to be capable of increasing the cytoplasmic 
level of mRNAs from the major late promoter transcription 
unit up to 10-fold (Nordivist et al, 1987). This function 
appears to be associated with the left-hand end of the E4 
transcription unit (Sandler and Ketner, 1989) . An unknown 
product from region E4 is also required for adeno- 
associated virus (AAV) to replicate in human cells 
(Doerfler, 1986).
An unidentified diffusible E4 product has been 
demonstrated to be essential for efficient virus particle 
assembly (Falgout and Ketner, 1987). Nothing is known 
about the functions of other E4 proteins.
VA RNA and Late mRNA Translation
At late times after AdV infection, the majority of viral 
mRNAs are transcribed from the major late promoter (MLP) . 
Five families of 3' coterminal mRNAs (L1-L5) are derived 
from a primary transcript, all of which contain an 
identical 5' noncoding tripartite leader segment 2 00 
nucleotides in length, joined to the various coding 
regions by the splicing of three small exons (fig.3). 
Transcription from the MLP accounts for nearly 3 0% of the 
total RNA polymerase II activity at late times (Ginsberg,
1984) . The MLP of AdV has been intensively studied as it 
is reported to be the strongest promoter in most in vivo
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transcription systems (Ginsberg, 1984).
The AdV genome encodes two low m.w. RNAs designated virus 
associated RNA (VA RNA) I and II which are produced in 
large amounts late during infection. Neither VA RNAI or 
VA RNAII is post-transcriptionally processed. Both RNAs 
are approximately 160 nucleotides long and are transcribed 
from two closely spaced transcription units located within 
the LI cotermination family. Studies of viral mutants 
have shown the VA RNAI is required for efficient 
translation of viral mRNAs at late times. Svensson and 
Akusjarvi (1986 and 1984b) reported that mutants defective 
in the production of VA RNAI have substantially reduced 
levels of L2, L3 and L5 mRNAs. Although normal levels of 
mRNA were found from LI and L4, the LI pre-mRNA was found 
to be defective in splicing all except one of its normal 
three mRNA products. A double mutant lacking both VA 
RNAs was shown to grow very poorly, producing 5- to 6- 
fold less virus compared to wild-type. Since a virus 
lacking the VA RNAII species grows like wild-type, it is 
likely that VA RNAII serves a similar function to VA RNAI. 
VA RNAII has been shown to partially substitute for 
defective VA RNAI species in lytic growth.
Virion component and abundant non-virion proteins are 
encoded by late mRNAs. Each member of a family has the 
tripartite leader spliced to the body of the mRNA (Chow et 
al, 1977) . Although the abundant form of each late mRNA
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has the standard tripartite leader, variant forms of
almost any late mRNA can be detected. These variant forms 
frequently have a fourth leader mapping at 22 m.u. , 
spliced between the second and third leader of the 
standard set (fig.3). The structure of the mRNA for fibre 
is particularly complex. Various combinations of leader 
sequences, i.e. X, Y or Z, mapping at 77, 79 and 85 m.u. 
respectively, are inserted between the standard third 
leader and the main body of fibre mRNA (Chow et al, 1979). 
It is believed that E3 splice sites in this area are 
interfering with the fibre splice sites and, as no 
function can be found for these aberrant fibre mRNAs, that 
they are a non-essential by-product of the splicing 
process. Only 10% of the virion components synthesised
during the late stage are assembled into viral particles.
The major event governing the transition from the early 
mode to the late mode of gene expression appears to be DNA 
replication. Unreplicated DNA, when introduced into AdV 
infected cells which are in late phase, still fail to
express the late viral genes (Ginsberg, 1984) . A
termination site for late transcription has been mapped at 
99 m.u. RNA sequences from the r-strand between 91.9 
m.u., the poly(A) site of fibre mRNA, and 99 m.u. are 
confined to the nucleus and rapidly degraded (Dressier and 
Fraser, 1987).
The protein products of each MLP family are shown in 
figure 3. Briefly, the proteins with known function are
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Structure of mRNAs Originating at the 
Major Late Promoter
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Fig. 3 Structure of mRNAs originating from the MLP at late 
times after infection. The mRNAs are divided into five 
families (L1-L5) , each having coterminal 31-ends and a 
common set of 51 leaders spliced onto the RNA body. The 
i-leader, which is found on a fraction of the mRNAs, is 
shown in parenthesis. The position of the VA RNA genes 
are shown by open arrows (=>).
as follows:-
LI - the most abundant mRNA encodes the virion polypeptide 
Ilia which is a minor component of the virus particle 
located in the vertex region of the virion.
L2 - three polypeptides are coded by this region, 
designated III, V and pVII. Polypeptide III forms part of 
the penton base. Polypeptides V and pVII constitute the 
major proteins found in AdV chromatin. pVII is tightly 
bound to the viral DNA and it has been proposed that the 
polypeptide V forms a protein shell around a nucleoprotein 
particle consisting of polypeptide VII and the viral DNA.
L3 - this region encodes three extensively studied 
polypeptides, pVI, hexon and 23kD. pVI is believed to be 
associated with the hexon capsomere on the inside of the 
virus particle. The hexon is the major structural 
component of the virion and the 24 0 hexon capsomeres form 
the facets of the icosahedron. The hexon appears to be 
well conserved throughout most mammalian AdV. Boursnell 
and Mautner (1981) revealed that the two ends of the hexon 
molecule were well conserved between the strains examined 
and that variation is more common within the central 
region which is thus likely to contain the type-specific 
antigenic determinants. p23kD has been shown to be 
responsible for the proteolytic cleavage of many of the 
AdV polypeptides.
L4 - polypeptide VIII is known to be a minor component
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of the virus particle however no function is known for the 
other products of this region except that they are 
believed to be non-structural.
L5 - a single polypeptide, the fibre protein, is encoded 
by this region. The fibre is present at the vertices of 
the virion and attaches to the cellular receptors. It has 
been shown to be composed of a dimeric structure with a 
characteristic rod and knob appearance. For a review of 
the above see Ginsberg (1984) and Doerfler, (1986) .
The number and length of the fibre varies according to the 
species and subgroup of AdV. Four of the six human AdV 
subgenera are well endowed with fibres of different 
length:- A - 28-31nm; B - 9-llnm; C - 23-31nm; D - 12-
13nm? E - 17nm; F - 28-33nm. The relevance of these
differences to the pathogenicity, if any, is not yet known 
although it must play a significant role in the tissue 
tropism as defined by attachment of the virus, not ability 
to replicate, to various cell types. Avian AdV, except 
the EDS virus, have been found to code for two fibres of 
different lengths extending from different sites on the 
penton base (Ginsberg, 1984).
mRNAs have been detected from the LI family at early times 
after infection which initiate at the MLP. The level of 
early mRNAs at the MLP is approximately one tenth that of 
other early promoters. One of the mRNAs found is thought,
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due to finding a polypeptide product of 14kD, to be 
functional (Akusjarvi and Persson, 1980).
DNA Replication
A model for AdV DNA replication is shown in figure 4. As 
described previously, the origins of AdV DNA replication 
are known to lie at the ends of the viral genome. Hay et 
al (1984) isolated the AdV origins of replication from 
both the right and left ends of the genome which were 
functional on linear autonomously replicating mini­
chromosomes. The mini-chromosomes contained two cloned 
ITRs and required non-defective AdV as a helper. 
Replicated molecules were found to be covalently attached 
to protein and DNA synthesis was initiated at the correct 
nucleotide even when the origins were not located at 
molecular ends. The activity of the embedded origins led 
to the generation of linear mini-chromosomes from 
circular or linear molecules thus suggesting that the 
sequences within the AdV origin of replication position 
the protein priming event at the AdV terminus.
Following each initiation event a daughter strand is 
synthesised in a 5'-to-3' direction. Initiation events 
that produce type I and type II molecules occur at 
approximately the same frequency at either end. Thus, 
when initiation occurs at the right molecular end the 
parental 1-strand serves as a template and the parental r- 
strand is displaced and vice versa for the left end. 
Since the 3'- terminus of the 1- and r-strands are
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identical, it seems likely that all initiation events 
proceed by the same molecular mechanism.
One of the remarkable features of AdV DNA replication is 
the use of a protein to prime DNA synthesis. The initial 
event in DNA replication is believed to be the binding of 
the pTP to the terminus of the parental genome. This is 
thought to be mediated by the conserved terminal 
nucleotide sequences and may be aided by the presence of 
the TP attached to the parental DNA. Berkner and Sharp 
(1983) demonstrated that cloned viral DNA with EcoRI 
linkers on the termini were 100-fold less efficient in DNA 
replication than wild-type virus. This was thought to be 
due to the lack of a residual peptide, after proteolytic 
digestion of viral DNA, at the termini.
A total of five proteins are required for efficient DNA 
replication in Ad2, the most intensively studied so far. 
The pTP, the DBP, AdV DNA polymerase and two cellular 
factors, nuclear factors I and II (NFI and NFII). DNA 
replication does not occur in the absence of the DBP which 
binds strongly to the single-stranded DNA (ssDNA) during 
replication, which is thought to stabilise the event, and 
interacts with the AdV DNA polymerase. AdV DNA polymerase 
contains an intrinsic exonuclease activity. It is thought 
that an associated nuclease removes misincorporated and 
mispaired nucleotides thus increasing the fidelity of the 
DNA synthesis.
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Fig. 4 Model for AdV DNA replication. Newly synthesised 
DNA strands are depicted by bold lines, parental DNA 
strands by light lines. Arrows indicate the direction of 
chain elongation. The bracketed circular "panhandle" 
forms are theoretical intermediates. Adapted from 
Ginsberg (1984) .
NFI is known to be a sequence-specific DNA binding 
protein. The first 18bp of the viral genome have been 
demonstrated to be adequate to support a limited degree of 
initiation and replication (Hay and McDougall, 1986). 
Howevier, the presence of sequence elements in the region 
between nucleotides 19-48, the NFI binding site, greatly 
enhances the efficiency of the initiation reaction. NFII 
has been shown to possess topoisomerase I activity but the 
enhancement of DNA replication by NFII is completely 
dependant on the presence of NFI; in the absence of NFI, 
NFII does not stimulate DNA replication.
Studies on nuclear factors have also been used to 
demonstrate the relationship of different AdV species to 
each other. Interestingly, the question of the origin of
EDS virus (mammalian origin or distinct from both avian
and animal AdV?) is further confused by these studies to
date. Although most information indicates that EDS virus 
is an AdV of mammalian origin (personal communication, Dr. 
N. Spibey), Endo et al (1986) demonstrated that while a 
nuclear factor from MDBK cells would bind, with varying 
efficiency, to all mammalian AdVs examined, it did not 
demonstrate any binding capacity to the EDS virus genome.
It has recently been reported that a sixth protein, 
nuclear factor III (NFIII), may enhance Ad2 DNA 
replication. NFIII is also a sequence-specific DNA 
binding protein and has been found to bind to a region in 
the AdV origin, adjacent to the NFI binding site (Pruijn
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et al, 1987).
AdV DNA replication is therefore controlled in a complex 
manner. In addition, the method of DNA replication for 
each type of AdV, although requiring the conserved 
sequences contained within the terminal 18bp of the ITR, 
does not necessarily utilise, or be enhanced by, NFI, II 
or III. Harris and Hay (1988) demonstrated that 
initiation of Ad4 was not enhanced by either NFI or NFIII, 
or by a combination of the two as is Ad2, but was shown to 
be stimulated by an unknown cellular factor which has not 
been demonstrated to be a stimulant for Ad2 initiation. 
Thus different AdVs have different DNA sequence 
requirements for the initiation of DNA replication 
involving a variety of cellular enhancers many of which 
are, as yet, unidentified.
The model in fig.4 indicates two possible pathways for AdV 
DNA replication. Both pathways have been deduced from EM 
studies of AdV DNA replication. Support of the 
"panhandle" structure during DNA replication is provided 
by Hay et al (1984) . Experiments investigating the 
regeneration of deleted viral ITR sequences showed a 
sequence-independent requirement for inverted sequences in 
this process, suggesting that repair, results from the 
formation of a "panhandle" structure by a displaced single 
strand. However, whether "panhandle" formation is an 
obligatory, or major, pathway in AdV replication remains
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to be seen.
Oncogenicity and Transformation
Based on their ability to induce tumours in newborn 
hamsters, the human AdV were classified into different 
subgroups as described earlier. The highly oncogenic 
group A viruses induce tumours with high frequency and the 
latent period is very short whereas the moderately 
oncogenic group B cause tumours in only a small fraction 
of the animals and tumours become apparent only after a 
relatively long latent period. Cells transformed by AdVs 
can have a wide range of properties, ranging from the 
ability to divide indefinitely in tissue culture 
(immortalisation) to the ability to cause tumour formation 
in immunocompetent animals. Thus AdV transformed cells 
are usually defined as mammalian cells that have an 
altered phenotype resulting from infection with virus or 
from transfection with viral DNA. The CAVs are reported 
to be highly oncogenic as defined by the phenotypic 
changes occurring in CAV transformed cells and their 
ability to induce tumours rapidly in newborn hamsters 
(Sarma et al, 1967; Kinjo et_al, 1968; Dulac et al, 1969).
Transformation by AdVs requires the integration of the 
left 14%, El region, of the virus genome into the cellular 
chromosome although the entire viral genome can be 
inserted. Analysis of the integration pattern of the viral 
DNA sequences appears to indicate that there is no 
specific integration site into the cellular DNA. In
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addition, the site of integration, as well as all viral 
genes except Ela, plays no important role in the 
maintenance of the transformed phenotype (Graham et al, 
1977; Spector, 1983; Ginsberg, 1984). The relative role 
of each part of the El region in the transformation of 
cells is shown in figure 5. The areas described have been 
defined by a variety of workers using both constructed and 
natural mutants of various AdVs (for a review see 
Doerfler, 1986).
Ela proteins are required for the efficient expression of 
early viral genes whose products are essential for DNA 
replication. Ela proteins can activate transcription of 
viral and non-viral genes both transiently and stably 
introduced into cells. Ela proteins can also stimulate the 
expression of some endogenous cellular genes. The 
observation that Ela proteins transcriptionally stimulate 
cellular genes has led to the suggestion that the basis of 
Ela mediated transformation may be the activation of 
cellular genes involved in normal growth control. 
Consistent with this possibility, Ela mutants that fail to 
activate transcription are also transformation-defective 
(Lillie et al, 1986). Two functional regions have been 
localised on the closely related Ela products: the 243 and 
the 289 a.a. phosphoproteins, one of which is required for 
efficient transactivation, the other for transcriptional 
repression. The 289 a.a. protein contains both regions 
and appears to function mainly as a transactivator whereas
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the 243 a.a. protein lacks the transcriptional activation 
domain and appears to function as a transcriptional 
repressor. It is possible that Ela proteins deregulate 
cell growth by repressing the transcription of specific 
cellular regulatory genes.
This is in agreement with the findings of Jochemsen et al 
(1986) who reported that the difference in oncogenic 
potential of Ad5 and Adl2 was due to the different 
capacities of the Ad5 and Adl2 Ela-encoded proteins to 
modulate cellular gene expression. Support is also given 
to this theory by the fact that the Ela regions of all 
highly oncogenic AdV so far examined, human and non­
human, are closely related (Kimelman et al, 1985).
One of the cellular targets implicated in the process of 
transformation by the AdV Ela proteins is a 105kD cellular 
protein. This protein has been shown to form stable 
protein/protein complexes with the Ela polypeptides. It 
has recently been identified as the product of the 
retinoblastoma gene and subsequently is the first 
demonstration of a physical link between an oncogene and 
an anti-oncogene (Whyte et al, 1988).
Adenovirus Vectors
The use of AdV as vaccine vectors is a rapidly growing 
field of study. The observation that certain regions of 
the AdV genome may be deleted without detectable loss of 
replication ability and stability of the virus in vitro,
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Fig.5 Sequences required for cell transformation by AdV 
DNA or virions. Adapted from Ginsberg (1984).
for example E3, El if the virus is grown in 293 cells and 
certain areas of E4 (for a review see Berkner, 1988), has 
lead to many groups investigating the virus as both a 
vaccine vector and as a complex expression vector. 
Without deletion of viral sequences the human AdV virion 
capsid can accommodate up to 2kb of additional DNA and, if 
compensating deletions of viral DNA are made, as much as 
7kb of foreign DNA can be inserted. It has been reported 
that AdV genomes greater than 105% of the wild type genome 
in size will not be packaged (Munz and Young, 1987).
AdV vectors used as expression vectors have been 
demonstrated to be efficient in post-translational 
processing, including glycosylation, phosphorylation and 
carboxylation. This ability, combined with the 
transforming capabilities of AdV generating stable 
integrants and the wide host range of AdVs in general, 
makes it an ideal expression vector. Inserted genes have 
already been demonstrated to be expressed at high levels 
by the AdV vectors e.g. the HSV1 thymidine kinase (TK) 
gene; human B-globin genes; polyomavirus middle T antigen; 
and SV40 large T antigen (Yamada et al, 1985; Karlsson et 
al, 1986: Davidson and Hassell, 1987; Berkner et al, 1987; 
Thummel and Tjian, 1981 respectively). In addition to the 
expression of these foreign genes, the AdV expression 
vectors facilitate the study of gene expression of 
otherwise "difficult" genes. This aspect was clearly 
demonstrated by Saito et al (1986) who utilised an Ad5- 
hepatitis B virus (HBV) construct, carrying 87% of the
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total HBV genome, to analyse the genomic organisation of 
the virus, a feat which had hitherto proved limited due to 
the lack of an in vitro system to propagate HBV in human 
cells. Control of these foreign genes has been tested 
under a number of promoters e.g. the AdV major late 
promoter (MLP) and the SV4 0 early promoter.
Adenovirus Vectors and Vaccines
AdV vaccines have already been demonstrated to be safe and 
effective with, for example, Ad4 and Ad7 being used as 
human vaccines and the CAV vaccines being one of the most 
widely used and effective veterinary viral vaccines. In 
addition, the ability of AdV to be administered orally 
makes the potential use of of AdV vectors for vaccine 
production particularly attractive.
Again, as with the expression vectors, a variety of models 
have been tested to determine the efficacy of AdV vaccine 
vectors. A herpes simplex virus glycoprotein B 
(HSVgpB) /AdV vector has been shown not only to induce 
production of circulating antibody in infected mice but to 
be able to protect mice against a subsequent challenge 
with HSV (McDermott et al. 1989) . A variety of AdV
vectors encoding HIV products, e.g. gpl60, gpl4 0, env 
protein, are presently being studied by a large number of 
groups but more importantly their efficacy as vaccines is 
being evaluated.
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However, the inability to test any human vaccine vectors 
in their natural host (testing in simian species has been 
used to date) has proved a stumbling block in the complete 
testing and use of these engineered viruses. The finding 
that cotton rats are permissive for human AdV, producing 
very similar clinical symptoms, may aid to some degree but 
it does not overcome the problem altogether (Pacini et al. 
1984) . The study of both wild-type and mutant AdV in 
cotton rats has raised some interesting questions. 
Ginsberg et al (1987) revealed that Ela deletion mutants : 
and therefore by analogy Ela/insertion vectors: produced 
no viral pneumonia, an extremely beneficial factor for 
vectors deleted in this region. However, it was also found 
that Ela and E3 deletions in the viral genome lead to the 
viruses becoming latent within lymphocytes. The 
significance of this finding will obviously have great 
relevance to the use of AdV vectors. Questions remain, 
however, as to whether this latency is of significance to 
the host. The continued expression of the inserted 
"foreign" gene and AdV proteins might be either beneficial 
or extremely detrimental. Additionally, latency might be 
due to the fact that the virus and viral mutants are 
infecting/replicating in a non-host animal which poses the 
questions whether an Ela or E3 deletion would mutant lead 
to latency in its natural host.
The CAVs therefore provide an excellent solution to this 
problem. If the genome organisation could be determined 
and the position of E3 mapped accurately the CAVs would
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provide an excellent animal model for the AdV vectors. In 
addition, when this is combined with the fact that 
excellent CAV vaccines are already in widespread use, the 
use of a vaccine strain as an AdV vector may overcome many 
of the problems that it is feared may occur when trying to 
initiate the use of AdV hosts as vaccine vectors as the 
"safety" of the host itself, unless altered dramatically 
by the insertion of foreign genes which could be quickly 
checked by passage and testing of the vector in controlled 
dogs, is already beyond question. Latency of vectors 
within lymphocytes could be fully examined if present and 
its long term effect upon the inoculated animals 
investigated. The vectors, expressing for example the 
rabies virus glycoprotein, could be fully tested in vivo 
in their natural hosts providing not only a good animal 
model for the human, and other, AdV but, if successful, 
perhaps one of the first commercially viable mammalian 
engineered viral vaccines.
Objectives
The purposes of the present study were two-fold. Firstly 
an investigation into the genomic organisation of the CAVs 
was required as a prerequisite to their development as 
viral vectors along the lines of those developed by Haj- 
ahmed and Graham (1986b). Secondly, an investigation into 
the molecular basis of pathogenicity in the CAVs was 
undertaken. To this end commercially available vaccine 
strains were utilised in order to compare their genomic
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organisation to both the human adenoviruses and wild-type 
CAVs.
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C H A P T E R  1 
General Materials and Methods
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The material and methods detailed below are used 
repeatedly throughout the experiments in the following 
chapters. Any method specifically relating to work in an 
individual chapter is detailed in the materials and 
methods section of that chapter.
Viral Strains
Canine Adenovirus Type 2 Strains
Toronto - kindly given by Dr.C. Cornwell (University 
of Glasgow).
Manhattan - kindly given by Dr.W. Wunner (Wistar Inst., 
Philadelphia, U.S.A.).
Glasgow - a faecal isolate from dogs with enteric 
disease (Macartney et al., 1988).
Epivac (2) - Epivac DH vaccine strain (Wellcome
2
Foundation) lot number B16013A.
Kavak - Kavak DA vaccine strain (Duphar) lot number
2
16014-B.
Nobivac - Nobivac DH vaccine strain (Intervet) batch
2
number 107.
Vaxitas - Vaxitas DA vaccine strain (ICI Tasman) lot
2
number 438.
Canine Adenovirus Type 1 Strains:-
RI 127 - kindly given by Dr.C. Cornwell, University
of Glasgow.
Boostervac - Boostervac DH vaccine strain (C-Vet) lot 
number 2012
Epivac (1) - Epivac DH vaccine strain (Wellcome) lot
number B TCD 280A
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Culture of Monolayer Cells 
Cell Types
CAV is routinely grown in Madin and Darby canine kidney 
cells (MDCK). However, the Vaxitas strain of CAV-2 is 
grown in normal mink fibroblasts (NMF) or Mv-l-Lu a mink 
cell line established by Kniazoff, Nelson, Rees and Darby 
in 1964 (personal communication, ICI Tasman) from near 
term Aleutian mink foetuses (American type culture 
collection number CCL 64). MDCK and NMF cell lines 
kindly provided by Prof. 0. Jarrett, University of
Glasgow? Mv-l-Lu kindly provided by ICI Tasman.
Media
MDCK and Mv-l-Lu cell lines were maintained in Eagle's 
Minimum Essential Medium supplemented with 2mM L-
glutamine, 400 units/ml penicillin/streptomycin, 2.5pg/ml 
Amphotericin B, lx Eagle's non-essential amino acids and 
10% foetal bovine serum. The complete medium is referred 
to as 10% MEM.
NMF cells were maintained in Dulbecco's Minimum Essential 
Medium supplemented with 2mM L-glutamine, 4 00 units/ml
penicillin/streptomycin, 2.5pg/ml Amphotericin B and 10% 
foetal bovine serum. The complete medium is referred to
as 10% DMEM.
All media and supplements were purchased from Imperial 
Laboratories Ltd., Wiltshire.
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Cell Culture
2
Stock monolayer cells were passaged in 180cm plastic
flasks with 40ml of media and routinely subcultured 1:3
twice weekly. Cells were removed from the plastic by
rinsing with versene (0.02% Ethylenediaminetetraacetic
acid (EDTA) in phosphate buffered saline (PBS)) followed
by 0.01% trypsin in 0.02% EDTA. Resuspended cells were
transferred to new flasks and gassed with 5% carbon
dioxide in air. The flasks were then incubated on a level 
o
surface at 37 C.
Preparation of Viral Stocks
Vaccinal strains were prepared by resuspending the
vaccines in 1ml sterile distilled water (dH O) and then
2
mixing with an equal volume of chloroform to remove
distemper virus. The aqueous phase was removed and passed
through a 0.22jim filter (Millipore) . The resultant
suspensions of Epivac, Kavak, Nobivac, Vaxitas and
Boostervac were then ready for inoculation into the
relevant cell cultures. Cell monolayers (70% confluent)
were inoculated with virus and incubated for 3 - 4 days
until a strong cytopathic effect (cpe) became apparent.
The flasks containing infected cells were then freeze
o
thawed 3x at -20 C. The supernatant was then
centrifuged at 2000r.p.m. for 10 minutes and the
o
clarified supernatant stored at -2 0 C until required. 
Isolation of Viral DNA
Viral DNA was extracted from infected monolayers when 70%
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of the cells showed cpe. All media was removed and 5mi of
cell lysis buffer (lOmM Tris(hydroxymethyl)aminomethane
(Tris), lOmM EDTA, 1% sodium dodecylsulphate (SDS) added 
2
to each 180cm roux. The cultures were incubated for 10
minutes at room temperature. The viscous lysate was
decanted and 5M sodium chloride (NaCl) was added to a
final concentration of 1.25M. This solution was incubated
on ice for 3 hours and precipitated chromosomal DNA was
removed by centrifugation at 28,000g for 20 minutes in a
Beckman JA20 rotor. Protease (type XI, Sigma) was added
to the supernatant to a final concentration of 3 00ug/ml
o
and the solution was incubated at 37 C for 3 hours 
(Hirt,1967).
The solution was then extracted twice with phenol and
twice with chloroform, a l/10th volume of 5M NaCl was
added and the DNA precipitated with ethanol (EtOH) at 
o
20 C overnight. The precipitated viral DNA was washed
twice with 70% EtOH and dried in a vacuum dessicator.
Finally the viral DNA was resuspended in TE buffer (lOmM
o
Tris pH7, ImM EDTA) and stored at -20 C until required.
Restriction Endonuclease Cleavage of DNA
The required volume of DNA in TE buffer was transferred to
a microfuge tube. To this was added 0.2 volumes of the
relevant restriction buffer; either low (lOmM Tris pH7.5,
lOmM MgCl , ImM dithiothreitol (DTT)), medium (50mM NaCl, 
2
lOmM Tris pH7.5, lOmM MgCl , ImM DTT) or high salt (lOOmM
2
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NaCl, 50mM Tris pH7.5, lOmM MgCl , ImM DTT) according to
2
the manufacturers specifications. The restriction enzyme
was added (one enzyme unit per jig of DNA to be digested) ,
followed by sufficient distilled water to bring the buffer
to the correct concentration. The mixture was incubated 
o
at 37 C for 60 minutes.
Agarose Gel Electrophoresis
Agarose gel electrophoresis was conducted on a horizontal
perspex bed submerged in TBE buffer (table 1.1). Agarose
(2.4g) was suspended in 300ml of TBE and was dissolved by
boiling in a microwave oven. This solution of 0.8%
agarose in TBE was used consistently throughout this study
unless otherwise stated in each individual chapter. When
o
the molten agarose had cooled to approximately 50 C it 
was poured onto the perspex bed and left to solidify with 
the well-forming comb in position. The comb was then 
removed and the gel submerged in the electrophoresis tank.
Samples were prepared for electrophoresis by the addition 
of a 1/4 volume of loading solution (10% Ficoll (mw 
400,000), 0.05% Bromophenol Blue, 0.05% Orange G, 0.05%
Xylene Cyanol FF). The samples were then loaded into the 
wells and a constant potential difference of 50V was 
applied across the gel for approximately 16 hours. The 
gel was then removed from the electrophoresis tank, 
immersed in distilled water containing 0.5pg/ml ethidium 
bromide (EtBr) for 20 minutes and then left to destain in 
distilled water for a further 20 minutes. The DNA was
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visualised on a 302nm transilluminator (UV Products Ltd.) 
and photographed on polaroid film.
Polyacrylamide Gel Electrophoresis
Restriction enzyme digests were also subjected to 
electrophoresis in 6% polyacrylamide, in order to 
visualise fragments between 50 and 500 base pairs (bp) in 
size. Polyacrylamide gels were conducted on a vertical 
gel set (Bio-Rad). The glass plates were thoroughly 
cleaned and placed into the casting stand as per 
manufacturers specifications.
The constituents of the gel were as follows:- 25.3ml dH 0,
2
4ml TBE buffer, 10ml stock acrylamide (2 0% acrylamide, 1% 
methylenebisacrylamide in water) , 24}il
tetramethylethylenediamine (TEMED) and finally 480jil 10% 
of ammonium persulphate (APS) freshly prepared in water). 
This mixture was then poured between the glass plates, the 
well forming comb inserted and the gel left to polymerise 
for 45 minutes.
All polyacrylamide gels were run under a constant current 
of 3 6mA for 3 hours or 3mA overnight. Samples were 
prepared for electrophoresis by the addition of a 1/4 
volume of loading dye (as for agarose gel 
electrophoresis). Gels were stained in EtBr, visualised 
and photographed as stated above.
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Isolation of Plasmid DNA 
Small-scale
Small-scale plasmid isolations were carried out after the
method of Holmes and Quigley (1981). Bacteria were
patched out on L-agar plates (table 1.1) and grown
o
overnight at 37 C. A large loopfull was then placed 
directly into microfuge tubes containing lOOjil of STET 
buffer (table 1.1) and resuspended thoroughly. Then 8pl 
of a freshly prepared solution of lysozyme (lOmg/ml in 
water) was added and the tubes left at room temperature 
for 5 minutes. The tubes were placed into a boiling 
waterbath for 40 seconds and then spun in a bench-top 
microfuge at 13,000g for 10 minutes. The supernatants 
were removed to fresh tubes containing lOOjil TE where the 
solutions were extracted 2x with phenol, 2x with 
chloroform and finally EtOH precipitated.
The DNA was pelleted in a bench-top microfuge at 13,000g
for 10 minutes, washed 2x with 70% ethanol and dried in a
vacuum dessicator. The pellets were resuspended in TE and 
o
stored at -20 C until required.
Large-scale
Bacteria carrying the required plasmid were grown
overnight in 200ml L-broth (table 1.1) containing the
appropriate antibiotics. The cells were harvested by
o
centrifugation (9000r.p.m./10 minutes/5 C),resuspended in 
2ml of 25% sucrose in 0.05M Tris pH8.0, and left on ice 
for 5 minutes. Lysozyme, freshly prepared at 20mg/ml in
55
0.25M EDTA pH8.0, was added (0.3ml) and the mixture left 
on ice for a further 15 minutes. 2ml of 0.25M EDTA pH8.0 
was added and the mixture left on ice for a further 5 
minutes. Next, 4ml of Brij/Doc solution (table 1.1) was 
added, mixed gently and left on ice for 3 0 minutes.
The mixture was then centrifuged (18,00Or.p.m./45 
o
minutes/4 C) in a Beckman JA20 rotor. The supernatant was
gently removed to a sterile universal container and CsCl
added (0.95g/ml supernatant). EtBr was added to a final
concentration of 200^ig/ml and the mixture transferred to a
12ml heat sealable tube (Beckman). The tubes were sealed
using a Beckman heat sealing apparatus and then
centrifuged in a Beckman Ti50 fixed angle rotor at
o
38,000r.p.m. for 60 hours at 18 C. The plasmid DNA band 
was easily visualised in the centrifuge tube and was 
extracted by side puncture of the tube using a 1ml syringe 
and a 23 gauge needle.
EtBr was removed from the DNA by repeated extraction with
CsCl saturated iso-propanol. Extractions were continued
until no visible colour remained in the aqueous phase.
The CsCl was removed by dilution of the sample to 5ml with
o
TE followed by ethanol precipitation at -2 0 C for one
hour. Following this, the DNA was pelleted in a Beckman
o
JA20 rotor (15,000r.p.m./45 minutes/4 C) and washed 3x
with 70% ethanol in water (v/v) . The pellets were then
dried in a vacuum dessicator, resuspended in TE pH7.5 and 
o
stored at -20 C until required.
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T A B L E  1.1 
Preparation of Stock Solutions
20X SSC
NaCl 175.3g
Sodium citrate 88.2g
dH 0 to 11
2
adjusted to pH7.0 with NaOH
2Ox SSPE
NaCl 174g
NaH PO .H O 27.6g
2 4 2
EDTA 7.4g
dH O to 11
2
adjusted to pH7.4 with NaOH
Ethidium Bromide/lOmg/ml)
EtBr 0.lg
dH O to 10ml
2
o
store at 4 C in the dark
5M NaCl
NaCl 292.2g
dH O to 11
2
0.5M EDTA
EDTA 186.lg
dH O to 11
2
adjust to pH8.0 with NaOH
1M Tris
lOx TBE
Tris base 121.lg
dH O to 11
2
adjust to required pH with HC1
Tris base 108g
Boric acid 55g
0.5M EDTA 20ml
dH O to 11
2
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Denhardt's Solution 
Ficoll
20% SDS
L-Broth
Polyvinylpyrrolidone 
(PVP)
BSA
(pentax fraction V) 
dH 0 
2
o
Store at -20 C
Sodium dodecylsulphate 
dH O 
2
Tryptone 
Yeast extract 
NaCl 
dH O 
2
adjust to pH7.2 with NaOH
L-Aqar
L-broth 
Difco agar
Ampicillin
5g
5g
5g
to 500ml
2 0g
to 100ml
15g
5g
5g
to 11
100ml 
1. 5g
Ampicillin (sodium salt) 50mg/ml in dH 0
2
o
Store at -20 C
Use at final concentration of 50jig/ml
Tetracycline
Tetracycline hydrochloride 15mg/ml in dH 0/
2
ethanol (50%v/v) 
o
Store at -20 C
Use at final concentration of 15jig/ml
Streptomycin
Streptomycin sulphate 50mg/ml in dH 0
2
o
Store at -2 0 0
Use at final concentration of 50^ig/ml
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Prehybidisation Solution for Nitro-cellulose
5xSSPE
50% Formamide 
lx Denhardts
200jig/ml Denatured Calf Thymus DNA
Denatured Calf Thymus DNA (lOmq/ml)
Calf Thymus DNA lOmg/ml in dH O
2
Solution boiled in a microwave oven and then 
sonicated for 3 minutes.
STET Buffer
Brij/Doc
Sucrose 8g
Triton X-100 5ml
0.5M EDTA pH8.0 10ml
1M Tris pH8.0 5ml
dH O to 100ml
2
Brij 58 lOg
Sodium deoxycholate (DOC) 4g
TE pH8.0 to 11
X-gal(4Omg/ml)
5-bromo-4-chloro-3-indolyl- 
B-D-galactoside (X-gal) 40mg
dimethyl formamide 1ml
o
Store at -20 C
IPTG(50mq/ml)
Isopropyl-thiogalactoside 50mg
dH O 1ml
2
o
Store at -20 C
AIX Plates
IPTG (5Omg/ml) lul [ per
X-gal (4Omg/ml) lul r 100ml
Ampicillin (5Omg/ml) lulJ L-Agar
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C H A P T E R  2
Comparison of Wild-tvpe. Vaccine and Reference Strains of 
Canine Adenovirus and Construction of a Physical Map 
of the Vaccine Strain Vaxitas CAV-2
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I N T R O D U C T I O N
Respiratory disease is one of the most important problems 
encountered in canine medicine. Two serologically 
related, but not identical, canine adenoviruses (CAV-1 and 
CAV-2) now appear as the primary cause of respiratory 
infections in dogs. Different immunological techniques 
have been used to distinguish between the CAVs but many of 
these typing procedures are either tedious or require 
further experimentation to establish their specificity 
and/or sensitivity. Preparation and evaluation of the 
adequate reagents for serological analysis of such closely 
related viruses is also a time consuming task especially 
when the number of "atypical" or "intermediate" results 
must be kept to a minimum.
Restriction endonuclease analysis has recently been found 
to be the most useful tool for the identification of the 
CAVs. However, the published data on the restriction 
enzyme analysis of the CAVs has been limited. Many groups 
have reported the restriction enzyme cleavage patterns of 
CAV-1 and CAV-2, confirming their distinctiveness, but in 
the majority of cases this has involved only the reference 
strains and as yet only one physical map of a CAV, that of 
a reference strain of CAV-1, has been published (reviewed 
in the general introduction).
The interest in CAV as a virus vector indicated that 
genomic analysis of the existing vaccine strains may prove
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valuable and, in addition, may help to elucidate the 
mechanism of attenuation at the DNA level. A physical map 
of, CAV-2 would also enable a more direct comparison with
the CAV-1 genome and the human AdV.
It was hoped that the use of a range of restriction
enzymes would reveal one or two which would yield a range
of fragments of suitable size to enable the cloning of the 
entire CAV-2 genome. This would enable a physical map to 
be constructed and also the orientation of the CAV genome 
to be established with respect to the human AdVs. Any 
alteration in the genome structure or function of the CAVs 
compared to the human AdVs could then be investigated.
The wild-type strains used in this study were designated 
Glasgow CAV-2 and RI127 CAV-1. Glasgow CAV-2 was obtained 
from the faeces of pups with enteric disease, an unusual 
site of isolation for CAV-2, thus indicating that it may 
prove to be a variant strain when compared to the 
reference strains Manhattan and Toronto (Macartney et al, 
1988) . The CAV-1 wild-type strain, RI127, was obtained as 
a routine isolate by the Canine Infectious Disease 
Research Unit at the University of Glasgow.
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M A T E R I A L S  A N D M E T H O D S
Restriction Enzyme Analysis
Restriction endonucleases were purchased from Pharmacia 
and used according to the manufacturers specifications. 
Restriction enzyme digests were subjected to 
electrophoresis in 0.8% agarose, prepared and run in TBE. 
Lambda phage QJ DNA, cleaved by Hindlll (Pharmacia), was 
used as a size marker.
Restriction digests were also subjected to electrophoresis 
in 6% polyacrylamide prepared and run in TBE. Puc8 
plasmid DNA, cleaved by either Hpall or Haelll, was used 
as a size marker.
Construction and Analysis of Recombinant Plasmids 
Preparation and Ligation of DNA
The plasmid pBR322 was digested with PstI as was Vaxitas 
DNA. The restriction enzyme reactions were terminated by 
phenol extraction, followed by chloroform extraction and 
ethanol precipitation. The plasmid vector was then 
dephosphorylated using bacterial alkaline phosphatase 
(Maniatis et al., 1982).
Eight units of phosphatase/buffer mix (as supplied by
Pharmacia) was added to the vector DNA which had been
o
resuspended in 20pl TE and the mixture incubated at 37 C 
for 30 minutes after which the mixture was 
phenol/chloroform extracted and reprecipitated with
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ethanol.
The DNA samples were redissolved in water and mixed in the
ratio 3:1, Vaxitas:pBR322. The mixture was then incubated
with T4 DNA ligase (Pharmacia) in 66mM Tris pH7.2, lOmM
o
MgCl , lOmM DTT, ImM ATP at 14 C for 12 hours (Maniatis et 
2
al. , 1982).
Transformation with Plasmid DNA
Transformation of the ligated DNA into E.coli JM101 was 
carried out as described by Maniatis et al (1982) .
An overnight culture of JM101 was diluted 1:25 into fresh
o
L-Broth (table 1.1) at 37 C. When the culture reached an
OD of 0.2 the cells were harvested by centrifugation
650
o
(8K/10 minutes/4 C) in a Beckman JA20 rotor. The
supernatant was discarded and the pellet resuspended in
3.8ml 0.1M MgCl . The cells were again sedimented by
2
centrifugation as above and the pellet resuspended in
1.9ml 0.1M CaCl . This step was then repeated once more
2
and the final suspension of cells in 1.9ml 0.1M CaCl was
2
*
left on ice for a minimum of 1 hour.
200jil of the cell suspension was then added to lOOjil of
o
the ligated DNA solution and incubated at 0 C for 30
minutes. The cell/DNA mixture was then heat-shocked by
o
incubation at 42 C for 2 minutes and returned to ice for a 
further 30 minutes. The mixture was then added to 1ml of
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o
L-broth and incubated at 37 C for 1 hour to allow 
expression of the antibiotic resistance genes. Finally, 
0.1ml samples of the transformation mix were spread 
directly onto agar plates containing antibiotics.
Transformants were initially selected on L-agar (table 
1.1) containing 15|ig/ml tetracycline. Individual 
colonies were then patched out onto L-agar containing 
either tetracycline (15pg/ml) or ampicillin (50jig/ml) .
Transformants containing recombinant plasmids were 
selected as ampicillin sensitive. Recombinant plasmids 
were initially analysed using small-scale plasmid 
isolation techniques and those containing the required 
insertions were isolated by the large-scale plasmid 
isolation method (chapter 1).
*
Excess cells were mixed with a sterile solution of 50%
glycerol in water (v/v) in a ratio of 2:1 to give a final
concentration of approximately 16%. This mixture was then
o
divided into 300)il aliquots which were stored at -70 C 
until required.
Cloning of the Terminal Fragments of Glasgow and Vaxitas 
Vector
The plasmid vector Bluescript M13+ (Stratagene) was double 
digested with either Sall/Smal or EcoRI/Smal. The entire 
reaction from each digestion was run on a 0.8% agarose gel 
and the linear Sall/Smal and EcoRI/Smal fragments were cut
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out and purified. This method facilitated the removal of 
any uncut vector and also the small polylinker fragments 
(Sail to Smal 33bp: EcoRI to Smal 8bp) thus preventing 
recirculisation of the vector.
Viral DNA
lOOjig of Vaxitas DNA and 200pg of Glasgow DNA were
pretreated with proteinase K (Sigma) before digestion to
remove any remaining terminal protein. In addition, 50%
of each sample was pretreated with S nuclease
1
(Pharmacia). Briefly, 8 units of SI nuclease were added
to the DNA along with a 1/10 volume of lOxSl buffer (2M
NaCl, 0.5M sodium acetate (pH4.5), lOmM ZnSO , 5%
4
glycerol) and water to make up the correct volume. The
o
mixture was incubated at 37 C for 15 minutes. A 1:100 
volume of 0.5M EDTA was then added to stop the reaction.
Next, protease type XI, at lOmg/ml in water, was added to
S treated and untreated samples to a final concentration 
1
o
of 500pg/ml and the mixture returned to 37 C for a further
3 hours. The mixture was then extracted with an equal
volume of phenol (2x) and then chloroform (2x) before 
ethanol precipitation. The washed (70% EtOH) and dried 
pellets were then resuspended in TE ready for restriction
endonuclease digestion.
The viral DNA was then divided into two; one half was
digested with EcoRI, the other half with Sail. Upon
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completion of the digestions, the DNA was again extracted 
2x with phenol, 2x with chloroform and finally ethanol 
precipitated. The DNA was resuspended in TE and was then 
ready for ligation to Bluescript.
Ligation and Transformation
The ligations were carried out as described previously 
with the difference that excessive vector was present 
giving an approximate ratio of 1:1, vector:viral DNA. The 
ligated mixture was then transformed into E.coli DS941 
(provided by Prof. D. Sherrat, Dept. of Genetics, 
University of Glasgow) as described above.
The DNA/cell mixture was plated directly onto AIX plates
(table 1.1) in 0.1ml aliquots. The agar plates were 
o
incubated at 37 C for 24 hours and any white colonies then 
screened, following small scale plasmid isolation, by 
restriction enzyme analysis. Those recombinants 
containing the required insert were then re-isolated using 
the large scale plasmid isolation technique (chapter 1) .
Transfer of DNA from Agarose Gels to Nitro-cellulose 
CAV-2 DNA digested with BamHI, EcoRI, PstI and Kpnl was 
separated on a 0.8% agarose gel and transferred to 
nitro-cellulose by the method of Southern (1975).
Briefly, the gel was denatured in 1.5M NaCl/0.5M NaOH for 
one hour at room temperature and the neutralised in a 
solution of 1M Tris (pH8.0)/1.5M NaCl for a further hour
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at room temperature. The gel was then ready for blotting. 
20xSSC (table 1.1) was used consistently as the transfer 
medium and the gel was allowed to blot overnight to allow 
complete transfer to the nitro-cellulose. The nitro­
cellulose was then removed form the gel, cut with a
scalpel as required, briefly washed in 2xSSC, air dried
o
and finally baked at 80 C for two hours.
Nick Translation of DNA
32
DNA was nick translated to prepare P-labelled DNA (Rigby 
et al., 1977) using a commercial nick translation kit
(Amersham). The radioactive label, :<x-32P dATP , was
purchased from Amersham at a specific activity of 
3000jiCi/mM.
The reactions were carried out according to the
manufacturer's instructions and the mixtures were
o
incubated at 14 C for 2 hours. Unincorporated label was
removed from the incorporated label by passing the
reaction through a Sephadex G-50 column equilibrated with
STE (table 1.1). Orange G (lOmg/ml) was used as a marker
for the unincorporated label. All nick translations
8
yielded labelled DNA with >10 cpm. The labelled DNA was 
o
stored at -20 C in lead containers and used within four 
days of nick translation.
Molecular Hybridisation
The baked nitro-cellulose filters were placed in a plastic
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o
bag and prehybridised (table 1.1) overnight at 42 C.
The nick translated DNA (200pl) was denatured by adding
lOpl 0.5M NaOH, boiling for 3 minutes, cooling on ice and
finally neutralised with 15jil 1M HC1 and 50jal 1M Tris
pH7.0. The probe was then injected into the plastic bag
containing the filter and the bag was resealed. The bag
o
was further incubated at 42 C overnight. The filters
were then removed from the bags, washed 3x in
o
2XSSC/0.1%SDS, then 3x in 0.2xSSC/0.1%SDS at 42 C, dried 
and subjected to autoradiography.
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R E S U L T S
Restriction Enzyme Analysis of CAV-2 DNA
Three restriction enzymes, BamHI, PstI and Hpall, were 
used to cleave the purified DNA of the Glasgow isolate, 
the CAV-2 reference strains Manhattan and Toronto A26/61 
and a reference strain of CAV-1, RI127. The separated DNA 
fragments are shown in Fig. 2.1. CAV-1 is easily 
distinguishable from the CAV-2 reference strains and the 
Glasgow isolate. The Glasgow strain appears identical to 
both prototypic strains of CAV-2 using BamHI and PstI. 
However, the Hpall digestion shows slight variation 
between Glasgow and the reference strains. At least one 
additional Hpall site is apparent resulting in the loss of 
a 1.8 kilobase (kb) fragment and the appearance of a l.Okb 
fragment.
Two enzymes, BamHI and PstI, were then used to digest the 
purified DNA of the vaccine strains Vaxitas CAV-2, Kavak 
CAV-2, Nobivac CAV-2 and Epivac CAV-2 together with that 
of the Glasgow isolate (Glasgow CAV-2). The pattern of 
fragments produced is shown in figure 2.2.
PstI fragments A,B,E,F and G are common to all strains. 
Fragment C is common to all strains except Vaxitas in 
which it is not apparent. Further, fragment C of the 
other vaccine strains is slightly increased in size 
compared to Glasgow CAV-2. Fragment D is again common to 
all isolates but is decreased in size in all vaccine
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strains with the maximum deletion, approximately 0.3kb, in 
Vaxitas. Fragment H is represented as a single discreet 
fragment in Glasgow but in the vaccine isolates varies 
from 1.3kb to 3.0kb in size. In addition, three fragments 
were visible on acrylamide which were of a constant size 
in all strains.
BamHI fragments A,B,D,E and F are common to all isolates. 
However, fragment A varies in size, with Vaxitas having 
the largest and Glasgow the smallest fragment. Fragment 
C, while not apparent in Vaxitas, is common to all other 
isolates but is slightly larger in the vaccinal strains 
than in Glasgow.
A direct comparison of Glasgow CAV-2, as a wild-type
strain, and Vaxitas CAV-2, as the vaccine strain differing 
most widely from wild-type, was now undertaken. 
Restriction profiles of Glasgow (A) and Vaxitas (B) can be 
seen in figure 2.3. Virus DNA was digested with BamHI, 
EcoRI, Kpnl, PstI, Sail and Smal. The size of fragments 
generated by digestion with each of these enzymes can be 
seen in table 2.1. PstI fragments B and F in Vaxitas were 
demonstrated to consist of two co-migrating fragments by 
double digestion of the PstI clones with a range of
restriction enzymes.
Molecular Cloning of Vaxitas CAV-2 Fragments
The number (11) and range of sizes (0.2kb - 6.0kb) of
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fragments generated by digestion with PstI indicated these 
as suitable fragments for cloning into a plasmid vector. 
Nine of the eleven PstI fragments were cloned into the 
PstI site of pBR322. Two terminal fragments, Sail B and 
EcoRI C, were cloned as Sall-blunt and EcoRI-blunt
fragments in the plasmid vector Bluescript M13+
(Stratagene: Fig. 2.4). The right-hand terminal PstI
fragment, PstI G (Glasgow)/PstI H (Vaxitas), was subcloned 
from this. The single Vaxitas Sail B clone isolated 
contained an insert of approximately lkb, as compared to 
the Glasgow Sail B fragment, and this clone was used for 
subcloning the terminal PstI fragment. The left-hand 
terminal clone, EcoRI C, was used in the hybrisiation
mapping experiments instead of PstI C.
Recombinant plasmids were digested with PstI and
electrophoretic mobility of the inserted Vaxitas DNA 
fragments compared with that of PstI cleaved whole virus 
DNA. Final confirmation of each cloned fragment was 
obtained by hybridisation of each clone against Southern 
transfers (Southern, 1975) of PstI digested Vaxitas DNA. 
All the PstI clones and the EcoRI C clone hybridised with 
a single PstI fragment of Vaxitas whole virus DNA except 
the cloned termini which exhibited the characteristic 
homology due to the terminal repeats (Fig.2.5). Homologous 
inverted terminal repeats (ITR) are reported to have been 
found in all adenoviruses so far examined (Ginsberg, 
1984).
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Physical Map of Vaxitas CAV-2
The maps shown in Fig. 2.6 were constructed using the data 
from molecular hybridisation experiments and restriction 
fragment sizes. The hybridisation results for one 
restriction enzyme, BamHI, digestion of Vaxitas DNA are 
given as an example in figure 2.7. The hybridisation 
results are summarised in table 2.2. Due to the 
considerable heterogeneity at the termini of Vaxitas, 
most clearly seen in EcoRI C and Sail B fragments 
(fig. 2.3), the size of the most predominant species was 
taken. The Smal sites at map units (m.u.) 0.75 and 99.25 
were also located by sequence analysis which is discussed 
later. As an area existed within the genome which was not 
covered by any of the above clones, the region between the 
end of EcoRI C and the beginning of PstI A (1.2 6kb) the 
cloned EcoRI B fragment was used to confirm the position 
of the PstI fragments J and K within this region.
The physical maps of Glasgow CAV-2 DNA used for comparison 
were kindly provided by Dr. N. Spibey. The order of BamHI 
fragments within PstI B was determined by KpnI/BamHI 
double digestion of the cloned PstI B fragment. The 
physical maps of the CAV genomes were orientated with 
respect to the human adenovirus genome (HuAdV) by probing 
southern transfers of Glasgow DNA with cloned fragments of 
HuAdV types 5 and 12 hexon coding region (Spibey and 
Cavanagh, 1989) . All data from the molecular 
hybridisation experiments were confirmed by restriction
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endonuclease digestion of the Vaxitas recombinant 
plasmids.
Comparison of the Physical Maps of Vaxitas and Glasgow 
CAV-2
From figure 2.6 it is apparent that the restriction maps 
of Glasgow and Vaxitas are very similar. However, three 
sites of variation between the two strains can clearly be 
seen. The first two involve insertions at either end of 
the Vaxitas genome: right terminal PstI fragment Glasgow 
1.3kb, Vaxitas 3.0kb; left terminal PstI fragment Glasgow 
4.4kb, Vaxitas 4.7kb. The third change occurs in the PstI 
D fragment. This fragment is present as 4.4kb in Glasgow 
but 4.1kb in Vaxitas. The deletion which has occurred in 
the vaccine strain removes a Kpnl site resulting in the 
loss of the 0.6kb Kpnl fragment.
Table 2.1 lists the size of each restriction fragment for 
each virus to enable a clearer comparison.
Restriction Enzyme Analysis of CAV-1 DNA
Two restriction enzymes, PstI and Sail were used to cleave
the purified DNA of the CAV-1 reference strain RI 127 and
the CAV-1 vaccine strains Boostervac CAV-1 and Epivac CAV-
1. The separated DNA fragments are shown in figure 2.8.
The physical map of CAV-1 DNA (RI 127) is shown in figure
c
2.9 courtesy of Dr. A. M Clory (University of Glasgow). 
PstI digestion of CAV-1 DNA produces 11 fragments, 8 of 
which are visible on 0.8% agarose. Sail digestion
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produces three fragments. The terminal Sail C fragment 
exhibits considerable heterogeneity within the vaccine 
strains with Boostervac appearing to consist of two
distinct species. Variation is also apparent in the
larger, Sail A and B, fragments but the size of the large 
fragments produced by this enzyme , 17.7kb and 11.9kb,
does not facilitate easy interpretation of this. A 
similar observation can be made in the PstI digest.
Heterogeneity can clearly be seen in the PstI G fragment. 
Unfortunately, it is impossible to distinguish whether the 
variation in the larger fragments occurs in PstI B, C or D 
or a combination thereof. Further digests with other 
enzymes were therefore undertaken.
Figure 2.10 displays the separated fragments obtained from 
digestion of the three CAV-1 strains with Kpnl, BamHI, 
Smal and EcoRI. The EcoRI 2.3kb and 0.8kb fragments show 
the characteristic heterogeneity very clearly and confirms 
the variation as terminally associated insertions within 
the CAV-1 vaccine strains. The EcoRI 3.6kb fragment 
similarly shows the presence of a deletion in this 
fragment of the vaccine strains. The remaining enzyme 
digestions? Kpnl, BamHI and Smal; exhibit the same 
features although less clearly. The insertions can be 
noticed in the Kpnl E and BamHI C fragments but the size 
and separation of the larger terminal fragments does not 
allow for a clear demonstration of relatively small 
changes in size. The deletion can similarly be noticed in
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Kpnl C and Smal A although still to a lesser degree than 
in EcoRI D due to their larger size and lesser separation. 
The restriction pattern obtained by digestion of the CAV-1 
strains with BamHI was also analysed on acrylamide, figure 
2.11. This demonstrated that the 0.4kb fragment D present 
in wild-type CAV-1 was no longer present in the vaccine 
strains thus indicating that the deletion in the genomes 
of the vaccine strains was contained within this region, 
around 80 m.u.
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F I G U R E  2.1
Restriction Enzyme Analysis of Wild-type 
and Reference Strains of Canine Adenovirus
23.1
9.42
6.68
4.36
2.32
2.03
0.56
I R t s1mamnH
A A B C  D A  B C D A B C D  
Pst  I BamHI Hpa 11
Fig.2.1 Restriction enzyme analysis of the CAV genome. The 
wild-type isolates RI 127 CAV-1 (lane A) and Glasgow CAV-2 
(lane B) are compared to the two prototypic CAV-2 strains, 
Manhattan (lane C) and Toronto (lane D), using the 
restriction enzymes PstI# BamHI and Hpall. The CAV-1 
isolate is clearly distinguishable from the CAV-2 strains. 
Variation in the Hpall digestion of the CAV-2 strains is 
marked. Hindlll digested DNA fragments are used as m.w. 
markers.
F I G U R E  2.3
Comparison of the Restriction Enzyme Profiles of 
Glasgow and Vaxitas CAV-2
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Fig.2.3 A direct comparison of the restriction profiles of 
Glasgow (G) and Vaxitas (V) CAV-2. Viral DNA was digested 
with BamHI (1), EcoRI (2), Kpnl (3), PstI (4), Sail (5) 
and Smal (6). Variation in size between the terminal 
fragments of Glasgow and Vaxitas can easily be seen and 
are described within the text. Hindlll digested A  DNA 
fragments represent m.w. markers.
F I G U R E 2.4
Physical Map and Polylinker of the Plasmid
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Fig. 2.4 Physical map and the polylinker of the plasmid 
vector Bluescript M13+ (Stratagene). Primer recognition 
sequences are indicated.
F I G U R E  2.5
Confirmation, by Hybridisation, of the Isolation of 
the PstI fragments of Vaxitas CAV-2
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Fig. 2.5 Confirmation of the isolation and cloning of the 
PstI fragments of Vaxitas CAV-2. Each fragment was nick 
translated and hybridised to Southern transfers of viral 
DNA cleaved with PstI. Each fragment bound only to a 
single viral PstI fragment of identical size except the 
terminal fragments which bound to themselves and to each 
other due to the presence of an inverted terminal repeat 
within the viral genome. Group A and group B represent 
Southern transfers of PstI digested Vaxitas DNA from two 
different 0.8% agarose gels. PstI digested Vaxitas DNA 
32
probed with P-labelled whole virus DNA is demonstrated 
for each gel (V). Confirmation of the clones of Pst K, J 
and I was carried out by probing transfers of PstI 
digested viral DNA from 2% agarose gels (data not shown).
T A B L E  2.1
Sizes of fracrments generated after cleavage of CAV-2 DNA 
with BamHI, EcoRI, Kpnl, PstI, Sail and Smal
Restriction enzyme Fragment CAV-2 Glasgow CAV-2 Vaxitas
length (Kbp) length (Kbp)
BamHI A 13.86 14.06
B 8.1 8.1
C 6.2 8.1
D 2.0 2.0
E 0.7 0.7
F 0.6 0.6
EcoRI A 19.0 20.4
B 8.8 8.8
C 3.5 3.8
PstI A 6.0 6.0
B 4.6 4.6
C 4.35 4.6
D 4.35 4.1
E 3.9 3.9
F 3.1 3.1
G 3.0 3.1
H 1.3 3.0
I 0.32 0.32
J 0.26 0.26
K 0.2 0.2
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Kpnl
Sail
Smal
Table 2.1.
electrophoretic
polyacrylamide
A
B
C
D
E
F
G
H
I
10.2
5.2 
3.6 
3.05 
3 . 05 
2.85
2.3 
0.7 
0.6
10.5
5.2
5.2 
3.6
3.05
3.05 
2.85 
0.7
A
B
A
B
C
D
E
F
G
H
I
28. 0
3.2
6.75
5.3
5.3 
4.55
4.4 
3.85 
0.72 
0.233 
0.233
28.3
5.2
6.75
6.1
5.5
5.3
4.4 
3.85 
0. 72 
0.233 
0.233
Fragment sizes were calculated from 
mobilities in 0.8% agarose (>500bp) and 6% 
(50 - 500bp).
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T A B L E  2.2
Hybridisation between PstI fragments and 
restriction enzyme digests of CAV-2 DNA
Cloned PstI
fragment Bam HI EcoRI Kpnl PstI Smal
A A B A D  A C E G F
B B C D E F A  B F  B B
* *
C A C  A C  A G  C G  D H I
D C A B I G  D B D
E B A C E H E  A F
F B A E F F A
G A A B  D H  G F G
* *
H A C  A C  A G  C H  D H I
*
I B A E I A
*
J A B A J C
*
K A B A K C
#
Hybridisation relatively weak, and due to inverted 
terminal repeated sequences.
*
Hybridisation detected on DNA transferred to 
nitro-cellulose from 2% agarose
Table 2.2 Hybridisation results from nick translated PstI 
clones probed against Southern transfers of Vaxitas DNA 
digested with a range of restriction enzymes.
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F I G U R E  2.6
Physical Maps of the Vaxitas and Glasgow CAV-2 Genomes
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Fig. 2.6 Schematic restriction maps of Vaxitas and Glasgow 
CAV-2 genomes. Accurate sizes of each fragment given in 
table 1. Glasgow map and fragment sizes courtesy of Dr. 
N. Spibey, Glasgow University ( Spibey and Cavanagh, 
1988).
F I G U R E  2.7
Hybridisation Results From Southern Transfers of 
BamHI Digested Vaxitas DNA
I I
Psii
clone
D G V 
(VaxH)
B H
(VaxG)
Fig. 2.7 Hybridisation results from BamHI digested
Vaxitas DNA probed with nick translated PstI clones. 
Groups A and B represent Southern transfers of BamHI cut
3 2
Vaxitas DNA from two distinct 0.8% agarose gels. P-
labelled whole virus DNA was used to probe a single track 
(V) . The PstI clone used for probing each track is
indicated. Results for PstI clones I, J and K are not 
shown but are consistent with their position on the viral 
genome.
F I G U R E  2.8
Preliminary Restriction Enzyme Analysis 
of CAV-1 Vaccine Strains
X A B C X A  B C 
PstI Sol I
Fig. 2.8 Restriction enzyme analysis of CAV-1 vaccine 
strains Boostervac (lane A) and Epivac (lane C) compared 
to the wild-type isolate RI 127 (lane B). RI 127 and the 
two vaccine strains were digested with PstI and Sail. 
Variation in the terminal fragments is apparent. Hindlll 
digested X DNA fragments were used as m.w. markers.
F I G U R E  2.9
Physical Map of the Wild-type CAV-1 Strain RI 127
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Fig. 2.9 Physical Map of the genome of the wild-type
isolate of CAV-1, RI 127. Map kindly provided by Dr. A. 
S. McClory, University of Glasgow. Fragments are labelled 
alphabetically according to size i.e. largest labelled A 
etc.
F I G U R E  2.10 
Restriction Enzyme Analysis of CAV-1 Vaccine Strains
X A B C A B  C A B C A B C  X 
Kpnl  BamH I S m a l  EcoRI
Fig. 2.10 Restriction profiles of the CAV-1 vaccine 
strains: Boostervac (lane A) and Epivac (lane C): and
wild-type strain RI 127 (lane B) obtained using the 
restriction enzymes Kpnl, BamHI, Smal and EcoRI. 
Variation within the terminal fragments and an internal 
deletion is most apparent in the EcoRI digest. Other 
digests exhibit the variation less clearly due to the size 
of the fragments (see text). Hindlll digested \ DNA 
fragments were used as m.w. markers.
F I G U R E  2.11
Analysis of BamHI Digestion of the CAV-1 Strains on
Acrylamide
A B C
Fig. 2.11 BamHI digested Boostervac (lane A), RI127 (lane 
B) and Epivac (lane C) CAV-1. The 0.4kb Bam D fragment 
demonstrated by wild-type is no longer present in the 
vaccine strains. Hpall digested pUC8 was used as a size 
marker.
D I S C U S S I O N
The distinct DNA cleavage patterns of CAV-1 and CAV-2 
reported here are consistent with the published findings 
of several authors (Hamelin et al, 1984; Assaf et al, 
1983? Darai et alf 1985; Hamelin et al, 1986; Macartney 
et al, 1988).
Both the present isolate, Glasgow CAV-2, and that of 
Hamelin et al (1986) show a similar Hpall polymorphism. 
However, the two isolates are not identical, evinced by a 
difference in digestion with BamHI. The difference 
between the restriction patterns of the enteric isolate of 
Hamelin et al and the prototypic Toronto A2 6/61 strain led 
that group to postulate that "relatively small changes in 
the original CAV-2 DNA sequence allowed the virus to 
replicate at an unusual site in the dog". While it is 
unlikely that the variation in the Hpall digestion 
patterns between the various strains of CAV-2 is
responsible for the ability of the virus to replicate
enterically, it is likely that the Hpall variation is
indicative of other, more significant, genomic
alterations.
The cleavage patterns of all the CAV-2 strains are 
essentially the same. From the published data on the 
restriction enzyme analysis of the prototypic Manhattan 
and Toronto strains, there is no evidence to suggest that 
they are different strains of CAV-2. No method has been
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found with which to differentiate between Manhattan and 
Toronto, either by immunological or molecular techniques. 
All the available evidence points to the fact that they 
are simply different isolates of the same strain of CAV-2.
Minor differences are apparent, however, when the wild- 
type Glasgow isolate and the vaccine strains are compared 
to each other and to the prototypic strains. The termini 
of each.vaccine strain are increased in size with regard 
to the wild-type Glasgow isolate and the two prototypic 
strains. This increase cannot simply be due to strain 
variation as all the vaccine strains are derived from the 
Manhattan or the Toronto A2 6/61 prototype isolates. As 
stated, minor differences were observed in the Hpall 
restriction profiles of Glasgow and the two prototype 
isolates but no large increase or variation in the size of 
the terminal fragments can be seen. Thus it must be 
concluded that the terminal variation is not strain 
dependent but has occurred via some other route.
Similarly, the CAV-1 vaccines exhibit terminal variation 
when compared to the wild-type reference strain although 
none showed variation as marked as that of Vaxitas CAV-2 
compared to wild-type CAV-2. Liu et al (1988) described 
viable isolates with aberrant genomes from a CAV-1 vaccine 
strain (CCL, Conaught Labs.). The genome length of the 
viable isolates was found to be 480bp shorter than wild- 
type CAV-1. The 480bp deletion, from the information and
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restriction enzyme map given in the paper, would appear to 
be in the same region as the deletion in the CAV-1 vaccine 
strains described here, i.e. BamHI D is no longer apparent 
within the vaccine strain genome. Liu et al speculate 
that this deletion, 83-91m.u., is situated in E3 and is 
directly involved in the attenuation of the virus, thus 
implying that E3 is responsible for virulence. The 
vaccine strain was found to still display the 480bp 
deletion following several passage in dogs.
However, their assumption that the deletion is based in E3 
was solely due to the fact that Tsukiyama et al (1988) 
reported that the left-hand terminal region of the 
canine adenoviruses demonstrated transforming ability; 
presumed due to the presence of Ela at this end of the 
genome; and that by alignment of the CAV-1 genome with the 
human adenoviruses, the deletion occurs in E3. No 
analysis of the CAV-1 vaccine strain genome was carried 
out to confirm this speculative position of the deletion.
The most significant alteration in restriction enzyme 
profile among the canine adenoviruses examined was however 
displayed by Vaxitas CAV-2. Therefore, it was selected 
for further analysis and the construction of a physical 
map of the virus genome.
Considerable difficulty was experienced in cloning the 
terminal fragments of both Vaxitas and Glasgow. Several 
methods were attempted repeatedly without success.
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Presumably, this was due to an inability to remove all of
the terminal protein from the genome even with extensive
Proteinase K, NaOH or S nuclease treatment. Finally,
1
only by using vast amounts of viral DNA were the terminal 
clones obtained. However, it is not known whether the S
1
treatment was effective or if a few genomes within the
vast amount used were simply derelict of the TP.
Similar numbers of terminal clones were obtained with and
without S treatment, except for the Sail B clone from 
1
Vaxitas where only one clone was ever obtained.
Alternatively, residual protein may have been present at 
the time of ligation of the terminal fragments to the 
vector. It is feasible that the remaining protein was 
then removed following ligation and transformation into E. 
coli by DNA repair. Finally however, all four terminal 
clones were obtained and confirmed by restriction enzyme 
analysis and hybridisation.
Unfortunately, the only Sail B clone of Vaxitas, which 
exhibits considerable heterogeneity in the size of this 
fragment, obtained did not contain the 2.0kb insertion of 
the dominant species but instead contained approximately 
l.Okb of additional DNA as compared to wild-type. 
Repeated attempts to secure a clone of the larger Sail B 
fragment also failed and it was therefore necessary to 
confine further studies of this area to the clone already 
obtained. It should be noted however that the clone
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hybridised strongly to all sizes of Sail B exhibited by 
Vaxitas and contained all known restriction enzyme sites 
belonging to the larger species. Thus the only difference 
between the heterogeneously sized Sail B fragments appears 
to be restricted to the size of the additional DNA 
present. Plaque purification of Vaxitas was also
impossible at this time as no cell line could be located 
which would allow plaque formation by this virus. 
Attempted purification by high-dilution methods resulted 
in the normal heterogeneic population by the DNA analysis 
stage.
The cleavage maps of Vaxitas, which was originally 
derived from the Manhattan strain, and Glasgow are 
essentially the same. The differences which do exist 
between Vaxitas and the field isolate, i.e. the 
additional DNA sequences near the genome termini and a 
small deletion at around 90 m.u., have probably come 
about as a result of continuous passage in tissue 
culture. Variation in the genomic termini of human AdV, 
consisting of either multiple repeats of viral DNA 
sequences or the insertion of mammalian DNA into the 
viral genome, have been described.
Larsen and Tibbetts (1985) and Larsen et al (1986) 
described variant species within Ad3 containing both 
insertions and deletions within the ITR. Their initial 
studies examined only high multiplicity passage (HMP)
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virus but upon further examination it was found that even
parental low level passage Ad3 contained some variants at
low levels. Therefore it was maintained that the
variation was not due to HMP but may be due to serial
passage in tissue culture. All the variant species
examined contained multiple tandem repeats of HeLa cell
DNA with no relevant homology to the viral DNA. However,
they found that insertions in the left-hand terminal (LHT)
rendered Ela defective and the resultant virus was only
competent for growth in 293 cells which constitutively
express Ela. Brusca and Chinnadurai (1983) described Ad2
mutants, which were stable and viable, containing inserts
of up to lllObp at the right-hand terminal (RHT) but, as
with Ad3, those containing insertions or deletions at the
LHT were defective for Ela expression and were viable only
in 293 cells. This is a significant difference between
the terminal insertions of Ad3/Ad2 and CAV-2 as, although
Vaxitas is non-permissive in MDCK cells but only in mink
fibroblasts and vice versa for Glasgow, there is no
evidence to suggest that the Vaxitas Ela is not
functional. Both Glasgow and Vaxitas replicate extremely
well within their respective cell lines yielding titres of 
7 8
10 -10 pfu/ml consistently. In addition, although the 
size of the insertions or duplications at the LHT of the 
other vaccine strains, both CAV-1 and CAV-2, are much 
reduced compared to Vaxitas, they are fully competent for 
growth in MDCK cells although they do not yield such high 
titres as wild-type virus. This is however probably 
associated with the attenuation process. Little is known
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of the conditions under which the vaccine strains were 
attenuated except that Vaxitas was attenuated in mink 
fibroblasts and the CAV-1 vaccines in pig kidney cells 
i.e. "foreign" cell lines, a process which would certainly 
reguire initial passage of the virus at high multiplicity. 
It is therefore conceivable that the additional DNA 
sequences in CAV have arisen by a similar mechanism to 
those in human AdVs.
Hammarskjold and Winberg (1980) reported that a DNA 
sequence located between 290 and 390bp from the LHT of 
Adl6 contained recognition signals for encapsidation of 
the viral DNA. The location was determined by analysing a 
series of spontaneous mutants of Adl6 which arose during 
serial passage in HeLa cells and carried duplications of 
2 00-500bp of left terminal sequences at the right end of 
the genome. A duplication of about 390bp sequences from 
the left end at the right end enabled the subgenomic viral 
DNAs containing both molecular ends to be encapsidated. 
However, the incomplete virus particles containing the 
left end sequences at the right end did not promote 
encapsidation of the RHT sequences.
Serial passage of Adl2 in Vero cells '(Werner and zur 
Hausen, 1978) resulted in insertions of 190-280bp at the 
RHT and deletions of 70bp at the left end of the genome. 
Similar alterations were observed when the virus was 
serially passaged in other, normally non-permissive, cell
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lines. Serial passage resulted in the generation of host 
range mutants with duplications of the ITR and its 
adjacent sequences from the LHT at the RHT. Similarly, 
Schwartz et al (1982) reported that after serial passage 
of Adl2, in cells of the human melanoma cell line, 
variants with enhanced growth properties were isolated 
which carried additional sequences of regularly increasing 
size at the right end of the genome. Sequence analysis of 
these variants indicated that these extra sequences were 
of viral origin. They originated from either the extreme 
right or left ends of the genome, consisting of the ITR 
and different segments of the adjacent unique sequences.
Equine AdV (EAdV) DNA prepared from infected bovine kidney 
cells (MDBK) was found to contain additional sequences of. 
100-700bp at the LHT (Ishiyama et al# 1986). These
aberrant viral genomes were produced even after the first 
passage of the wild-type EAdV in MDBK cells and their 
relative amounts did not significantly change during 
serial passage. One viral DNA contained a duplication of 
the ITR and another contained 270bp of additional 
sequences derived from the right terminal region added to 
the left terminal ITR. While the former DNA was packaged 
into virions the latter was not. This was presumed to be 
due to the alteration of the distance from the LHT to the 
DNA packaging signal. It is interesting to note however, 
that these aberrant viral genomes were only produced in 
MDBK cells and not in equine cells in which the virus 
grows extremely well and produces wild-type genomes.
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Reiterated DNA sequences have been found in a number of
different viruses. Moss et al (1981) described the
presence of a set of 13-17 tandem 70bp repeats near both 
ends of the genome of Vaccinia virus, the evolution of 
which appeared to be mediated by recombinational events. 
Analysis of virulent and vaccine strains of bovine herpes 
virus type 1 (BHV-1) revealed a 14bp sequence at the left 
end of the genome repeated between 8 and 38 times 
(Hammerschmidt et alf 1986).
Illegitimate recombination and aberrant replication have 
been proposed as mechanisms by which reiterated DNA
sequences arise (Smith, 1976). Subsequent homologous
recombination could increase the number of copies of the 
repeated sequence. Selection of variant genomes would be 
based on replication and encapsidation efficiency. It is 
interesting that the repeated sequences in BHV-1, the 
human and equine AdVs and possibly CAV are in the regions 
of the genome associated with viral DNA replication. 
Furthermore, the growth characteristics of the CAV vaccine 
strains, except Vaxitas, suggests that DNA replication is 
impaired to a limited degree.
Further work was then undertaken to define the nature and 
location of the additional DNA sequences within the 
vaccine strains and their effect, if any, on viral DNA 
replication.
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C H A P T E R  3
Sequence Analysis of the Glasgow CAV-2 ITR and the 
Additional DNA Sequences Present in the CAV Vaccine
Strains
89
I N T R O D U C T I O N
The physical maps of CAV-1 and CAV-2 described in the 
previous chapter indicate that the heterogeneity in all 
the vaccine strains is confined to the terminal regions. 
The exact point of insertion/duplication, however, remains 
unclear. The possibilities are that the variation is
confined to the ITR or that they occur directly before or
within the Ela (LHT) and E4 (RHT) genes. AdV variants 
have never been described with additional DNA sequences 
within a functional gene that are still competent for 
normal replication without helper viruses. It is 
therefore unlikely that the additional sequences lie 
directly within El or E4 although their function may be
altered in some way, either suppressed or enhanced.
Sira et al (1987) reported that the ITR of a vaccine
strain of CAV-1 [Connaught Laboratories Ltd., CAV-1 (CCL)]
contained multiple reiterations of a 40bp sequence. A
range of terminal clones were isolated that contained
varying numbers of this repeat, with a minimum of 1 to a
maximum of 7. The repeat contained the sequence
AGG(N) GCCTA (nucleotides 27-39) which closely resembles 
4the consensus sequence of the human AdV NFI binding site
(TG(N) GCCAA: nucleotides 25-38). The virus therefore
6-7
appears to have reiterated copies of an essential part of 
the AdV origin of DNA replication. It is possible that 
the CAV vaccine strains presently under examination may 
reveal a similar structure. The human AdVs, Adl6 and Adl2,
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also exhibited repeats of the ITR, and adjacent sequences 
(reviewed in chapter 2), although the repeats contained 
the whole ITR and not small fractions of it as in the CAV- 
1 strain reported by Sira et al (1987).
The final alternative, from all variation found so far in 
AdV, is that the additional sequences are cellular in 
origin as with the Ad3 variants (reviewed in chapter 2).
This chapter therefore deals with the attempted 
localisation of the additional sequences within the 
vaccine strains by means of restriction enzyme analysis 
and nucleotide sequencing. Sequence analysis was carried 
out to show any homology to known sequences, either viral 
or cellular. In addition, due to repeats of the ITR, 
either whole or partial, being the most common reported 
phenomenon to explain additional terminal sequences within 
AdV genomes, it was necessary to define the DNA sequence 
of the Glasgow CAV-2 ITR. This would allow direct 
comparison of a wild-type ITR and the additional sequences 
within the vaccine strains.
Kavak CAV-2 was discarded from future analysis upon 
discovery that it was produced by Wellcome for Duphar and 
was identical to Epivac CAV-2. All DNA sequence analysis 
was carried out on an IBM PC using the Beckman Microgenie 
DNA Sequence Analysis Package.
91
M A T E R I A L S  A N D  M E T H O D S
Extraction of DNA from Acrarose Gels
The required DNA bands, from restriction enzyme digested
DNA run on agarose gels, were cut out from the gel using a
sterile scalpel. The fragment of agarose was then placed
o
in a sterile microfuge tube and left at -20 C until frozen 
(approximately 30 minutes). The fragment was then thawed
and placed in the column of a Spin-x tube (NBL), spun in a
bench-top microfuge for 15 minutes after which the DNA in 
TBE had spun through the filter and the agarose was 
retained by it.
The DNA solution was then extracted with an equal volume
of phenol (2x) and chloroform (2x) and finally ethanol
precipitated. After pelleting, washing and drying, the
o
DNA was resuspended in TE and stored at -20 C until 
required.
Electroelution of DNA From Polyacrylamide Gels 
Polyacrylamide gels were prepared and run as described 
previously (chapter 2, materials and methods).
The required DNA bands were cut out from the gels using a 
sterile scalpel. The slice of acrylamide was then placed 
in a 5cm length of dialysis tubing which had previously 
been boiled in 0.5xTBE. The dialysis tubing was then 
clamped at one end, 0.5ml of 0.5xTBE placed into the 
tubing and the other end was also clamped after ensuring
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that all air was removed.
The tubing was then placed in a horizontal gel tank, 
filled with 0.5xTBE, parallel to the electrodes. A 
constant potential difference of 120V was applied across 
the gel tank for 2 hours. The current was then reversed 
3x for 5 minutes each time to ensure that no DNA was 
attached to the tubing which was then removed from the 
tank and the buffer removed from within it to a sterile 
tube. The slice of acrylamide was discarded after a 
visual check on a transilluminator that all the DNA had 
been extracted.
The buffer containing the DNA was extracted with an equal
volume of phenol (2x) followed by chloroform (2x) and the
DNA was recovered by ethanol precipitation. The DNA
pellet was washed 2x in 70% EtOH, dried, resuspended in TE
o
and stored at -20 C until required.
Cloning Of Hpall Fragments In Bluescript
Bluescript vector was digested with Clal, extracted once
with phenol, twice with chloroform and the DNA was
recovered by ethanol precipitation. After washing twice
with 70% EtOH and drying, the DNA pellet was resuspended
o
in TE and stored at -20 C.
Viral DNA was initially digested with Sail and the entire 
reaction was loaded onto an agarose gel. The right-hand
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terminal (RHT) Sail fragments were then extracted from the 
agarose using Spin-x columns as previously described. 
Each of the Sail fragments were then digested with Hpall 
and loaded onto either a polyacrylamide gel (Epivac, 
Nobivac, Boostervac) ~ or an agarose gel (Vaxitas). The 
required Hpall fragment was removed from the relevant gel 
type, after electrophoresis and staining, and the DNA 
extracted as previously described.
The DNA samples were redissolved in TE pH7.5 and mixed in
the ratio 3:1, CAV Hpall fragment:ClaI cut Bluescript.
The mixture was then incubated with T ligase as described
4
previously. The ligated DNA was transformed into E.coli 
DS941. Recombinants were selected and screened as 
described previously.
Transfer Of DNA In Solution To Nitro-cellulose Paper (Dot- 
blots)
A small sheet of nitro-cellulose was marked into 1cm 
squares and 2pl of recombinant plasmid DNA (0.5mg/ml) was 
placed onto the centre of each square. The nitro­
cellulose was then allowed to air dry. Next, the 
nitro-cellulose was floated, DNA side up, on a solution of 
1.5M NaCl/ 0.5M NaOH for two minutes to denature the DNA. 
This was followed by floating the squares on a 
neutralising solution (1.5M NaCl/ 1M Tris pH8.0) for a
further two minutes. The nitro-cellulose was then air
o
dried and baked at 80 C for two hours. The filters were 
then prehybridised and hybridised as described previously.
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Empty Bluescript vector was used as a control.
Double Stranded Dideoxv Chain Termination Sequencing 
Dideoxy chain termination sequencing was carried out on 
double stranded DNA after the method of Sanger et al 
(1977). All stock solutions and buffers were prepared as 
described in table 3.1.
Radioactive Label
Deoxyadenosine 5-[alpha-35S]thiotriphosphate triethyl- 
ammonium salt (dATP, Sp isomer, Amersham) was used as the 
radioactive label throughout. The 35S-dATP was purchased 
at a specific activity of 1200 curies/mmol and a 
concentration of lOmCi/ml. The label was stored in 12pl 
aliquots in vapour phase liquid nitrogen.
Primers
The primers SK, KS, T3 and T7 were purchased from NBL and 
diluted to 2.5ng/jil. Additional primers were synthesised 
within the laboratory on an Applied Biosystems 381A DNA 
synthesiser. Laboratory synthesised primers were 
initially used at a concentration of 5ng/|il but an 
increase of this amount was often necessary and the final 
concentration used in each reaction is stated with each 
individual sequence if other than 5ng/jil.
All primers were aliquoted and stored at -20°C until 
required.
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Denaturation
To 2pg of DNA was added 4jil 1M NaOH/ 1M EDTA. Sterile
dH 0 was added to 20ul and the solution was incubated at 
2 ' 
room temperature for 5 minutes. 2ul of 2M NH Ac (pH5.4)
' 4
was then added and the mixture placed on ice immediately.
2.5 volumes (55ul) of ethanol was added and the solution 
o
placed at -70 C for 15 minutes. The ethanol precipitation 
was centrifuged in a bench top microfuge for 10 minutes 
and the pellet washed (70% EtOH) and dried. The DNA was 
resuspended in 8.5jil TE pH8.0 and kept on ice.
Annealing
To the 8. 5jil of DNA in TE was added 2^ il of primer, 1.5jj1
IOx annealing buffer and 3ul S-dATP. The mixture was
o
incubated at 37 C for 15 minutes when Ijil of Klenow 
(lu/jil, Pharmacia) was added and the solution carefully 
mixed. This now constituted the template/primer/label/ 
enzyme mix (T/P/L/E mix).
Sequencing Reaction
To 3jil of the T/P/L/E mix was added 2)il of the A, C, G or
0
T mix. The four reactions were then incubated at 42 C for
20 minutes after which 2jil of chase solution was added.
o
The reactions were then incubated at 42 C for a further 15
minutes. Finally 4ul of formamide/dye mix was added and
o
the samples heated to 95 C for 3 minutes prior to loading 
onto the sequencing gel. 5^1 of each reaction was loaded 
onto the gel for the first long run and the remainder of
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the reaction loaded, after reheating, for the short run.
Polyacrylamide Sequencing Gel
All solutions are as stated in table 3.2. Gel sets were 
purchased commercially and used as per manufacturer's 
instructions (Bio-Rad).
After the gels had been plugged and poured, with the well
forming comb inserted, they were left to set at room
temperature. All gels were then pre-run, in lxTBE at a
constant current of 3 0mA, for a minimum of 1 hour ensuring
that the temperature of the gel and buffer had reached 
o
50 C. The gel was then loaded and the current altered to
approximately 25mA, to retain a constant temperature of 
o
50 C, and the gel run until the bromophenol blue band 
reached the foot of the gel plates. If a long and short 
run were required, the remaining half of the sequencing 
reaction was then loaded and the gel run until the 
bromophenol blue band from the second loading reached the 
bottom.
All gels were fixed in 10% methanol/10% acetic acid for 15 
minutes before being dried onto Whatman 3MM paper and 
subjected to autoradiography overnight.
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T A B L E  3.1
Double Stranded DNA Sequencing 
Stock Solutions and Buffers
1) DeoxyNTP Stock Solutions
Stock solutions of lOmM dATP, lOmM dCTP, lOmM dGTP and
o
lOmM dTTP were prepared in dH O and stored at -20 C.
2
2) dNTP Working Solutions
Stock solutions of dATP, dCTP, dGTP and dTTP diluted 1:20
in dH 0 to give 0.5mM working solutions.
2
3) dNTP Mixes
35
(for use with k - S dATP)
0.5mM dCTP 
0.5mM dGTP 
0.5mM dTTP 
TE pHS.0
4) DideoxyNTP Stock Solutions
Stock solutions of lOmM ddATP, lOmM ddCTP, lOmM ddGTP and
o
lOmM ddTTP were prepared in dH 0 and stored at -20 C until
2
required.
o
A
o
c
o
G
O
T
20pl ipl 20pl 20pl
20pl 20jll iPi 20pl
20pl 2 0pl 20^ ll lya
'l A.. ~l £. U^ J. A Aiilz, \jy.ix onni o nn 1— J—
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T A B L E  3.1 (continued)
5) ddNTP Working Solutions
lOmM
ddNTP
ddATP
ddCTP
ddGTP
ddTTP
Dilution
in dH O 
2
3:200
1:500
1:200
1:20
Final
Concentration 
0.15mM 
0.02mM 
0.05mM 
0.50mM
6) dNTP/ddNTP Mixes
A mix 
C mix 
G mix 
T mix
25pl
o
A
o
+ 25pl 0.15mM ddATP
25pl C
o
+ 25pl 0.02mM ddCTP
25pl G + 25pl 0.05mM ddGTP
25pl
VJ
T + 25pl 0.50mM ddTTP
7) Chase Solution
lOmM dATP
lOmM dCTP
lOmM.dGTP
lOmM dTTP
dH O 
2
8) lOx Annealing Buffer
80pl
lOOmM Tris.Cl pH8.0 
50mM MgCl
0. 5mM
5pl > dNTP
mix
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T A B L E  3.1 (continued)
9) Formamide/Dye Mix
100ml formamide 
tm
5g Amberlite Mixed Bed Resin
stir gently for 
3 0 min then filter
Add: - O.lg Xylene cyanol FF 
O.lg Bromophenol Blue 
4ml 500mM EDTA 
Store at room temperature
10) Gel Fixing Solution
Methanol
Acetic Acid
dH O 
2
200ml 
200ml 
to 2L
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T A B L E  3.2
Sequencing Gel Stocks and Solutions
1) Stock Acrylamide
Acrylamide
methylene-bis-acrylamide
dH20
2) Urea Mix
Stock acrylamide
lOx TBE
Urea
dH20
76g
4g
to 2 00ml
3 0ml 
20ml 
84g
to 200ml
3) Gel Plug
Urea mix 
25% APS 
TEMED
4) Sequencing Gel
Urea mix 
25% APS 
TEMED
10ml 
7 Opl 
50pl
50ml
5 Opl
5 Opl
5) 25% APS
Ammonium persulphate
dH20
0.25g 
to 1ml
Divided into 12Opl alliquots and stored at -20°C
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R E S U L T S
Restriction Enzyme Analysis of the Sail B Fragments from 
Vaxitas and Glasgow
The two terminal Sail B clones Gil (Glasgow) and V27 
(Vaxitas) were further analysed by restriction 
endonuclease digestion in order to localise the site of 
insertion of the l.Okb fragment in Vaxitas. A total of 16 
enzymes were initially investigated as shown in figure 
3.1. By utilising the known sites of these enzymes in the 
Bluescript vector (see Fig. 2.4) it was possible to 
construct a putative restriction endonuclease map of the 
Sail B fragments (Fig. 3.2). The site of insertion of the 
l.Okb fragment in Vaxitas was now localised between the 
Smal site, constant in both Vaxitas and Glasgow, 0.2kb 
from the right-hand terminal (RHT) and the PvuII site 
l.lkb from the RHT in Glasgow and 2.2kb in Vaxitas.
Hpall Analysis of the Right-hand Termini of CAV-2 and 
CAV-1
Right-hand terminal Sail fragments (Sail B in CAV-2 ? Sail 
C in CAV-1) were electroeluted from agarose for all 
vaccine strains and the wild-type strains,Glasgow CAV-2 
and RI 127 CAV-1. The most dominant species within each 
vaccine of the Sail B (CAV-2) and Sail C (CAV-1) were 
selected. Boostervac CAV-1 exhibits two equally dominant 
species therefore both Boostervac Sail C fragments were 
taken and examined individually. Hpall digestion of all 
strains is shown in figure 3.3 on 5% acrylamide. Vaxitas
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and Glasgow Sail B fragments digested with Hpall are also 
shown on 0.8% agarose to further demonstrate the deletion 
in PstI D (fig. 3.3).
All inserts could now be clearly differentiated from wild- 
type fragments. Every vaccine strain examined appeared to 
exhibit an insert contained within a single Hpall fragment 
either by the appearance of a unique fragment (CAV-2 
vaccines) or enlargement of an existing fragment (CAV-1 
vaccines).
CAV-2
Hpall digestion of the wild-type Sail B fragment from 
Glasgow CAV-2 (Fig. 3.3) appears to comprise of four 
distinct fragments on acrylamide: 500, 180, 170 and 80
base pairs (bp): and one on agarose: 2.4kb. Epivac has
an additional fragment at approximately 160bp, Nobivac at 
approximately 23 0bp and both appear to retain all other 
fragments associated with wild-type. Conversely Vaxitas no 
longer contains the 80bp fragment and three additional 
fragments can now be seen at 60bp, 190bp and 600bp. In 
addition, the deletion associated with Vaxitas in PstI D, 
resulting in the loss of the 0.6kb Kpnl fragment, is now 
clearly exhibited on the agarose gel with the wild-type 
2.4kb fragment being reduced to 2.Okb in size.
CAV-1
Hpall digestion of the wild-type RI 127 isolate appears to
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result in three distinct fragments on acrylamide: 44 0, 180 
and 170bp: and 1 on agarose: 2.0kb. Boostervac Sail C
exhibits four fragments on acrylamide when digested with 
Hpall, 440bp,350bp, 240bp and 180bp. The 170bp fragment 
of wild-type is no longer apparent. Further analysis 
showed that the 350bp fragment was associated with the 
larger of the two Sail C fragments and the 24 0bp with the 
smaller of the two. Again the 170bp fragment is not 
present in the Hpall digest of the Epivac CAV-1 Sail C 
fragment but an additional fragment is present at 330bp 
with the 440bp and 180bp fragments still constant. The 
2.0kb wild-type fragment remains constant for all vaccine 
strains showing that the 0.6kb deletion does not extend 
into Sail C.
Molecular Cloning of the Variant Hpall Fragments 
Further investigation into the nature of the additional 
DNA found within the terminal regions of the vaccine 
strains necessitated that all the varying Hpall fragments 
of each vaccine strain be cloned. The enlarged (CAV-1) or 
unique (CAV-2) Hpall fragments from Boostervac CAV-1,
ITaU  T r'i n  O * T7 *"» J  TT1— ~ -  n iT 7  —>  ----------------- - 1 ------------------3   1-------j - l  -  T
X V U 1- .  \ ~ r \ v  —  £. d i l l *  v a o  V  £. W C I t J  U  l U l l C U  X 11U U > U l l t ;  t - L Q i .
site of the plasmid vector Bluescript. Boostervac was
chosen as the sole CAV-1 vaccine strain examined due to 
its uniqueness in having two distinct species.
The size of the cloned Hpall fragments were confirmed by 
restriction endonuclease digestion, visualised by
acrylamide gel electrophoresis alongside a Hpall digest of
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the relevant RHT Sail fragment. As an additional 
confirmation all clones were checked by molecular 
hybridisation against each vaccine strain i.e. Boostervac 
clones BT1 (350bp) and BL2 (240bp) were hybridised to 32P 
labelled Boostervac DNA; the Nobivac clone (N3) to Nobivac 
DNA? the Epivac clone (E4) to Epivac DNA etc. All 
hybridisations were carried out using the dot-blot method.
Both Vaxitas Sail B Hpall fragments at 600bp and 190bp 
were electroeluted and cloned into the Clal site of 
Bluescript also. Unfortunately a sufficiently large or 
clean enough yield of the 60bp fragment was not obtained 
to subclone. Analysis of this small fragment will be 
discussed later. The Vaxitas clones were confirmed as 
above. An example of the dot-blots for various clones is 
given in figure 3.4.
DNA Sequence and Analysis of the Glasgow ITR 
As all extra DNA associated with the vaccine strains 
appeared to be terminally associated it was necessary to 
obtain the DNA sequence of the Glasgow CAV-2 inverted 
terminal repeat from the Sail B and EcoRI terminal clones. 
This could then be used to compare to the vaccine inserts 
to confirm or eliminate direct or indirect repeats of this 
region. Both clones were sequenced from the termini using 
SK and T7 primers. The consensus sequence of the 
inverted terminal repeat is presented in figure 3.5. 
Sequence analysis (figure 3.6) demonstrated all known
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conserved AdV sequences exhibited by the ITR. The CAV-2 
ITR was demonstrated to be 82.5% homologous to the CAV-1 
ITR over 63bp. Three base changes were found to occur 
however between the 3' and 5' ITRs. Repeated sequence 
analysis confirmed that these base changes were real and 
not reading errors. However other, aberrant, clones of the 
EcoRI LHT fragment were also obtained. These consisted of 
minor variations, usually single base changes, in the ITR. 
One clone consisted of an additional 60bp outwith the ITR 
but also replacing the initial lObp, CATCATCAAT, 
demonstrated by the majority of the LHT clones and all RHT 
clones obtained (data not shown). These additional 
sequences were not included in the sequence analysis and 
comparisons with CAV-1 as they are believed to be the 
result of cloning aberrant genome termini.
DNA Sequence and Analysis of Vaccine Inserts 
The DNA sequence of the multiple cloning site and primers 
of the plasmid vector Bluescript are shown in figure 2.4. 
The figures associated with each vaccine insert are 
described below and a representative sequencing gel of 
each clone is shown as an example.
It should be noted that the orientation of these fragments 
within the Bluescript vector is not necessarily their 
orientation with respect to the virus genome. This aspect 
of the insertions will be resolved later.
Boostervac CAV-1
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BT1 (349bp): The larger of the Boostervac variant Hpall
fragments was sequenced using T3 and T7 primers (Fig.3.7). 
The consensus sequence is shown in Fig. 3.8. The sequence 
analysis (Fig. 3.9) revealed a 70% similarity over 184bp 
in the region of the HuAd2 (human adenovirus type 2) E2 
promoter and pVIII regions. When compared to the DNA 
sequence of Glasgow CAV-2 E2/E3 region (kindly provided by 
Mr. M. Macdonald, University of Glasgow) homology of >90% 
was revealed from bpl to bp247 of BT1.
BL2 (24 9bp) ; the smaller of the two variant Hpall 
Boostervac fragments was sequenced using the KS primer 
(Fig. 3.7). The DNA sequence is shown in figure 3.10. 
Sequence analysis (Fig. 3.11) demonstrated >90% homology 
over 176bp to the CAV-1 El region ( El sequence courtesy 
of Dr. A. McClory, University of Glasgow).
Nobivac CAV-2
N3 f231bp): The unique 231bp Hpall fragment was sequenced 
using T3 and T7 primers (Fig. 3.12). The DNA sequence is 
shown in figure 3.13. The sequence analysis (Fig. 3.14) 
revealed N3 was 97% homologous to the right-hand terminus 
of Glasgow CAV-2 over 167 bases. This homology extended 
from bplO of the ITR sequence to the end of the known 
Glasgow terminal sequences. It is therefore feasible that 
the homology will be continued further than the end of the 
ITR. This will be investigated in chapter 4.
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Epivac CAV-2
E4 f!64bp); the unique 164bp Hpall fragment of Epivac was 
sequenced using T3 primer (Fig. 3.12). The DNA sequence is 
shown in figure 3.15. Sequence analysis only revealed 
short regions of homology to other known AdV sequences 
(Fig. 3.16): 83.3% over 24bp to the Ad5 E3 region and
89.5% over 19bp to the Tupaia AdV Elb region. The two 
regions of homology however, are probably too short to be 
of any significance. However, homology of 67.1% over 79bp 
was also displayed against X. laevis mitochondrial DNA.
Vaxitas CAV-2
Vaxitas (193bp): the unique 193bp Hpall fragment of
Vaxitas was sequenced using the T7 and T3 primers (Fig. 
3.17). The DNA sequence is shown in Fig. 3.18. Sequence 
analysis revealed 98.9% homology over 190bp to the Ela 
region of CAV-2 and 70.9% over 172bp to the Ela region of 
CAV-1 (Fig. 3.20). In addition, several small regions of 
human AdV Ela's were found to display short regions of 
homology.
Vaxitas (631bp): the unique 6 31bp Hpall fragment of
Vaxitas was sequenced using the primers T7 and T3. The 
DNA sequence is shown in Fig. 3.19. Sequence analysis 
revealed 98.1% homology to the Ela region of CAV-2 and 
an average of 74.2% to the Ela region of CAV-1 (figure 
3.20). This is consistent with the results found from the 
sequence of the 193bp insert.
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Ficr. 3.1 Restriction enzyme analysis of the Glasgow 
CAV-2 (G) and Vaxitas CAV-2 (V) Sail B fragments in 
Sail/Smal Bluescript. The terminal clones were 
digested with
Gel A:- Snol (1), Xbal (2), SspI (3), Alul (4), NheT 
(5), AccI (6), Aval (7), Ndel (8), Sstll (9).
Gel B:- Xhol (10), Xcyl (11), Sau3A (12), Hindlll 
(13), PvuII (14), SphI (15), Haell (16). Hindlll 
digested DNA fragments were used as m.w. markers.
Restriction Enzyme Analysis of the Glasgow and Vaxitas
CAV-2 Sail B Fragments
G V G V G V G V G V G V  G V G V G  V
■
Fig. 3.2 Schematic physical map of the terminal Sail B clones of 
Glasgow and Vaxitas CAV-2. The Smal sites represent the terminals 
of the clones (inserted into Sall/Smal cut Bluescript as 
Sall/blunt fragments). Position of sites based on fragment size 
generated as indicated on agarose gels. Restriction enzyme sites 
marked in close proximity to each other e.g. Aval/Hpall/Sstll 
near terminal Smal, are not necessarily in the order indicated as
such precise mapping is not possible by restriction enzyme
analysis alone. The unique Nhel site of Vaxitas is thought to be 
positioned near the Kpnl site and that the second Nhel site
present in Glasgow has been lost in Vaxitas along with the second
Kpnl site.
RE With No Sites in Sail B Clones:-
Xbal
Ndel
Xhol
Xcyl
RE With A Single Site in Sail B Clones
AccI
Aval
SphI (position unknown)
Nhel (Vaxitas only)
F I G U R E  3.2
Schematic Restriction Enzyme Hap of the Glasgow and
Vaxitas Sail B Fragments
Genome Terminus Smal
Aval 
H a e ll/S s tll —
PvuII—
G
L
A
S
G
0
W
SstH- 
S n o l/H in d lll - 
PstI" 
AccI" 
P vu II-
H indlll* 
N he l? /K p n l..
Sspl-
K p m ^ j
BLUESCRIPT
Haell
H ind lll
Sail
Aval" 
 HafeH/SstH —I
Smal-
1.1 kb
2.ekb
PvuII— 1
S stll -  
S n o l/H in d lll-  
P s tl-  
A cc l- 
P vu II-
Genome Terminus
SspI—
KpnI/SspI —  
Haell
H ae ll—
H in d lll—  
Sail-
v
A
X
1
T
A
S
BLUESCRIPT
Fig. 3.4 Hpall clones in Bluescript were spotted onto 
nitro-cellulose and probed with 32P-labelled whole 
virus. A representative sample of the results obtained 
during the cloning of the 190bp and the 660bp fragments 
of Vaxitas Sail B are shown.
Spots 1, 2 and 5 show aberrant clones obtained
during the cloning procedure, probably chromosomal or 
fragmented Bluescript. Spots 3 and 4 represent two 
clones of the 190bp fragment and spots 6, 7 and 8,
three isolates of the cloned 600bp fragment. All were 
probed with Vaxitas DNA.
F I G U R E  3.4 
Molecular Hybridisation of CAV DNA to Hpall Clones
B l u e s c r i p t c VaxitasDNA
4 8
F I G U R E  3.5
Glasgow CAV-2 Inverted Terminal Repeat
->t 7 
- ->SK
10 20 30 AO 50 60
CATCATCAAT AATATACAGG ACAAAGAGGT GTGGCTTAAA TTTGGGCGTT GCAAGGGGCG
70 80 90 100 110 120
GGGTCATGGG ACGGTCAGGT TCAGGTCACG CCCTGGTCAG GGTGTTCCCA CGGGAATGTC
130 140 150 160 170 180
CAGTGACGTC AAAGGCGTGG TTTTACGACA GGGCGAGTTC CGCGGACTTT TGGCCGGCGC
190
CCGGGTTTTT GGGCGTT
Fig, 3.5 DNA sequence of the inverted terminal repeat 
(ITR) of Glasgow CAV-2. Sail B and EcoRI C terminal 
clones sequenced using the T7 and SK primers of Bluescript 
as indicated above (->) . The Sail B fragment cloned as a 
Sall/blunt fragment into the Sall/Smal sites of Bluescript 
and the EcoRI C as an EcoRI/blunt into the EcoRI/Smal 
sites of Bluescript thus allowing a known orientation (see 
Fig. 3.8). All Hpall sites within this region are 
underlined. Sequence conserved between species are 
also underlined.
F I G U R E  3.6
Sequence Analysis of the Glasgow CAV-2
Terminal Repeat
t
GLASGOU ITR 
CAV1 (RI 127) ITR
83 AGGTCACGCCCTGGTCAGGGTGTT CCCACGGGAATGTCCAGTGACGTCAAAGGCGTGGT
l l l l l l l  l l l l l  l l l l l l  III l l l l l l l l l l  I III l l l l l l l l l  I III I
55 AGGTCACACCCTGTTCAGGGCGTTTCCCACGGGAAAGACCA TGACGTCAATTGGGTGTT 
TTT 144
III
TTT 116
Matches = 52 Length = 63 Matches/length = 82.5 %
GLASGOW 3'-ITR 
GLASGOW 5'-ITR
1 
1
61 
61
121 
120
181 
180
CATCATCAATAATATACAGGACAAAGAGGTGTGGCTTAAATTTGGGCGTTGCAAGGGGCGG
l l l l l l l l l l  II I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I II I I I I I I I I
CATCATCAATGATGTACAGGACAAAGAGGTGTGGCTTAAATTTGGGCGTTGCAAGGGGCGG
GGTCATGGGACGGTCAGGTTCAGGTCACGCCCTGGTCAGGGTGTTCCCACGGGAATGTCCA
I III I III III III III III I III III III III III III III III III III III III III
GGTCATGGGACGGTCAGGTTC GGTCACGCCCTGGTCAGGGTGTTCCCACGGGAATGTCCA
GTGACGTCAAAGGCGTGGTTTTACGACAGGGCGAGTTCCGCGGACTTTTGGCCGGCGCCCG
III III III III III III III III III III III III III III III III III III III III I
GTGACGTCAAAGGCGTGGTTTTACGACAGGGCGAGTTCCGCGGACTTTTGGCCGGCGCCCG
GGTTTTTGGGCGTT 197
llllllllllllll
GGTTTTTGGGCGTT 196
Inverted
Matches = 194 Length = 197 Matches/length = 98.4%
GLASGOW ITR 
Ad10 ITR
1 CATCATCAATAATATACAGGACAAAG 26
I I I I I I I I I I I I I I I I llllll
1 CTTCATCAATAATATACCCCACAAAG 26
Matches = 22 Length = 26 Matches/length = 84.
GLASGOU ITR 
Ad12 ITR 
Ad18 ITR 
Ad31 ITR 
Ad5 ITR 
Ad10 ITR
CATCATCAATAATATAC
III III III III III I I
CATCATCAATAATATAC
III III III III III I I
CATCATCAATAATATAC
III III III III III I I
CATCATCAATAATATAC
III III III III III I I
CATCATCAATAATATAC
I I II I M I I I I I I I I I
CTTCATCAATAATATAC
Matches/length 
cf. Glasgow ITR
100%
100%
100%
100%
94.1%
Fig. 3.7 Long and short runs of sanger dideoxy
sequencing reactions on the Hpall clones BT1 and BL2
using the primer KS. Lanes 1 and 4 display long and
short runs of BL2 respectively. Lanes 2 and 3, long
and short runs of BT1 respectively.
F I G U R E 3.7
Boostervac CAV-1 Insertions BT1 (600BP) and BL2 (190BP) 
- Using the Bluescnpt Primer KS
1 3 4
F I G U R E  3.8
Boostervac CAV-1 - BT1
KS->
T3->
10 20 30 40 50 60
CGGCGCTAAA CCAATTCATT TGGGTGGAGT AATCCTGGGA GGCGCCTGCA GCATGTCCTG
70 80 90 100 110 120
TTTGCGGTTG GTAGCTCCAT ATATAAGGGG TTGGTATTTC TTTGGACATT GCTCAGTCTG
130 140 150 160 170 180
TGTTGGACTC GAGTCCTTGA CAGTATTTGT TGAGCAAAGC CTCGGCGTCG TTTCGCGTGC
190 200 210 220 230 240
GTAGCAGTTG TTCTTCTGAT TTGTGGTACA GACAGCTTCT CAGAAGGGAT CTGAGGGATC
250 260 270 280 290 300
TGTTTTTTAT TTTTAATGCC GTGGGGCAGC CTCTGCTTTG CTGAAAGATG GCATACATGT
310 320 330 340
TGGAAAAATG CGATTGCGCA GCTGCCTTGT CTGCTGGTTG TCCTCACCG
<-T 7
<-SK
Fig. 3.8 DNA sequence of Boostervac CAV-1 clone BT1, the 
larger of the two variant Hpall fragments contained within 
the vaccine strain. DNA sequence obtained using T3 and T7 
primers of Bluescript ( -> and <- ) as shown above.
F I G U R E  3.9
Sequence Analysis of the Boostervac Insertion BT1
BT1
CAV-2 E2 region
1 CGGCGCTAAACCAATTCATTTGGGTGGAGTAATCCTGGGAGGCGCCTGCAGCATGTCCTG
I II l l l l l l l l l l l l l l l l l l l l l l l l l l  II II Mi l l  I
380 CAGCACTAAACCAATTCATTTGGGTGGAGTAGTCCTGGGAGGCGCCGGCGGCGTGTCCCG
AUG pVIII?
61 TTTGCGGTTGGTAGCTCCATATATAAGGGGTTGGTATTTCTTTGGACATTGCTCAGTCTG
l l l l l l l l l l l l l l l l l l l  l l l l l l l l l l l l l l l l l l l l l l l  l l l l l l l l l l l l l l l l
320 TTTGCGGTTGGTAGCTCCACATATAAGGGGTTGGTATTTCTTTAGACATTGCTCAGTCTG
E2a TATA?
121 TGTTGGACTCGAGTCCTTGACAGTATTTGTTGAGCAAAGCCTCGGCGTCGTTTCGCGTGC
II l l l l l l l l l l l  l l l l l l l l l l l l l l l l l l l  III I I ...
260 TGCCGGACTCGAGTC TTGACAGTATTTGTTGAGCAAAGCTTCGGCGTCGTTTCGCGTGC
181 GTAGCA GTTGTTCTTCTGATTTGTGGTACAGACAGCTTCTCAGAAGGGATCTGAGGGAT
I Mi l  I II I Mi l l  III II III l l l l l l l l l l l  II l l l l l l l l l l l l l l l
201 GCAGCACGCTGCTGCTCTGACTTGTGGTAGAGACAGCTTCTTAGGAGGGATCT GAGGGAT
240 CTGTTTTTTATTTTTAATGCCGTGGGGCAGCCTCTGCTTTGCTGAAAGATGGCATACA T
MINIM MINIMI  MINIUM II11111111111 II 11111111 II I I  I
141 CTGTTTTTTATTTTTAATGCCGTGGGGGAGCCTCTGCTTTGTTGGAAGATGGCGTACAGT
299 GTTGGAAAAATGCGATTGCGCAGCTGCCTTGTCTGCTGGTTGTCCTCACCG 349
11111111111111 l l l l l l l  l l l l l l l l l l l  II I I I I I I I I11II I11
81 GTTGGAAAAATGCGGTTGCGCAGCTGCCTTGTCTGGTGGTTGTCCTCACCG 31
Matches = 321 Length = 351 Matches/length = 91.5%
7883
579130
BT1
Adenovirus type 2, complete genome STRAND L
. 141 CAGTATTTGTTGAGCAAAGCCTCGGCGTCGTTTCGCGTGCGTAGCAGTTGTTCTTCTGAT
MI N I MI  III I MI NI  Mi l l  I l l l l l l l  I II II Mi l l  I
27105 CAGTATTTGCTGAAGAGAGCCTCCGCGTCTTCCAGCGTGCGCCGAAGCTGATCTTCGCTT
I  -kit
Ad2 cap sites fop 72kD mRNA early (E2a)
201 TTGTGGTACAGACAGCTTCTCAGAAGGGATCTGAGGGATCTGTTTTTTATTTTTAATGCC
Mi l l  Mi l l  Mi l l  I Mi l l  I II II I I I I I I I I I I I I I I I I
27045 TTGTGATACAGGCAGCTGCGGGTGAGGGAGCGCAGAGACCTGTTTTTTATTTTCAGCTCT
/ *
donor splice 72kD mRNA (E2a)
261 GTGGGGCAGCCTCTGCTTTGCTGAAAGATGGCATACATGTTGGAAAAA TGCGATTGCGC
II I I I I  Mi l l  II l l l l l l l  III I I I I  I I Mi l l
26985 TGTTCTGGCCCCTGC TTTGTTGAAATATAGCATACAGAGTGGGAAAAATCCTATTTCTA
320 AGCT 323
I I I I
26918 AGCT 26921
Matches = 129 Length = 184 Matches/length = 70.1%
Fig. 3.9 Sequence analysis of the larger of the two 
Boostervac CAV-1 insertion sequences. 70.1% similarity is 
demonstrated to the E2/E3 promoter regions of Ad2 and the 
presumptive E2/E3 promoter region of Glasgow CAV-2. The 
Ad2 E2a TATA is situated at bp27118, ACTCTTAA: 13bp before 
the start of the demonstrated homology. No such sequence 
is demonstrated in either the Boostervac insertion 
sequence or the Glasgow sequence. However the Boostervac 
insertion sequence and the Glasgow sequence demonstrate 
possible E2a TATA's: ACTgTcAA: in the same region as the
Ad2 E2a TATA.
F I G U R E  3.10
Boostervac CAV-1 - BL2
T3
- >
10 20 30 40 50 60
CGGCCCTCCT CTCCTCAGCC TCAATCAAGC TAAAATCTAC CTGCCCTCTA GGCATTTCCA
70 80 90 100 110 120
AAGCATGGTC CCGTTGCAGA GCTCGCGTAA CATACAGGGA ATCTGGAAGC TGCAGATCGT
130 140 150 160 170 . 180
CTAGTCGAAA AGGGGATCGT CGCTGTCCCT CGCTAAGTGC TCTTCTCCGC ACTCTTCCTC
190 200 210 220 230 240
TACAGGACCC TGCCCGTCGA ACAGGACTCT GGAGGTCGTT GATTAGTCGC GCGGCCTGAC
TCAGATCTG
Fig.3.10 DNA sequence of Boostervac CAV-1 BL2 clone, the 
smaller of the two variant Hpall fragments within the 
Sail C fragment of the vaccine strain. DNA sequence 
obtained using the T3 of Bluescript ( -> ) as shown above.
F I G U R E  3.11
Sequence Analysis of the Boostervac Insertion BL2
BL2
CAV1E1 STRAND L
110 CTGCAGATCGTCTAGTCGAAAAGGGGATCGTCGCTGTCCCTCGCTAAGTGCTCTTCTCCG
Mi l l  l l l l l l l l l l l  Mi l l  I II111111 l l l l l l l  III l l l l l l l  III | | | | | I | | |
1853 CTGCAGATCGTCTAGTCGAAAAAGGGATCGTCGCTGTCCCTCGCTAAGTGCTCTTCTCCG 
170 CACTCTTCCTCTAC A GGACCC TGCCCGTCGAACA GGACTCTGG AGGTCGTTGATT
l l l l l l l l l l l l l l  I l l l l l l  l l l l l l l l l l l l l  I I II I I I II I I I I I I II II I I
1793 CACTCTTCCTCTACCACGGACCCCTGCCCCTCGAACACGGACTCTGGGAGGTCGTTGATT 
225 AGTCGCGCGGCCTGACTC AGATCTG 249
I I I I I I  I l l l l l l  II III l l l l l l l
1733 AGTCGCGCGGCCTGACTCCAGATCTG 1708
Matches = 138 Length = 146 Matches/Iength = 94.5%
BL2
CAV2E1 STRAND L
80 AGCTCGCGTAACATACAGGGAATCTGGAAGCTGCAGATCGTCTAGTCGAAAAGGGGATCG
I I I I  II l l l l l l l l l l l l  I II l l l l l l l  II I I I I  I I I I  I II III
2097 AGCTTGCATAACATACAGGGGG CGGGCAGCTGCAACTCATCTACCCGAATAATGGGTCG 
140 TCGCTGTCCCTCGCTAAGTGCTCTTCTCCGCACTCTTCCTCTACAG G ACCC TGCCCG
11111II111 Mi l l  II Mi l l  111111II111111 I I I I I I I  III I
2038 TCGCTGTCCCCTGCTAAAAGCGCTTCTTCGCACTCTTCCTCTTCCGCGGACCCCTGCTCC 
197 TCGAACA GGACTCT GGAGGTCGTTGATTAGTCGCGCGGCCTGACTC AGATCTG 249
I I I I  II III III I II I II I I I I I I I I I I I I I I  III II I Mi l l
1978 TCGAGCACGGAATCTTGGAGGTCGTTGATTAACTG GCGGTCTGGGTCCATATCTG 1924
Matches = 134 Length = 176 Matches/length = 76.1%
Fig. 3.12 Lanes 1 and 2 show the result of a Sanger 
dideoxy sequencing reaction using the primer T3 on the 
Hpall clones E4 (Epivac CAV-2 additional Sail B Hpall 
fragment) and N3 (Nobivac CAV-2 additional Sail B Hpall 
fragment) respectively. Lane 3, sequence obtained of 
the Nobivac insertion (N3) using the primer T7.
F I G U R E  3.12
Nobivac 230BP Insertion (N3) and Epivac 165BP Insertion 
fE4) - Using the Bluescript Primers T3 and T7
A C G T A C G T A C G T
F I G U R E  3.13
Nobivac CAV-2 - N3
10 20 30 40 50 60
CGGCCAAAAG TCCGCGGAAT CGCCCTGTCG TAAAACCACG CCTTTGACGT CACTGGACAT
70 80 90 100 110 120
TCCCGTGGGA ACACCTGACC AGGGCGTGAC CTGAACCTGA CCGTCCCATG ACCCCGCCCC
130 140 150 160 170 180
TTGCAAGACC CAAATTTAAG CCACACCTGT TTGTCCTGTA TATTAAGTAC AGTCATAAAA
190 200 210 220 230
TGTGGCGCGT GGTAAATGTT AAGTGCAAGT TTCCCTTTGG CGGTTGGCCC G
Fig. 3.13 DNA sequence of Nobivac CAV-2 unique Hpall
fragment sequenced using the Bluescript primer T3 ( -> )
as indicated above.
F I G U R E  3.14
Sequence Analysis of the Nobivac Insertion N3
N3
GLASGOW 5'-ITR STRAND L
1 CGGCCAAAAGTCCGCGGAA TCGCCCTGTCGTAAAACCACGCCTTTGACGTCACTGGACA
l l l l l l l l l l l l l l l l l l l  l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
176 CGGCCAAAAGTCCGCGGAACTCGCCCTGTCGTAAAACCACGCCTTTGACGTCACTGGACA
60 TTCCCGTGGGAACACC TGACCAGGGCGTGACCTGAACCTGACCGTCCCATGACCCCGCC
l l l l l l l  MINIMI  l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
116 TTCCCGTGGGAACACCCTGACCAGGGCGTGACCTGAACCTGACCGTCCCATGACCCCGCC
119 CCTTGCAAGACCCAAATTTAAGCCACACCTGTTTGTCCTGTATATTA 165
l l l l l l l l  l l l l l l l l l l l l l l l l l l l l  I I I I II I I I I II I I I I
56 CCTTGCAACGCCCAAATTTAAGCCACACCTCTTTGTCCTGTATATTA 10
Matches = 162 Length = 167 Matches/length = 97.0%
Epivac CAV-2 - E4
10 20 30 40 50 60
CGGCAGCCAT TCTGCAAAAT AACAAAACAC CACTAAGCAT AGCACCATCA CCAAGCATGA
70 80 90 100 110 120
AAACAGGTAA AAACAAAAGC AACACTTACT TATTCAGCAG TCACAAGAAT GTTGGGCTCC
130 140 150 160
CAAGTGACAG ACCAAGCCTA ATGCAAGGTG GGCACAGTCC TCCG
Fig. 3.15 DNA sequence of the Epivac CAV-2 unique Hpall
fragment. Sequenced using the Bluescript primer T3 ( -> )
as indicated above.
F I G U R E  3.16
Sequence Analysis of the Epivac Insertion E4
E4
Ad5 E3 transcription region 
69 AAAAACAAAAGCAACACTTACTTA 92
III I l l l l l l  l l l l l l l l l l
3517 AAATAATAAAGCATCACTTACTTA 3540
Matches = 20 Length = 24 Matches/length = 83.3%
E4
Tree shrew (Tupaia) adenovirus early region Elb STRAND L 
6 GCCATTCTGCAAAATAACA 24
I l l l l l l l  l l l l l l l l l
1613 GACATTCTGAAAAATAACA 1595
Matches = 17 Length = 19 Matches/length = 89.5%
E4
X.laevis mitochondrial DNA containing the D-loop and the 12S rRNA 
1 CGGCAGCCATT CTGCAAAATAACAAAACACCACTAAGCATAGCACCATCACCAAGCATG
I l l l l l l l  Mi l l  I I I I  l l l l l l  l l l l l  III I I I I  I II II
1 CTGCAGCCAACGCTGCAGAATAGGCAAACACTACTAA CATCCCACCTAAATAAATCAAA
60 AAAACAGGTAAAAACAAAA 78
I I I I  I I I l l l l l l
60 AAAAGAACAATAGACAAAA 78
Matches = 53 Length = 79 Matches/length = 67.1%
Fig. 3.17 Sanger dideoxy sequencing reaction on the 
Vaxitas 631bp and 193bp Sail B Hpall fragments using 
the primers T3 and T7. Lane 1 represents the 193bp 
Hpall fragment sequence, on a short run, with the 
primer T7. Lanes 2 and 3 show short runs of the 
sequence obtained, using the primers T7 and T3 
respectively, from the 631bp Hpall fragment.
F I G  U R E 3.17
Vaxitas CAV-2 631bp and 193bp Hpall Fragments 
- Using the Bluescript Primers T3 and T7
A C G T A C G T  A  C  G  T
m
iX
1 2 3
DNA Sequence
of the 193bp Hpall Fragment of Vaxitas CAV-2 SallB
10 20 30 AO 50 60
CCGGACTGCC TTGACTGTGA GTATTCTCAT GGCAGCCCCT CGCCGCCTAC TCTGCACGAT
70 80 90 100 110 120
CTTTTTGATG TTGAGCTGGA GACTTCTCAC AGCCCTTTTG TGGGCCTGTG TGATTCCTGT
130 140 150 160 170 180
GCGGAGGCTG ACACTGATTC GAGTGCGAGC ACTGAGGGTG ATTCTGGGTT TAGTCCTTTA
190
TCCACTCCGC CGG
Fig. 3.18 DNA sequence of the 193bp Hpall fragment unique
to Vaxitas CAV-2. Sequence data obtained using the primer
T7 of Bluescript as indicated above (— >).
F I G U R E  3.19
DNA Sequence
of the 631bp Hpall Fragment of Vaxitas CAV-2 SallB
T7 
- - >
10 20 30 40 50 60
CCGGTTTCAC TATTCCACCG CATCCCACCT CTCCTGCTAG CATTTCTGAC GACATGTTGC
70 80 90 100 110 120
TGTGCTTAGA GGAAATGCCC ACCTTTGATG ACGAGGACGA GGTTCGAAGC GCGGCGACCA
130 140 150 160 170 180
CTTTGAGCG GTGGGAAAAC ATTTTGACCC CCATGTGGGT CCTATTTTTG GCTGTTTGCG
190 200 210 220 230 240
CTGTGCTTTT TATCAAGAGC AGGATGATAA TGCACTTTGT GGGCTTTGCT ATCTAAAGGC
250 260 270 280 290 300
CCTTGCCGAA GTAAGTTTTA ATTTAAATGT TTGGGCAGGT TAAATGTTTG GGCAGGTTAA
310 320 330 340 350 360
ATGTTTTAGG TGTGTATTGA TTTTTAATTT TGCTTTTTAG TGCCTTTTGC TATGCCTGTA
370 380 390 400 410 420
CGTTCAGAAC CCGCTTCGGC TGGAGCTGAG GAGGAAGATG ATGAAGTTAT TTTTGTGTCT
430 440 450 460 470 480
GCCAAACCTG GGGGCAGAAA GAGGTCAGCA GCTACTCCCT GTGAGCCAGA TGGGGTCAGC
490 500 510 520 530 540
AAACGCCTTG CGTGCCAGAG CCTGAGCAAA CAGAACCTTT GGATTTGTCT TTGAAGCCAC
550 560 570 580 590 600
GCCCGAACTA ATCTCCTTGA GCACAAAGCA ATAAAGTAAT CTTGTTTAAC AAGTTGACAA
610 620 630
GGACGTGCTG TACTTTTTGT GAACTTTCCG G
<--T3
Fig. 3.19 DNA sequence of the unique 631bp Hpall
fragment of Vaxitas CAV-2 obtained using the primers T3 
and T7 of Bluescript as indicated ( -> ).
Sequence Analysis 
of the 631bp and the 193bp Hpall Fragments of 
Vaxitas CAV-2 SallB
193bp Fragment 
CAV1E1
1 CCGGACTGCCTTGACTGTGAGTATTCTCATGGCAGCCCCTCGCCGCCTACTCTGCACGAT
Mi l l  II II MINIMI  II Mi l l  I I I  II I II I III II III
492 CCGGAATGTCTCTCCTGTGAGTACTCCCATGGTGGCTCGTCACA CCGAGTCTTCATGAT 
61 CTTTTTGATGTTGAGCTGGAGACTTCTCACAGCCCTTTTGTGGGCCTGTGTGATTCCTGT
111II1111 I Mi l l  I I I I  I I I I I I I I I I I I  III
551 CTTTTTGATCTTGAGCTGGAAAATTCTCGTTCTCCTTCTCCGCTGCTGTGTGATTGGTGT 
121 GCGGAGGCTGACACTGATTCGAGTGCGAGCACTGAGGGTGATTCTGGGTTTA
1111111111111 III II I Ml III MM III I I I I
611 GCGGAGGCTGACAGTGAATCTACAATTTCCACGGAGACTGATGTTGGCTTTA 
Matches = 122 Length = 172 Matches/length = 70.9%
193bp Fragment 
Ad41E1a
47 
600
Matches = 28 Length = 33 Matches/length = 84.8%
193bp Fragment 
CAV2E1
1 CCGGACTGCCTTGACTGTGAGTATTCTCATGGCAGCCCCTCGCCGCCTACTCTGCACGAT
II I I I I I I I I I I I I I I I I I I I I  I I I I I I I I I I I I I
624 CCGGACTGCCTTGACTGTGAGTATCCTCATGGCAGCCCCTCGCCGCCTACTCTGCACGAT 
61 CTTTTTGATGTTGAGCTGGAGACTTCTCACAGCCCTTTTGTGGGCCTGTGTGATTCCTGT
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
684 CTTTTTGATGTTGAGCTGGAGACTTCTCACAGCCCTTTTGTGGGCCTGTGTGATTCCTGT
TACTCTGCACGATCTTTTTGATGTTGAGCTGGA 80
I I II III I I I I I I I I I I I II I I I I I I I I
TTCGCTTCACAATCTTTTTGATGTGGAGCTGGA 633
55
48455269
121 GCGGAGGCTGACACTGATTCGAGTGCGAGCACTGAGGGTGATTCTGGGTTTAGTCCTTTA
I I I I I t I I I I I I I I I I I I I I I I I I I I I I I M I I ! I I ! I I I I I I I I I I I I l I I I I I I I I I
744 GCGGAGGCTGACACTGATTCGAGTGCGAGCACTGAGGGTGATTCTGGGTTTAGTCCTTTG 
. 181 TCCACTCCGC
I I I l I I l I I I
804 TCCACTCCGC
Matches = 188 Length = 190 Matches/length = 98.9%
193bp Fragment
Adenovirus 3 left end, with inverted terminal rpt 
27 CATGGCAGCCCCTCG CCGCCTACTCTGCACGATCTTTTTGATGTTGAGCTGGA 81
II l l l l l l  III II Mi l l  l l l l l l l l l l l  I I I I I  I III I II
690 CAGTGCAGCCTTTCGATCCACCTACGCTGCACGATCTGTATGATTTAGAGATAGA 744
Matches = 41 Length = 55 Matches/length = 74.5%
193bp Fragment
Adenovirus type 7 left end of the genome 
42 CCGCCTACTCTGCACGATCTTTTTGATGTTGAGCTGGA 79
II Mi l l  I I I I I I II I I I I I I I I  I III I II
699 CCACCTACGCTGCACGATCTGTATGATTTAGAGGTAGA 736
Matches = 30 Length = 38 Matches/Iength = 78.9%
631bp Hpall fragment 
CAV2E1
1 CCGGTTTCA CTATTCCACCGCATCCCACCTCTCCTGCTA GCATTTCTGACGACATGTT
I I I I I I I I I I I I I I II I I I I I I II I I I II II I I I I II I I I I II I I I I I I I I I I I I I I
813 CCGGTTTCACCTATTCCACCGCATCCCACCTCTCCTGCTACGCATTTCTGACGACATGGT
59 GCTGTGCTTAGAGGAAATGCCCACCTTTGATGACGAGGACGAGGTTCGAAGCGCGGCGAC 
873 GCTGTGCTTAGAGGAAATGCCCACCTTTGATGACGAGGACGAGGTTCGAAGCGCGGCGAC
119 CACCTTTGAGCGGTGGGAAAACA TTTTGACCCCCATGTGGGTCCTATTTTTGGCTGTTT
l l l l l l  l l l l l l l l l l l  l l l l l l  I I I II I I I II I I I I I I I II I I I I I II I I I I I I I I I I
933 CACCTTTGAGCGGTGGGAAAACACTTTTGACCCCCATGTGGGTCCTATTTTTGGCTGTTT 
178 GCGCTGTGCTTTTTATCAAGAGCAGGATGATAATGCACTTTGTGGGCTTTGCTAT CTAA
I I I I I I I I I I I I I I I I I I I I I I I I I
993 GCGCTGTGCTTTTTATCAAGAGCAGGATGATAATGCACTTTGTGGGCTTTGCTATCCTAA
999999999999999994
999548169^79
237 AGGCCCTTGCCGAA GTAAGTTTT AATTTAAATGTTTGGGCAGGTTAAATGTTTGGGCA
i l l i n i u m  ii m u  mi  i i i i i i i i i i i i i i i i m i i i i i i i i i i i i i i i i i
1053 AGGCCCTTGCCGAAGGTAAGTTTTGAATTTAAATGTTTGGGCAGGTTAAATGTTTGGGCA 
295 GGTTAAATGTTTTAGGTGTGTATTGATTTTTAATTTT GCTTTTTAGTGCCTTTTGCTAT
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l  I MlI I II I I I I II I I II I I I
1113 GGTTAAATGTTTTAGGTGTGTATTGATTTTTAATTTTGGCTTTTTAGTGCCTTTTGCTTT .
354 GCCTGTACGTTCAGAACCCGCTTCGGCTGGAGCTGAGGAGGAAGATGATGAAGTTATTTT
III III III III III III III III III III III III III III III III III III III III
1173 GCCTGTACGTTCAGAACCCGCTTCGGCTGGAGCTGAGGAGGAAGATGATGAAGTTATTTT 
414 TGTGTCTGCCAAACCTGGGGGCAGAAAGAGGTCAGCAGCTACTCCCTGTGAGCCAGATGG
III III III III III III III III III III III III III III III III III III I I I I I I
1233 TGTGTCTGCCAAACCTGGGGGCAGAAAGAGGTCAGCAGCTACTCCCTGTGAGCCAGATGG 
474 GGTCAGCAAACGCCCTTGCGTGCCAGAGCCTGAGCAAACAGAACCTTTGGATTTGTCTTT
ii m u m  i i i i i n i i i  m m m m m m m m m m m m i
1293 GGCCAGCAAACCCCCTTGCGTGGCAGAGCCTGAGCAAACAGAACCTTTGGATTTGTCTTT 
534 GAAGCCACGCCCGAACTAATCTCCTTGAGCACAAAGCAATAAAGTAATCTTGTTTAACAA
III III III III III III III III III III III III III III III III III III I I I III
1353 GAAGCCACGCCCGAACTAATCTCCTTGAGCACAAAGCAATAAAGTAATCTTGTTTAACAA 
594 GTT
III
1413 GTT
Matches =591 Mismatches =5 Unmatched =7 Length =603 Matches/length =98.1%
631bp Fragment 
CAV1E1
279 TTAAATGTTTGGGCAGGTTAAATGTTTTAGGTGTGTATTGATTTTTAATTTTGCTTTTTA
l l l l l l  I IIII III II IIII I II I II I I I I  Mil l
943 TTAAAT TATGGGTGGGTCAATAGTTTCACAAAGGTTCTTATGTGTTCCTCTCTGTTTTA 
339 GTGCCTTTTGCTATGCCTGTACGTTCAGAACCCGCTTCGGCTGGAGCTGAGGAGGAAGAT
m u  i ii m u m  n m i n i  i i m i  ii i i ii i m
1002 GTGCCCTGCGCCATGCCTGTTCGCGCAGAACCTGTTGATGCTGATGCCG G AG AGGAT 
399 GATGAAGTTATTTTTGTGTCTGCCAAACCTGGGGGCAGAAAGAGGTCAGCAGCTACTCCC
l l l l l  II I I I I I I I I I I I I I I II I I ! I I I III III III III III I III II
1059 GATGAGGTCATTTTTGTGTCTGCTAAACCTGGTTCCAGAAAGAGGTCAGCGGTGACTTCC
459 TGTGAGCCAGATGGGGTCAGCAAACGCC TTGCGTGCCAGAGCCTGAGCAAACAGAACCT
I II III II III l l l l l l l  IIII l l l l l l  I l l l l l l  III I l l l l l l
1119 CGCGACTCAGTTGAAAGCAGTAAACGCCCTTGCTTGCCAGAGCCTGAACAA CTGAACCT
518 TTGGATTTGTCTTTGAAGCCACGCCCGAACTAATCTC CTTGAG 560
l l l l l l  I II I I I I I I I I I I I II III I l l l l l l
1178 TTGGATCTTTCCCTAAAGCCACGCCGCAATAAATTACTCTTGAG 1221
Matches = 203 Length = 284 Matches/length = 71.5%
1 CCGGTTTCAC TATTCCACCGCATCCCACCTCTCCTGCTAGCATTTCTGACGACATGTTG
i i i i i i i i i i m i  n n m i  n i i i i i i  n i n m i  n u n  ii
677 CCGGTTTCTCCTCTTCCTTCGTATTCCACTTCTCCTGCAAGTATTCCTGAGGACATGCTG
59 CTGTGCTTAGAGGAAATGCCCACCTTTGATGACGAGGACGAGGTTCGAAGCGCGGCGACC
m i  i n i i i i  i n n  1111111111111 in i n i i n i  ii i n i i n
737 TTGTGTCTAGAGGAGATGCCTACCTTTGATGACGGGGATGAGGTTCGGAGTGCGACCACC
119 ACCTTTGAGCG GT GGGAAAACAT TTTGACCCCCATGTGGGTCCTATTTTTGGCTGT
l l l l l l l l  I I l l l l l l l  I MINIM INI II II l l l l l l l  III
797 TCCTTTGAGAGCAGACGGGAAAAAAACTTTGACCCTAATGTTGGGTCTTTTTTTGGTTGT
175 TTGCGCTGTGCTTTTTATCAAGAGCAGGATGATAATGCACTTTGTGGGCTTTGCTATCTA
INI l l l l l  I III II l l l l l l l  II III I INI II II
857 CTGCGTTGTGCCTATTACCAGGAGCAGGGGGAGAATTCCATTTGTGGGCTTTGTTACTTA
235 AAGGCCCTTGCCGAAG TAAGTTTTAATTTAAATGTTTGGGCAGGTTAAATGTTT 288
III 11111111 INI INI I I l l l l l l l  I INI III II INI
917 AAGGCCCTTGCTGAAGGTAAGATAT TTTAAAT TATGGGTGGGTCAATAGTTT 968
Matches = 227 Length = 295 Matches/length = 76.9%
631bp fragment
Adenovirus type 7 (simian) left end of genome
497 GAGCCTGAGCAAACAGAACCTTTGGATTTGTCTTTGAAGC 536
III III l l l l l l l  I III I III I INI I INI
1351 GAGGTTGAACAAACAGTACCTTTGGACCTGTCCCTAAAGC 1390
Matches = 31 Length = 40 Matches/length = 77.5%
68
D I S C U S S I O N
Restriction enzyme analysis of the Sail B Glasgow and 
Vaxitas clones failed to reveal any restriction enzyme 
which cut within the additional Vaxitas DNA. The 
additional DNA always appeared to be excised within an 
existing Glasgow fragment, simply increasing it in size. 
Only by using a frequent 4bp cutter (Hpall) was it 
possible to isolate the additional sequences.
Hpall digestion of the Sail C fragment of CAV-1 vaccines 
demonstrated an increase in size in a single wild-type 
fragment thus creating a fragment of a size unique to 
each vaccine strain : 349bp (BT1), 249bp (BL2): and the
"loss" of one wild-type fragment : the 170bp fragment was 
consistently lost, the 44 0bp and 180bp fragments always 
retained.
The additional sequences within the CAV-2 vaccines however 
appear to have inserted either directly into a Hpall site 
(unlikely) or very near to an existing Hpall site. If the 
point of insertion is adjacent to an existing, i.e. wild- 
type,, Hpall site and the insertion carried a Hpall site 
near its own terminus, it is possible that any new 
fragment created in addition to those noted could be too 
small to be detected on acrylamide. This would also 
require that the insertion carried no other Hpall sites 
unless the fragments generated by digestion with Hpall 
were of a similar size to those generated upon digestion
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of wild-type Sail B, i.e. would co-migrate with wild-type 
fragments on acrylamide. Alternatively, but also
unlikely, the Hpall fragments demonstrated by Hpall 
digestion of the vaccine strain Sail B fragments, may not 
be "wild-type" but may be Hpall fragments encoded by the 
insertion which are of a comparable size to one, or more, 
of the wild-type fragments. This would require large
deletions in the RHT of each genome however and the 
generation of Hpall fragments almost exactly the same size 
as those generated by digestion of the Glasgow RHT with 
Hpall which is most improbable.
Upon Hpall digestion of the Sail B fragments from the CAV- 
2 vaccines, all wild-type bands appear to be retained: 80, 
160, 180, 500 and 2400bp (the 2400bp fragment varies in
size due to the deletion in Pst D), and an additional 
fragment, varying in size for each vaccine, becomes 
apparent. The CAV-2 vaccines Nobivac and Epivac exhibit 
one unique fragment each in addition to the wild-type 
fragments : 231bp and 164bp respectively. Vaxitas however 
exhibits three additional fragments (60bp, 193bp and
631bp) but all wild-type fragments except the 80bp are, 
apparently, again retained. The Hpall digest of the 
vaccine strains also demonstrates more clearly the
deletion within Pst D.
The DNA sequence of the Glasgow CAV-2 ITR exhibits all
known conserved AdV ITR sequences. The three base changes
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between the RHT and LHT ITRs cannot be explained but may 
be related to the aberrant Sail B clones obtained. As 
stated in chapter 2, it is not known whether the S
1
treatment of the viral genomes was successful or whether 
the terminal clones obtained arose from aberrant genomes 
that were derelict of the terminal protein. Alternatively, 
any residual protein may have been removed, following 
ligation and transformation, by DNA repair. It seems 
likely however that aberrant genomes are present within 
the Glasgow CAV-2 stock due to the isolation of RHT clones 
with either base changes in the ITR or additional DNA 
"external" to the normal ITR. As the sequence of the RHT 
found in the majority of Sail B clones obtained contains 
all conserved sequences and a highly conserved initial 
20bp (100% homologous to many other AdV both human and 
non-human) it was assumed to be a correct assessment of 
the DNA sequence of the Glasgow CAV-2 ITR.
The DNA sequence of the Toronto strain of CAV-2 has been 
published (Shinagawa et_al, 1987). Three base changes 
occur between the published Toronto CAV-2 ITR sequence and 
the Glasgow CAV-2 ITR sequence: at bp>47, 130 and 157 the 
Glasgow ITR has C, C and G respectively; at bp 47, 130 and 
157 the Toronto ITR has T, G, and C respectively. The 
Glasgow ITR also contains one additional base, at bpl85 
(Gj, not present in the Toronto ITR. The additional base 
in the Glasgow ITR gives rise to a Smal site which has 
been confirmed by restriction enzyme analysis.
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Hpall analysis of the Sail C fragments of the CAV-1 
strains revealed one fragment which was increased in size 
in the vaccine strains and three others which remain 
constant. The small increases in the 160bp fragment of 
wild-type, becoming 3 00bp in Epivac, 240bp and 350bp in 
Boostervac, do not account for the difference in size of 
the Sail C fragments. It must therefore be assumed that 
either the enlarged fragments are present in multiple 
copies or other fragments, which co-migrate with normal 
wild-type fragments, are present.
Sequence analysis demonstrated that no one region of the 
viral genome is exclusively repeated. The wide range of 
"type" of insertion appears to be unique when compared to 
other known additional sequences at the genome termini of 
AdV. Consistent with the Adl2, Adl6 and equine AdV 
additional sequences however (Werner and zur Hausen, 1978; 
Schwartz et al. 1982: Hammarskjold and Winberg, 1980:
Ishiyama et al. 1986), Nobivac CAV-2 appears to consist of 
a repeat of the ITR and perhaps the adjacent sequences. 
The smaller species of Boostervac CAV-1 also appears to be 
a repeat of the sequences adjacent to the LHT ITR, showing 
homology of >90% to the RI127 wild-type CAV-1 El region, 
which appears to have been duplicated at the RHT.
The Epivac CAV-2 insertion may be similar to those found 
within Ad3 genomes (Larsen and Tibbetts, 1985; Larsen et 
al, 1986). The variant Ad3 genomes were found to contain
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inserts of HeLa cell DNA. The Epivac clone does show 
homology to short regions of other AdV genomes (83.3% over 
24bp against the Ad5 E3 region, 89.5% over 19bp against 
the Tupaia AdV Elb region) but the length of the region of 
homology against X. laevis mitochondrial DNA (67.1% over 
194bp) gives the latter more credibility than the short 
regions of homology to other AdVs. This perhaps indicates 
that, as with Ad3, the Epivac CAV-1 insertion is derived 
from cellular DNA. However, there is not enough canine 
cellular DNA information available upon the data bank used 
to allow for more detailed comparison. Nor is there any 
further detailed information available on the CAV-2 
genome, other than the CAV-2 ITR (Shinagawa et al. 1987),
the Glasgow CAV-2 ITR, El and E3 regions, so it may be 
that the Epivac insertion has arisen from a part of the 
viral genome, with little or no homology to the human 
AdVs, for which there is no sequence data available at 
this time.
The larger of the two Boostervac CAV-1 species, however, 
contains a copy of the overlapping region between -E2 and 
E3, a region with strong similarity to the Ad2 E2a cap 
site and a possible E2a TATA box. Homology of >90% is 
demonstrated over 247bp of the Hpall clone containing the 
insert when the sequence is compared to the CAV-2 E2/E3 
region. Duplications of this area of the genome have not 
been reported for any other AdV.
Finally, the Vaxitas insertions (193 and 631bp) appear to
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consist exclusively of repeats of the CAV-2 El region. In 
addition, the two clones are highly homologous to adjacent 
areas of the El gene perhaps indicating that the two 
fragments exist adjacent to each other within the LHT of 
Vaxitas. Although this appears to be an almost exact copy 
of the Glasgow CAV-2 El region, the "mismatches" may be 
accounted for by strain differences. The orientation of 
the RHT El sequences within the LHT and their exact 
position with reference to the E4 gene cannot be revealed 
by restriction enzyme analysis alone. It was therefore 
necessary to analyse the site of insertion using DNA 
sequencing techniques.
It has been demonstrated, from the restriction enzyme map, 
that the vaccine strain insertions are not terminal, the 
0.2kb terminal Smal site is retained, but their exact 
location can only be found, as described above, by 
detailed sequence analysis. However, this raises the 
possibility that the insertions interfere with viral gene 
products. The site of insertion may either be between the 
end of the ITR and the E4 promoter or may be within the E4 
coding region. This may result in an alteration of the 
level of expression of E4 or in defective E4 products 
being produced.
It is known that mutants with deletions in E4 are 
defective for growth in normal AdV hosts. E4 deletion 
mutants are also defective for viral DNA accumulation,
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late mRNA and protein synthesis, fail to inhibit host cell 
protein synthesis and leads to the over-production of the 
72kD DNA binding protein, a product of E2. A diffusible 
E4 product is also believed to be involved in virus 
particle assembly (Falgout and Ketner, 1987). Sandler and 
Ketner (1989) also revealed that E4 deletion mutants were 
defective in the accumulation of both nuclear and 
cytoplasmic late mRNAs. However, they suggest that an E4 
product(s) acts directly or indirectly to stabilise viral 
late RNAs but does not directly affect the levels of 
transcription/translation. It is also hypothesised that 
E4 products may serve to circumvent the host cell defence 
response, designed to destabilise foreign RNAs. 
Alterations in the structure of this gene and its products 
may therefore have profound effects upon the vaccine 
strains which may not be easily detected while the 
vaccines are grown in vitro but may have a significant 
effect upon the functioning of the viruses within the 
natural host. However, to examine the site and effect of 
the insertions it was impractical to obtain the 
information necessary on all the vaccine strains. One 
vaccine strain was therefore chosen, Vaxitas CAV-2, for 
further detailed analysis for three reasons.
First, Vaxitas contains the largest of all the inserts 
examined so far and therefore demonstrates the widest 
variation from wild-type. Secondly, sequence data would 
provide the exact site of insertion with reference to E4 
and the origin of replication of the virus. In addition,
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chloramphenicol acetyltransferase (CAT) assays should 
provide sufficient data to demonstrate whether the 
insertion interferes with the functioning of E4. This 
would, in turn, perhaps enable the mechanism by which 
these aberrant genome arose to be elucidated upon. 
Additionally, it would reveal the sequence of the Vaxitas 
ITR and confirm the DNA sequence obtained, allowing for a 
few strain associated differences, from Glasgow for the 
CAV-2 ITR.
Finally, Vaxitas, alone amongst all the vaccine strains 
thus far examined, fails to replicate in dog cells even 
after continuous high multiplicity passage. This, 
combined with the size of the insertion (and perhaps the 
0.4kb deletion in Pst D) raises questions as to the 
viability of the vaccine. It is possible that the vaccine 
is acting more like a killed vaccine when inoculated into 
the dog rather than a live, attenuated vaccine. This may 
still allow the vaccine to raise a protective immunity. 
Previous research, however, has shown that killed CAV-2 
vaccines are significantly less effective than CAV-2 live 
vaccines (Koptopolous and Cornwell, 1981). It may be that 
analysis of the Vaxitas insertion may help to elucidate 
upon this although it may be that the presence of the 
insertion is only a "symptom1 of another, more 
significant, alteration in a major function of the viral 
genome.
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C H A P T E R  4 
Exact Position of the Additional DNA in the 
Sail B Fragment of Vaxitas CAV-2
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I N T R O D U C T I O N
The use of "designer" primers, i.e. primers synthesised to 
the specifications of the individual researcher, has 
considerably eased the process of sequencing large 
sections of DNA without the need to subclone small, 
usually Hpall or Haelll, fragments. They eliminate the 
requirement for sequencing overlapping fragments which 
duplicates much of the required sequence and vastly 
increases the bench time required, in order to correctly 
orientate the fragments in relation to each other. 
Commercially available and "in-house" synthesised primers 
were therefore exclusively used in the sequencing of the 
Vaxitas and Glasgow RHT from the Sail B fragments already 
cloned into the Bluescript vector.
Although the function of the E4 region in vivo has not 
been well characterised, the organisation of the E4 
promoter region and the DNA sequence of several AdV has 
been described (Ginsberg, 1984: Babiss, 1989). A summary 
of the known E4 control sequences and a schematic 
organisation of the human AdV type 2 E4 promoter region 
are shown in figures 4.1, 4.2 and 4.3. E4 is positioned at 
map units 91.3 - 99.1 and is transcribed in a leftward 
direction from a promoter at m.u. 99.1. With the exception 
of. three minor species, all E4 mRNAs have a 61-nucleotide 
leader sequence devoid of ATG codons, spliced to mRNA 
species, with or without additional introns, which extend 
to a polyadenylation signal at m.u. 91.3. As many as 20
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genes may be encoded within approximately 3 kb of DNA. Ela 
and E2a gene products regulate E4 transcription in a 
positive- and negative-acting fashion respectively. The 
72kD DNA binding protein specifically suppresses E4 
transcription (Handa and Sharp, 1984). An Ela product is 
also reported to act directly upon an E4 enhancer, E4F, 
increasing levels of transcription 10-fold (Raychaudhuri 
et al. 1987a).
This details the type of organisation that the CAV-2 RHT 
would be expected to demonstrate. CAV Ela sequence has 
been shown to contain regions highly homologous to the 
binding sites of nuclear factors utilised by Ad2 Ela 
(Spibey et al. 1989). It is feasible therefore, that some 
homology to the factors involved in the control of Ad2 E4 
would exist in the CAV-2 E4 promoter region. Alignment of 
any such sequences together with the identification of a 
possible TATA box (again initially by comparison with 
other E4 TATA regions) should help to elucidate on the 
effect of the Vaxitas insertion upon E4 and define its 
position within the virus RHT.
The NMF cell line used to date for the replication of 
Vaxitas was a cell line that had been isolated within the 
Department of Veterinary Pathology at the University of 
Glasgow. It is not the cell line used by ICI Tasman, the 
manufacturers of the Vaxitas CAV-2 vaccine. Due to a 
combination of factors the cell line was lost. All
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commercially available mink cell lines were purchased but 
none would facilitate the replication of the Vaxitas 
strain even after repeated attempts with high multiplicity 
passage virus.
ICI Tasman therefore kindly provided the Mv-l-Lu cell line 
in which the vaccine is grown commercially. This cell 
line of mink fibroblasts was derived from the CCL 64 line 
which is commercially available from Flow Laboratories but 
the commercially available CCL 64 proved non-permissive 
for growth of Vaxitas. The growth of Vaxitas in the Mv-1- 
Lu cells was therefore investigated with the hope that, as 
it was the virus "natural" in vitro cell line, virus yield 
would be comparable to, if not an improvement on, that 
from the NMF cell line.
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F I G U R E 4.1
schematic Organisation of the Human Adenovirus Type.. 2
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Fia. 4.1 Schematic organisation of the E4 promoter region 
of Ad2 as derived from the published DNA sequence of the 
Ad2 genome (Ginsberg, 1984).
F I G U R E  4.2
E4 RNA Splicing
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Fia. 4.2 Organisation of E4. E4 RNAs are represented as 
arrows with the arrowhead at the 3' end. Breaks in the 
lines represent the genomic locations and sizes of 
introns. The most abundant E4 mRNAs that accumulate in 
the presence of cyclohexamide are indicated by the heavy 
arrows, the sizes of the mRNAs are shown to the right and 
the peptides they encode when translated in vitro are 
shown to the left. Position "P" at m.u. 99.1 denotes the 
E4 promoter.
F I G U R E  4.3
Control of Ela and E4 Transcription
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Fio. 4.3 DNA-protein interactions within the upstream 
promoter region of the human AdV E1A and E4 genes, derived 
from Jones et al (1988) . The position of the binding sites 
and the names of the factors are indicated.
* binding sites shown represent consensus sequences.
*E4F binds to the same sequences as ATF but its activity 
is induced upon infection and it is only seen in whole 
cell extracts.
+E4TF1 binds in the same region as E4F2 but the binding 
site is different.
M A T E R I  A L S A N D  M E T H O D S
Plaque Purification of Vaxitas 
Cell Line
The Mv-l-Lu cell line was passaged in 10% MEM with the 
addition of 5% lactalbumin hydrolysate (LH) to the media 
every third passage (25ml of a 25% solution of lactalbumin 
hydrolysate was added to each 500ml of 10% MEM) . The 
regular enrichment of the media was recommended by ICI 
Tasman who kindly supplied the cell line. LH was not 
present in the media during any transfections. The LH was 
purchased from Gibco (UK) Ltd.
Plaque Purification Media
A stock media consisting of 2xMEM with 20% HFCS was
prepared. Sea plaque agarose was dissolved by boiling in
water to a concentration of 1.2%. The stock agarose was
o
allowed to cool and was stored at 4 C until required. The
final media was prepared by melting the 1.2% agarose in a
o
microwave oven, allowing it to cool to 40 C and mixing it
with an equal volume of 2x MEM which had been prewarmed to 
o
37 C.
Preparation and Infection
Confluent flasks of cells were split 1:20 into six well
plates (Sterilin) and grown to 80% confluency. A volume
of 0.1ml of a range of stock virus concentration was then
6 1 
added, ranging from 10 p.f.u./ml to 10 p.f.u./ml. The
o
virus stock was incubated on the cells at 37 C for 1 hour
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when it was removed. Two ml of media containing 0.6%
o
agarose was added and the cells incubated at 4 C for 30
minutes or until the agarose had set. The plates were
o
then transferred to a 37 C incubator and left for 3-5 
days.
Plaque Isolation
The tip of a sterile plastic pasteur pipette was removed 
by a sterile scalpel within the confines of a class II 
tissue culture hood. The end of the pastette was then 
inserted through the agarose and the piece of agarose 
directly over the plaque removed. It was quickly dropped 
into a plastic microfuge tube containing 0.5ml of 10% MEM. 
The agarose was then dispersed in the media and the 
mixture added to a confluent test-tube monolayer of Mv-1- 
Lu cells.
Amplification
o
The infected test-tube monolayers were incubated at 37 C
for 5-7 days, or until a CPE became apparent, when they
were freeze/thawed 3x and the supernatant was clarified.
Half of the supernatant was then inoculated again onto
test-tube monolayers until a CPE appeared when they were
freeze/thawed 3x, the supernatant was clarified and the
2
entire supernatant placed onto a 25cm flask. The other
half was kept as stock virus. This process was continued 
2 2 
through a 75cm flask to a 150cm flask and finally to two 
2
180cm flasks, one of which was kept for stock virus, the 
other was used for the standard viral DNA preparation.
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R E S U L T S
Sstll Analysis of the Sail B Fragments of Glasgow and 
Vaxitas CAV-2
The Sail B clones of Glasgow and Vaxitas yield three 
fragments upon digestion with the restriction enzyme Sstll 
(Fig. 3.1). The Glasgow Sail B clone gave fragments of 
0.2kb, 0.5kb and approximately 6.0kb while the Vaxitas
Sail B clone gave fragments at 0.2kb, 1.6kb and
approximately 5.6kb. The Vaxitas insert was therefore 
contained totally within the 1.6kb Sstll fragment. As 
further proof, the Sstll fragments 0.2kb and 0.5kb 
(Glasgow) and the 0.2kb and 1.6kb (Vaxitas) were isolated 
from an agarose gel using Spin-x columns. These fragments 
were then digested with Hpall and examined on an 
acrylamide gel alongside the purified Sail B fragments 
from each virus (Fig. 4.4).
Fragment sizes and a schematic diagram of the Sstll and 
Hpall sites are shown in Fig. 4.5. Obviously the 
orientation of the Hpall fragments within the 1.6kb Sstll 
fragment of Vaxitas cannot be determined except for the 
174bp fragment (terminal, with an overlap into the 1.6kb 
Sstll confirmed by sequence data from the ITR (Fig. 3.6)) 
and the 560bp fragment which is reduced to the 4 00bp and 
160bp fragments upon digestion with Sstll. The 
orientation of these two Hpall fragments is confirmed by 
the digestion of the Glasgow Sail B and the Glasgow Sstll 
0.5kb fragments. As no other suitable restriction enzyme
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sites had been found with which to isolate and clearly map 
the multiple Vaxitas insertions as defined by the 
additional Hpall fragments it became necessary to 
determine the sequence of the Glasgow and Vaxitas Sail B 
clones from the termini of the virus to the internal Sstll 
site i.e. approximately 0.7kb from the terminus in 
Glasgow, approximately 1.8kb in Vaxitas.
DNA Sequence of the Right-hand Terminal of Glasgow CAV-2 
As the Sail B fragment of Glasgow was already cloned into 
the vector Bluescript, continuous sequence was most easily 
obtained by using both commercially available primers and 
unique primers synthesised to known sequence as it became 
available. All non-commercial primers were synthesised 
using an Applied Biosystems DNA Synthesiser. A schematic 
representation of the Glasgow Sail B clone within 
Bluescript and the primers used, both commercial and non­
commercial, is shown in Fig.4.6. The DNA sequence obtained 
using this method is shown in Fig. 4.7.
Confirmation of the exact size and positioning of the 
Hpall fragments within this region of Glasgow CAV-2 is now 
possible. Three Hpall sites are contained within this 
region as expected; at 174bp, 181bp and 262bp from the 
terminus, yielding fragments of 174bp, 7bp, 81bp and 
390bp, the latter being the foremost part of the 560bp 
Hpall fragment which extends past the Sstll site. The 
size of the Sstll fragments can also be confirmed as 160bp
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and 474bp.
DNA Sequence of the Right-hand Terminal of Vaxitas CAV-2 
As the Vaxitas Sail B fragment was already cloned into 
Bluescript, as with Glasgow Sail B, it too was directly 
sequenced using commercial and non-commercial synthesised 
primers as before. The sequencing strategy using these 
primers is shown in Fig.4.8. The DNA sequence obtained by 
using this method is shown in Fig. 4.9.
All Hpall sites can now be confirmed and, in addition, it
is apparent that several of the fragments appearing on
acrylamide consist of two co-migrating fragments. Hpall 
sites can be found 174bp, 181bp, 354bp, 516bp, 570bp,
759bp and 1386bp from the terminus of the genome thus 
yielding eight fragments in this area of the RHT: 627bp,
390bp, 189bp, 174bp, 173bp, 162bp, 54bp and 7bp in size.
The 174bp and 173bp would co-migrate; the 162bp and the 
wild-type 160bp Sail/Hpall fragment, positioned past the 
Sstll site to which the sequence data runs, would co- 
migrate. The 390bp fragment is part of the 560bp wild-type 
Hpall fragment which contains the Sstll site. The 627bp, 
189bp and 54bp fragments were apparent as "additional" 
fragments on acrylamide.
Therefore, it is apparent that the RHT of Vaxitas contains 
six unique Hpall fragments. As the 627bp and the 189bp 
fragments had already been sequenced this allowed for 
confirmation of the sequence data and synthesised primer
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recognition sites.
The exact size of the Vaxitas RHT Sstll fragments are 
shown to be 160bp and 1.598kb, whereas the Glasgow RHT 
Sstll fragments are 160bp and 474bp. Thus the additional 
DNA in the RHT of this particular isolate of Vaxitas CAV-2 
amounts to 1.124kb.
The Vaxitas ITR can also be seen to contain all recognised 
AdV conserved sequences in this region.
DNA Sequence Analysis of the Glasgow RHT
The analysis of the ITR has already been discussed in 
chapter 3. No similarity was demonstrated to any other 
AdV sequence available on the data bank.
Sequence Analysis of the Vaxitas CAV-2 RHT
The DNA sequence analysis data is shown in Fig. 4.10. From 
the data base, all similarity demonstrated to the Vaxitas 
ITR was identical to that demonstrated to the Glasgow ITR 
and was therefore, apart from a few confirmatory examples, 
omitted from Fig. 4.10. However, the inserted DNA found 
in Vaxitas revealed strong homology to the El region of 
several adenovirus strains: HuAdV 3, HuAdV 12, simian AdV 
7, CAV-1 and Glasgow CAV-2. The strongest similarity was 
demonstrated against the Glasgow CAV-2 El region which 
exhibited 98.4% homology over 1380bp. The "copy" of the 
El region is found in the opposite orientation from the El
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region at the RHT, i.e. with the duplicated El promoter 
adjacent to the ITR. A direct comparison with the entire 
RHT of Glasgow CAV-2 was now undertaken to reveal the 
exact point of insertion with reference to Glasgow.
Comparison of Glasgow CAV-2 RHT and Vaxitas CAV-2 RHT 
A direct comparison of the DNA sequences of the Glasgow 
RHT and the Vaxitas RHT can be found in Fig.4.11. The ITR 
of both strains (bp 1 - 197) show 99.5% homology, the only 
difference being a single base change at bp27 from a C in 
Glasgow to a T in Vaxitas. Homology between the two then 
ceases until past the Vaxitas insertion where it resumes 
at bp229 in Glasgow and bpl353 in Vaxitas. The homology
then continues until the end of the known sequence with 
only four mismatched bases giving a homology of 99.1% over 
424 bases. This is a perfect join in the Vaxitas sequence 
between the Ela insertion and reversion to wild-type
sequence. The loss of 3 0bp of the Glasgow sequence has
occurred directly at the site of the Ela insertion into 
Vaxitas thus explaining the loss of the 81bp Hpall 
fragment from Vaxitas Sail B. The "insertion11 has 
therefore occurred within a Hpall fragment as follows :-
a) the initial 16bp of the Glasgow 81bp Hpall fragment 
have been retained by both species - point *.
b) the Glasgow 81bp Hpall fragment then contains 3 0bp not 
found in the Vaxitas sequence.
c) at the same point *, Vaxitas contains an almost perfect 
1.115kb copy of the Glasgow CAV-2 Ela.
d) finally, the last 35bp of the 81bp Glasgow Hpall
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fragment are retained by both species. The sequence of 
both then reverts back to being highly homologous until 
the end of the known sequence of this area of the genome. 
This is demonstrated schematically in figure 4.12.
The DNA sequences of both Glasgow and Vaxitas were also 
translated, in all three reading frames, to demonstrate 
the predicted amino acid sequences and to demonstrate any 
open reading frames. These are demonstrated in figures 
4.13 (Vaxitas RHT) and 4.14 (Glasgow RHT). The Glasgow 
RHT can again be seen to demonstrate all presumptive 
control signals for the E4 promoter region. The Vaxitas 
RHT confirms that all presumptive control sequences are 
present for both the reiterated Ela and E4. However, a 
number of translational stops are apparent which are not 
present in the open reading frames of the Glasgow CAV-2 
Ela. The frame shifts demonstrated when the two DNA 
sequences were compared (Vaxitas reiterated Ela vs Glasgow 
Ela in figure 4.10) have thus introduced a number of 
translational stops in the Vaxitas predicted amino acid 
sequences of the reiterated Ela. A comparison of the 
Glasgow la orfl and the Vaxitas reiterated Ela equivalent 
"orfl is shown in figure 4.15.
A schematic representation of the organisation of the 
right-hand terminal region of Vaxitas CAV-2 is shown in 
figure 4.16.
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Nobivac CAV-2 Analysis
Further analysis of the Nobivac insertion was carried out 
to elucidate whether the remainder of the Nobivac 
insertion would show further homology to newly sequenced 
areas of the Glasgow genome. The 231bp insertion had 
already demonstrated 97% homology to the Glasgow ITR over 
167 bases. The homology demonstrated against the newly 
available sequence of the Glasgow and Vaxitas RHT to the 
Nobivac insert is shown in figure 4.17. As before, the
insert shows 97% homology over 167 bases to the Glasgow
ITR and now also 97.6% homology over the same 167 bases to 
the Vaxitas ITR (comprising bases 1-165 of the Nobivac 
insertion, two bases of the Glasgow and Vaxitas ITRs being 
unmatched). In addition, the remainder of the entire 
Nobivac insertion, bases 165-231, exhibit 95.6% homology 
to 68 bases of the Glasgow RHT past the end of the ITR and 
97.1% homology to the same region of the Vaxitas RHT i.e.
past the ITR and the site of the Vaxitas insertion. The
two areas are not directly continuous, however, the first 
165bp of the insertion being in the opposite orientation 
to the remaining 66 bases as judged by their relative 
homologies to the Vaxitas and Glasgow genomes. This 
remains true irrespective of the orientation of the 
inserted fragment within the Nobivac genome which is at 
present unknown. Figure 4.18 demonstrates, schematically, 
the homology between the Nobivac insertion and the Vaxitas 
and Glasgow RHT.
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Effect on the Genome of Vaxitas when Passaged in a New 
Permissive Cell Line (Mv-l-Lu)
Stock virus from the cell line NMF was inoculated into the 
cell line Mv-l-Lu. The supernatant from the first pass 
infected cells was clarified as before and kept as first 
passage virus stock. The infected cells were lysed and 
the viral DNA purified as before. The CPE and rate of 
infection appeared identical to that exhibited by
infection of NMF but remarkably, the viral DNA showed an
increase of approximately 2kb at the LHT after only one 
pass in the new cell line (Fig. 4.19). The size of the RHT 
appears not to have altered by any degree that can be 
detected by restriction enzyme analysis on an agarose gel. 
The variation in genome size remained constant for each 
first pass of "old" stock virus i.e. stock from the NMF 
cell line.
Plague Purification of Vaxitas from the Mv-l-Lu Cell Line 
Mv-l-Lu cells infected with a low dose of the Vaxitas 
strain (<lp.f.u./cell) demonstrated that Mv-l-Lu cells 
were permissive for the formation of plaques. Viral 
plaques were therefore isolated and the virus from each
individual plaque amplified to yield sufficient viral DNA
to be isolated for restriction enzyme analysis. All 
plaque purifications demonstrated a heterogeneous mixture 
of the virus as before and revealed that the additional 
excess 2. Okb at the LHT was now a stably integrated part 
of the viral genome (Fig. 4.20).
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Fig. 4.4 The Sstll fragments 0.2kb, 0.5kb (Glasgow)
and 1.6kb (Vaxitas) were purified from the cloned Sail 
B fragments and digested;with Hpall to demonstrate the 
additional Hpall fragments within the RHT of the 
vaccine strain. The 0.-7kb Pstl/Sstll fragment of both 
the Glasgow and Vaxitas Sail B clones were also 
purified and digested with Hpall.
pUC8 DNA digested with Hpall.
Glasgow 0.2kb Sstll fragment digested with 
Hpall.
Glasgow 0.5kb Sstll fragment digested with 
Hpall.
Vaxitas 1.6kb Sstll fragment digested with 
Hpall.
Glasgow Pstl/Sstll 0.7kb fragment digested 
with Hpall.
Vaxitas Pstl/Sstll 0.7kb fragment digested 
with Hpall.
Vaxitas 5.2kb Sail B fragment digested with 
Hpall.
Vaxitas 5.2kb Sail B fragment digested with 
Hpall/Sstll.
Glasgow 3.2kb Sail B fragment digested with 
Hpall/Sstll.
Glasgow 3.2kb Sail B fragment digested with 
Hpall.
pUC8 DNA digested with Haelll.
A schematic diagram of the fragments obtained is 
provided above. All fragment sizes are as judged from 
the digested pUC8 DNA m.w. markers.
Lane (1)
Lane (2)
Lane (3)
Lane (4)
Lane (5)
Lane (6)
Lane (7)
Lane (8)
Lane (9)
Lane (10)
Lane (11)
F I G U R E 4.4
Hpall/Sstll Analysis of the SallB Fragments of 
Glasgow and Vaxitas CAV-2
F I G U R E  4.5
Schematic Diagram of the Hpall and Sstll Sites
in the Right-hand Terminal Region of Glasgow and Vaxitas
CAV-2
GLASGOU
PstI Sstll Sstll
I 700 | 500 | 160 bp
i 1 i i 1----- 1— |— p1---- *
560 170 560 81 7 174 bp
< > < >
<---> 430 <--->400
130 160
VAXITAS
PstI Sstll
I 700 I 1600
Sstll
| 160 bp
J i i 1 n  i----r— i---------r-r1----*
560 170 560 60 170 180 190 600 7 174 bp
< > <  >
<---> 430 <---> 400
130 160
Fig.4.5 Schematic diagram shows estimated sizes and 
positions of all Hpall fragments shown on an acrylamide 
gel with Sstll and PstI sites shown for reference. The 
orientation of the five Hpall fragments within the 1.6kb 
Sstll fragment is hypothetical. All fragment sizes are 
shown in base pairs (bp).
F I G U R E 4.6
DNA Sequencing Strategy
For Use On The Glasgow Right-hand Terminus Of
Glasgow CAV-2
Smal Sstll Sstll Sail
I I
— 1 - -II- -
T7 -->
SK -->
H/T1 - - >
HMB --> 
H3
Commercial Primers (NBL)
T7 : 5' AATACGACTCACTATAG 3'
SK : 5' TCTAGAACTAGTGGAT C 3'
Synthesised Primers
H/T1 : 5' CAGTGACGTCAAAGGCG 3'
HMB : 5' GTGCTGTACTTTTTGTG 3*
H3 : 5' ATCCTCATAGCTCTCCT 3'
Fig. 4.6 Sequencing strategy to obtain the DNA sequence 
of the Glasgow right-hand terminal up to and including the 
internal Sstll site nearest the Sail site.
F I G U R E  4.7
DNA Sequence of the Right-hand Terminal 652bp of
Glasgow CAV-2
T7/SK
10 20 30 40 50 60
CATCATCAAT AATATACAGG ACAAAGAGGT GTGGCTTAAA TTTGGGCGTT GCAAGGGGCG
70 80 90 100 110 120
GGGTCATGGG ACGGTCAGGT TCAGGTCACG CCCTGGTCAG GGTGTTCCCA CGGGAATGTC
130 140 150 160 170 180
CAGTGACGTC AAAGGCGTGG TTTTACGACA GGGCGAGTTC CGCGGACTTT TGGCCGGCGC
....... >H/T1 Sstll Hpal I
190 200 210 220 230 240
CCGGGTTTTT GGGCGTTGTG CCTATTTGTG GTTTTGTGGT TGACAGGGTG ACAAGGACGT
Hoall
250 260 270 280 290 300
GCTGTACTTT TTGTGAACTT TCCGGGCCAA CCGCCAAAGG GAAACTGCAC TTAACATTTA
■.... >HMB Hpal I
310 320 330 340 350 360
CCACGCGCCC ACAATTTATG ACTGTACTTG GCACCACTTC CTCAAACGCC CCGTTATATT
370 380 390 400 410 420
CCTTTTCGTT TTCCACACGC CCTACTTTGA GGACTATATA AACGCTGTGC TTGGCATTTC
TATA E4
430 440 450 460 470 480
ATCCTCATAG CTCTCCTCTG ACAGCCAGCC GTCCGTGAGT ACTATGGCAG CTTTAGGAGT
•...... >H3 donor splice? met?
490 500 510 520 530 540
GTCTATGGGA GCATGTTTTT GTCTGAGGCT TCACAAGAGT CTAGTGGAGA GTGTGTGTGC
550 560 570 580 590 600
TCAACTGAGA CTTACGAACT TTTTGCCTTC TGAACTCGCC GTGTGGTGTT TAGCCTTATT
donor splice?
610 620 630 640 650
AGGGCCCAGG AAGTGCGTCC GTGTCCTACC TTGCCGCGGC TGTTTCGGTT TA
Sstll
Fig 4.7 Hpall sites are underlined for ease of 
recognition and comparison to the restriction enzyme data. 
Sstll sites and sequences conserved between all species of 
adenovirus so far examined are also underlined. 
Recognition sequences for synthesised primers are 
indicated by arrows (----- >).
Presumptive TATA, initiating methionine and two 
possible donor splice sites (as judged by sequence 
homology to human AdV E4 regions) are indicated. Ad2 
initial donor splice is situated 61bp downstream of the E4 
promoter and contains no ATG prior to the first intron. 
The consensus sequence for the Ad2 E4 donor splice at 
99m.u. is AAC/GTGAGT and at 94.4m.u. is CTG/GTAAGG. Two 
possible donor splice sites are indicated on the sequence 
above one at 451bp, tcC/GTGAGT and one at 584bp, 
gTGGTGttT. It is likely that the presumptive splice site 
at 451bp is correct, thus placing the folowing ATG in a 
non-coding region.
F I G U R E  4.8
DNA Sequencing Strategy 
For The Right-hand Terminus Of 
Vaxitas CAV-2
Smal Sstll
T 7 [->
SK (->
H/T1 f->
RMD <-|
RME f->
HMA f->
HMB -^> 
H3
|— ><—j |— > 600bp <— | 
T3 T7 T7 f'ment T3 
190bp 
fragment
Commercial Primers
T7 : 5' AATACGACTCACTATAG 3'
SK : 5' TCTAGAACTAGTGGATC 3'
T3 : 5' ATTAACCCTCACTAAAG 3'
Synthesised Primers
H/T1 : 5' CAGTGACGTCAAAGGCG 3'
RMD : 5' GGTGCCAGTTCCTCCAC 3'
RME : 5' GAGGTGGGATGCGGTGG 3'
HMA : 5' TATTTTTGGCTGTTTGC 3'
HMB : 5' GTGCTGTACTTTTTGTG 3'
H3 : 5' ATCCTCATAGCTCTCCT 3'
Fig. 4.8 Sequencing strategy used to obtain the DNA 
sequence of the right-hand terminal of Vaxitas CAV-2 up 
to and including the Sstll site nearest to the Sail site. 
The subcloned fragments, 190bp and 600bp, which had 
already been sequenced are indicated within the overall 
picture and were used as confirmation of sequence data 
obtained from the synthesised primers.
Sstll Sail
I I
 L _ / /  _ .!_**★***
F I G U R E  4.9
DNA Sequence of the Right-hand Terminal 1.776KB of
Vaxitas CAV-2
10 20 30 40 50 60
CATCATCAAT AATATACAGG ACAAAGAGGT GTGGCTTAAA TTTGGGTGTT GCAAGGGGCG
70 80 90 100 110 120
GGGTCATGGG ACGGTCAGGT TCAGGTCACG CCCTGGTCAG GGTGTTCCCA CGGGAATGTC
130 140 150 160 170 180
CAGTGACGTC AAAGGCGTGG TTTTACGACA GGGCGAGTTC CGCGGACTTT TGGCCGGCGC
....... >H/T1 Sstll Hpal I
190 200 210 220 230 240
CCGGGTTTTT GGGCGTTTAT TGATTTTGCG GTTTAGCGGG TGGTGCTTTT ACCATGTTTG
Hpall
250 260 270 280 290 300
CGGAAGATTT AGTTGTTTAT GGAGCTGGTT TTGGTGCCAG TTCCTCCACG GCTAATGTCA
310 320 330 340
......... >RMD
350 360
AAGTTTATGT CAATATAACA GAAACACTCT GTTCTCTGTT TACAGCACCC CACCCGGTGG
370 380 390 400 410
Hpal I 
420
TTTTTCGCCA CGCCTTTGGG TTAATTTTAT TTCCCTATAC GCGGCCTTAA ATTCTCAGTG
430 440 450 460 470 480
CAGACGAAAG AGGACTACTC TTGAGTGCGC ACGGAGAAGA GTTTTCTCTT CGCTGTGTCT
490 500 510 520 530 540
CATATATTTT CTGAAAAATG AAATATACTA TTGTGCCGGC GCCGCGCAAT CTCCATGATT
550 560 570
Hpal I 
580 590 600
ATGTTTTAGA GCTACTGGAA GAGTGGCAGC CGGACTGCCT TGACTGTGAG TATTCTCATG
610 620
T3 ->Hpa11
630 640 650 660
GCAGCCCCTC GCCGCCTACT CTGCACGATC TTTTTGATGT TGAGCTGGAG ACTTCTCACA
670 680 690 700 710 720
GCCCTTTTGT GGGCCTGTGT GATTCCTGTG CGGAGGCTGA CACTGATTCG AGTGCGAGCA
730 740 750 760/
Hpal I
770 780
CTGAGGGTGA TTCTGGGTTT AGTCCTTTAT CCACTCCGCC GGTTTCACTA TTCCACCGCA
790 800 810
T7 -> 
820
<-T7 RME<........
830 840
TCCCACCTCT CCTGCTAGCA TTTCTGACGA CATGTTGCTG TGCTTAGAGG AAATGCCCAC
850 860 870 880 890 900
CTTTGATGAC GAGGACGAGG TTCGAAGCGC GGCGACCACC TTTGAGCGGT GGGAAAACAT
910 920 930 940 950 960
TTTGACCCCC ATGTGGGTCC TATTTTTGGC TGTTTGCGCT GTGCTTTTTA TCAAGAGCAG
970 980 990
..... >HMA
1000 1010 1020
GATGATAATG CACTTTGTGG GCTTTGCTAT CTAAAGGCCC TTGCCGAAGT AAGTTTTAAT
1030 1040 1050 1060 1070 1080
TTAAATGTTT GGGCAGGTTA AATGTTTGGG CAGGTTAAAT GTTTTAGGTG TGTATTGATT
1090 1100 1110 1120 1130 1140
TTTAATTTTG CTTTTTAGTG CCTTTTGCTA TGCCTGTACG TTCAGAACCC GCTTCGGCTG
1150 1160 1170 1180 1190 1200
GAGCTGAGGA GGAAGATGAT GAAGTTATTT TTGTGTCTGC CAAACCTGGG GGCAGAAAGA
1210 1220 1230 1240 1250 1260
GGTCAGCAGC TACTCCCTGT GAGCCAGATG GGGTCAGCAA ACGCCCTTGC GTGCCAGAGC
1270 1280 1290 1300 1310 1320
CTGAGCAAAC AGAACCTTTG GATTTGTCTT TGAAGCCACG CCCGAACTAA TCTCCTTGAG
1330 1340 1350 1360 1370 1380
CACAAAGCAA TAAAGTAATC TTGTTTAACA AGTTGACAAG GACGTGCTGT ACTTTTTGTG
HMB...................>
1390 1400 1410 1420 1430 1440
AACTTTCCGG GCCAACCGCC AAAGGGAAAC TGCACTTAAC ATTTACCACG CGCCCACATT
HpalI<--T3
1450 1460 1470 1480 1490 1500
TTATGACTGT ACTTGGCACC ACTTCCTCAA ACGCCCCGTT ATATTCCTTT TCGTTTTCCA
1510 1520 1530 1540 1550 1560
CACGCCCTAC TTTGAGGACT ATATAAACGC TGTGCTTGGC ATTTCATCCT CATAGCTCTC
1570 1580 1590 1600 1610 1620
CTCTGACAGC CAGCCGTCCG TGAGTACAAT GGCAGCTTTA GGAGTGTCTA TGGGAGCATG
- ->H3
1630 1640 1650 1660 1670 1680
TTTTTGTCTG AGGCTTCACA AGAGTCTAGT GGAGAGTGTG TGTGCTCAGC TGAGACTTAC
1690 1700 1710 1720 1730 1740
GAACTTTTTG CCTTCTGAAC TCGCCGTGTG GTGTTTAGCC TTATTAGGGC TCAGGAAGTG
1750 1760 1770
CGTCCGTGTC CTACCTTGCC GCGGCTGTTT CGGTTTA
Sstll
Fig. 4.9 Sequence of the RHT of Vaxitas CAV-2 including 
the ITR. All Hoall sites are underlined. Sequences 
conserved between all species of adenovirus so far 
examined and Sstll sites are also underlined. 
Recognition sequences of synthesised primers are depicted
as arrows (-- >) . Sequence data from the subcloned 160bp
and 600bp fragments used as confirmation are indicated as 
T3* and T7*.
F I G U R E  4.10
Sequence Analysis of the Vaxitas CAV-2 
Right-hand Terminus
VAXITAS RHT 
Adenovirus type 3 E1a
597 CATGGCAGCCCCTCG CCGCCTACTCTGCACGATCTTTTTGATGTTGAGCTGGA 649
690 CAGTGCAGCCTTTCGATCCACCTACGCTGCACGATCTGTATGATTTAGAGATAGA 744
* *  * *  * *  *  *  *  *  *  * *  *
Matches = 41 Length = 55 Matches/length = 74.5%
428 AAGAGGACTACTCTTGAGTGCGCACGGAGAAGAGTTTTCTCTTC 471
512 AAGAGGCC ACTCTTGAGTGC CAGCGAGAAGAGTTTTCTCCTC 553
* * * ** *
Matches = 38 Length = 44 Matches/length = 86.4%
VAXITAS RHT
Adenovirus type 12 E1a
428 AAGAGGACTACTCTTGAGTGCGCACGGAGAAGAGTTTTCTCT 469
437 AAGAGGCC ACTCTTGAGTGC CAGCGAGAAGAGTTTTCTCT 476
Matches = 37 Length = 42 Matches/length = 88.1%
VAXITAS RHT
Adenovirus type 7 (simian) E1a
1256 GAGCCTGAGCAAACAGAACCTTTGGATTTGTCTTTGAAGC 1295
1351 GAGGTTGAACAAACAGTACCTTTGGACCTGTCCCTAAAGC 1390
* *  * *  * *  * *  *
Matches = 31 Length = 40 Matches/length = 77.5%
VAXITAS RHT 
Adenovirus type 7 Ela
612 CCGCCTACTCTGCACGATCTTTTTGATGTTGAGCTGGA 649
699 CCACCTACGCTGCACGATCTGTATGATTTAGAGGTAGA 736
*  * *  *  *  *  * *
Matches = 30 Length = 38 Matches/length = 78.9%
428 AAGAGGACTACTCTTGAGTGCGCACGGAGAAGAGTTTTCTCTTC 471
504 AAGAGGCC ACTCTTGAGTGC CAGCGAGAAGAGTTTTCTCCTC 545
* * ★ ** *
Matches = 38 Length = 44 Matches/length = 86.4%
VAXITAS RHT
equine adenovirus (ead) 5' inverted terminal repeat
CATCATCAATAATATACAGGACAAAGAGGTGTGG
CATCATCAATAATATACAGGACACACGGGCATGG
34
34
Matches = 29 Length = 34 Matches/length = 85.3%
VAXITAS RHT 
CAV-1 ITR
CATCATCAATAATATACAGGACAAAGAGGTGTGGCTTAAAT TTGGGTGTTGCAAGGGGC
CATCATCAATAATATACAGGACAAAGAGGTGTGGCCTAAATGTTGTTTTTTTTTAAAAAA
60 GGGGTCATGGGACGGTCAGGTTCAGGTCACGCCCTGGTCAGGGTG TTCCCACGGGAATG
i i i ii ii i mini iiiii m m  i i
61 GTTTTTGTCTGATTGTTTTGACAAGGTCACACCCTGTTCAGGGCGTTTCCCACGGGAAAG
119 TCCAGTGACGTCAAAGGCGTGGTTTTACGACAGGGCGAGTTCCGCGGACTTTTGGCCGGC
179 GCCCGGGTTTTTGGG
i m i n i m
162 G TGGTTTTTGGG
Matches = 129 Mismatches = 38 Unmatched = 24 
Length = 191 Matches/length = 67.5%
VAXITAS RHT
CAV1 (RI 127) E1 REGION
404 GCCTTAAATTCTCAGTGCAGACGAAAGAGGACTACTCTTGAGTGCGCACGGAGAAGAGTT
340 GCTTTAAATTCACTGCAGAGACGAAAGAGGAGTACTCTTGAGTGCGCACGGAGAAGAGTT 
TATA Ela
464 TTCTCTTCGCTGTGTCTCATATATTTTCTGAAAAATGAAATATACTATTGTGCCGGCGCC
mi iiiii iii ii 111 ii ii i m m  m m  ii
400 TTC TCTCAGCGAATCTGCCAAAAATGAAGTTAACTCTTGAGCCGGCACC
121 ACCA TGACGTCAATTGGGTGTTTTT GT GGAC TTTGGCCCGT
met E1a orf!
59
524 
449 
584 
. 509 
644 
569 
704 
629 
764 
686 
823 
746 
883 
806 
939 
866 
999 
926 
1058 
977 
1118 
1026 
1178 
1083 
1238 
1143 
1297 
1203 
Matches=682
GCGCAATCTCCATGATTATGTTTTAGAGCTACTGGAAGAGTGGCAGCCGGACTGCCTTGA
INI  III Mi l l  1111111 l l l l l l l l l l l l l  l l l l l l l l l l l  l l  ll
GCGCTGTCTTCATGAATATGTTTCTCAGCTACTGGAAGATTGGCAGCCGGAATGTCTCTC
CTGTGAGTATTCTCATGGCAGCCCCTCGCCGCCTACTCTGCACGATCTTTTTGATGTTGA
MINIMI  II Mi l l  II I II II II I III II 111111111111 I I I I
CTGTGAGTACTCCCATGGTGGCTCGTCACCACCGAGTCTTCATGATCTTTTTGATCTTGA
GCTGGAGACTTCTCACAGCCCTTTTGTGGGCCTGTGTGATTCCTGTGCGGAGGCTGACAC
I I I II I I Mi l l  I I I I  I I I I I I I I I I I I I I I II I I I I I I I I I I I
GCTGGAAAATTCTCGTTCTCCTTCTCCGCTGCTGTGTGATTGGTGTGCGGAGGCTGACAG
TGATTCGAGTGCGAGCACTGAGGGTGATTCTGGGTTTAGTCCTTTATCCACTCCGCCGGT
III II I III III I I I I  III I I I I  I I I I  111111111111
TGAATCTACAATTTCCACGGAGACTGATGTTGGCTTTA CTTTGAACACTCCGCCGGT 
TTC ACTATTCCACCGCATCCCACCTCTCCTGCTAGCATTTCTGACGACATGTTGCTGTG
III II I I I I  II II I I I I  11111111 II III I I I I  l l l l l l  II I I I I
TTCTCCTCTTCCTTCGTATTCCACTTCTCCTGCAAGTATTCCTGAGGACATGCTGTTGTG
CTTAGAGGAAATGCCCACCTTTGATGACGAGGACGAGGTTCGAAGCGCGGCGACCACCTT
I I I I I I I Mi l l  l l l l l l l l l l l l l  III I I I I I I I I II III I III I I I I
TCTAGAGGAGATGCCTACCTTTGATGACGGGGATGAGGTTCGGAGTGCGACCACCTCCTT 
T GAGC GGTGGG AAAACATTTTGACCCCCATGTGGGTCCTATTTTTGGCTGTTTGCG
I M i l l  III I I I I  I III Mi l l  M I N I  II l l l l l l l  III Mi l
TGAGAGCAGACGGGAAAAAAACTTTGACCCTAATGTTGGGTCTTTTTTTGGTTGTCTGCG
CTGTGCTTTTTATCAAGAGCAGGATGATAATGCACTTTGTGGGCTTTGCTATCTAAAGGC
Mi l l  I III II l l l l l l l  II III I 1111111111111 II l l l l l l l
TTGTGCCTATTACCAGGAGCAGGGGGAGAATTCCATTTGTGGGCTTTGTTACTTAAAGGC 
CCTTGCCGAA GTAAGTTTTAATTTAAATGTTTGGGCAGGTTAAATGTTTGGGCAGGTTA
l l l l l l  III Mi l l  II l l l l l l l  I I I I I  III II I I I I  II I
CCTTGCTGAAGGTAAG ATATTTTAAAT TATGGGTGGGTCAATAGTTT CA CA
end orf1
AATGTTTTAGGTGTGTATTGATTTTTAATTTTGCTTTTTAGTGCCTTTTGCTATGCCTGT
II III I I III II I I II I I I I I I I I II I II I I I I I I I I
AAGGTTCT TATGTGTTCCT CTCTG TTTTAGTGCCCTGCGCCATGCCTGT
met orf2
ACGTTCAGAACCCGCTTCGGCTGGAGCTGAGGAGGAAGATGATGAAGTTATTTTTGTGTC
II l l l l l l l  I I I I I I  II III II 11111III II l l l l l l l l l l l
TCGCGCAGAACCTGTTGATGCTGATGC CGGA GAGGATGATGAGGTCATTTTTGTGTC 
TGCCAAACCTGGGGGCAGAAAGAGGTCAGCAGCTACTCCCTGTGAGCCAGATGGGGTCAG
III l l l l l l l l  I I I II I I I I I I I I I I I III II I II III II III
TGCTAAACCTGGTTCCAGAAAGAGGTCAGCGGTGACTTCCCGCGACTCAGTTGAAAGCAG
CAAACGCCCTTGCGTGCCAGAGCCTGAGCAAACAGAACCTTTGGATTTGTCTTTGAAGCC
I I I I I I I I I I II I I I I I II I I I I I I I III I I II I I I I I I I I I II l l l l l l
TAAACGCCCTTGCTTGCCAGAGCCTGAACCAACTGAACCTTTGGATCTTTCCCTAAAGCC
ACGCCCG AACTAATCTC CTTGAG
l l l l l l l  II III I l l l l l l
ACGCCCGCAATAAATTACTCTTGAG 
end orf2
Mismatches=198 Unmatched=45 Length=925 Matches/length=73.7%
Vaxitas RHT
Glasgow LHT and E1a Region (E1a sequence courtesy of Dr A. McClory) 
1 CATCATCAATAATATACAGGACAAAGAGGTGTGGCTTAAATTTGGGTGTTGCAAGGGGCG
l l l l l l l l l l l l l
1 CATCATCAATAATATACAGGACAAAGAGGTGTGGCTTAAATTTGGGCGTTGCAAGGGGCG
61 GGGTCATGGGACGGTCAGGTTCAGGTCACGCCCTGGTCAGGGTGTTCCCACGGGAATGTC
61 GGGTCATGGGACGGTCAGGTTCAGGTCACGCCCTGGTCAGGGTGTTCCCACGGGAATGTC
121 CAGTGACGTCAAAGGCGTGGTTTTACGACAGGGCGAGTTCCGCGGACTTTTGGCCGGCGC
121 CAGTGACGTCAAAGGCGTGGTTTTACGACAGGGCGAGTTCCGCGGACTTTTGGCCGGCGC 
end ITR
181 CCGGGTTTTTGGGCGTT TATTGATTTTGCGGTTTAGCGGGTGGTGCTTTTACCA TGTTT
I I I I I I I I I  II I I I I I  I l l l l l l l l l l l l l l l l l l  l l l l l l l l l l l l l l l l l l  Hi l l
181 CCGGGTTTTTGGGCGTT TATTGATTTTGCGGTTTATCGGGTGGTGCTTTTACCACTGTTT
240 GCGGAAGATTTAGTTGTTTATGGAGCTGGTTTTGGTGCCAGTTCCTCCACGGCTAATGTC
l l l l l l
241 GCGGAAGATTTAGTTGTTTATGGAGCTGGTTTTGGTGCCAGTTCCTCCACGCCTAATGCT
300 AAAGTTTATGTCAATATAACAGAAACACTCTGTTCTCTGTTTACAGCACCCCACCCGGTG
III III III I III III III III III III III III I I l l l l l l l l l l  I I I I I  Mi l l  I
301 AAAGTTTATGTCAATATAACAGAAACACTCTGTTCTTTGTTTACAGCGCCCCACCCGGCG
360 GTTTTTCGCCACGCCTTTGGGTTAATTTTATTTCCCTATACGCGGCCTTAAATTCTCAGT
III III III III I III III III III III III III III III III III I l l l l l l  I I I I  I
361 GTTTTTCGCCACGCCTTTGGGTTAATTTTATTTCCCTATACGCGGCCCTAAATTCTCA T
TATA E1a
420 GCAGACGAAAGAGGACTACTCTTGAGTGCGCACGGAGAAGAGTTTTCTCTTCGCTGTGTC
I I I I I II I I I I I I I I I I I II I I I I I I I I I I I I II I I I I I I I I III l l l l l l  III l l l l l l
420 GCAGACGAAAGAGGACTACTCTTGAGTGCGCACGGAGAAGAGTTTTCTCTTCGCTGTGTC
480 TCATATATTTTCTGAAAAATGAAATATACTATTGTGCCGGCGCCGCGCAATCTCCATGAT
III III III I I I I I I I I I I I III III III III III III III III III III III III III
480 TCATATATTCTCTGAAAAATGAAATATACTATTGTGCCGGCGCCGCGCAATCTCCATGAT
met E1a (orf1)
540 TATGTTTTAGAGCTACTGGAAGAGTGGCAGCCGGACTGCCTTGACTGTGAGTATTCTCAT
III III III III III III III III III I I I III I III III III III III III I III I I
540 TATGTTTTAGAGCTACTGGAAGAGTGGCACCCGGACTGCCTTGACTGTGAGTATCCTCAT
600 GGCAGCCCCTCGCCGCCTACTCTGCACGATCTTTTTGATGTTGAGCTGGAGACTTCTCAC
600 GGCAGCCCCTCGCCGCCTACTCTGCACGATCTTTTTGATGTTGAGCTGGAGACTTCTCAC
660 AGCCCTTTTGTGGGCCTGTGTGATTCCTGTGCGGAGGCTGACACTGATTCGAGTGCGAGC
I III III III I III III III III III III III III III I III I I III III III I I I III I
660 AGCCCTTTTGTGGGCCTGTGTGATTCCTGTGCGGAGGCTGACACTGATTCGAGTGCGAGC
720 ACTGAGGGTGATTCTGGGTTTAGTCCTTTATCCACTCCGCCGGTTTCA CTATTCCACCG
III III III I III III III III III III I III III III III III I I I l l l l l l l l l l l
720 ACTGAGGGTGATTCTGGGTTTAGTCCTTTGTCCACTCCGCCGGTTTCACCTATTCCACCG
779 CATCCCACCTCTCCTGCTAGCATTTCTGACGACATGTTGCTGTGCTTAGAGGAAATGCCC
! M  111 M  11! 1111!! 11I I II I ! 111! I i I ! 111 11111111 III 11 III 111 III I
780 CATCCCACCTCTCCTGCTAGCATTTCTGACGACATGGTGCTGTGCTTAGAGGAAATGCCC
999999999799
99999999999999999^
^783720595819005^52548
^99999999999999
899999999999999999
839 ACCTTTGATGACGAGGACGAGGTTCGAAGCGCGGCGACCACCTTTGAGCGGTGGGAAAAC
I I I I I II I I I II I I I II I II I I I I I I I I I I I III I  I I II I I I I I I II I I I I I I I I I I I I I
840 ACCTTTGATGACGAGGACGAGGTTCGAAGCGCGGCGACCACCTTTGAGCGGTGGGAAAAC
899 A TTTTGACCCCCATGTGGGTCCTATTTTTGGCTGTTTGCGCTGTGCTTTTTATCAAGAG
I III II I I I I I I I I I  I I I I I III  I I I I I I I I I I II
900 ACTTTTGACCCCCATGTGGGTCCTATTTTTGGCTGTTTGCGCTGTGCTTTTTATCAAGAG 
958 CAGGATGATAATGCACTTTGTGGGCTTTGCTAT CTAAAGGCCCTTGCCGAA GTAAGTT
I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I l l l l l l l l l l l l l l l l l l  l l l l l l l
960 CAGGATGATAATGCACTTTGTGGGCTTTGCTATCCTAAAGGCCCTTGCCGAAGGTAAGTT
end
1016 TT AATTTAAATGTTTGGGCAGGTTAAATGTTTGGGCAGGTTAAATGTTTTAGGTGTGTA
II l l l l l l l l l l l l l l l l l l l l l l l l l l ll l l ll l l ll l ll l l ll l l ll l l l l l l l l l l
1020 TTGAATTTAAATGTTTGGGCAGGTTAAATGTTTGGGCAGGTTAAATGTTTTAGGTGTGTA 
orf1 met E1a (orf2)
1075 TTGATTTTTAATTTT GCTTTTTAGTGCCTTTTGCTATGCCTGTACGTTCAGAACCCGCT
I II II III I III I I I l l l l l l l l l l l l l l l l l l l l  I I I I I I I I I I II I I I I I I I I I I I
1080 TTGATTTTTAATTTTGGCTTTTTAGTGCCTTTTGCTTTGCCTGTACGTTCAGAACCCGCT 
1134 TCGGCTGGAGCTGAGGAGGAAGATGATGAAGTTATTTTTGTGTCTGCCAAACCTGGGGGC
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
1140 TCGGCTGGAGCTGAGGAGGAAGATGATGAAGTTATTTTTGTGTCTGCCAAACCTGGGGGC 
1194 AGAAAGAGGTCAGCAGCTACTCCCTGTGAGCCAGATGGGGTCAGCAAACGCCCTTGCGTG
l l l l l l l l l l l l l l l l l l l l I I I I l l l l l l l I I I  I III  II III I I I I I  I I l l l l l l  II
1200 AGAAAGAGGTCAGCAGCTACTCCCTGTGAGCCAGATGGGGCCAGCAAACCCCCTTGCGTG 
1254 CCAGAGCCTGAGCAAACAGAACCTTTGGATTTGTCTTTGAAGCCACGCCCGAACTAATCT
I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I
1260 GCAGAGCCTGAGCAAACAGAACCTTTGGATTTGTCTTTGAAGCCACGCCCGAACTAATCT
end orf2
1314 CCTTGAGCACAAAGCAAT AAAGTAATCTTGTTTAACAAGTT
1320 CCTTGAGCACAAAGCAATAAAGTAATCTTGTTTAACAAGTT 
, polyA Ela
Matches = 1335 Mismatches = 18 Unmatched = 8 
Length = 1361 Matches/length = 98.1 percent
Fig. 4.10 Presumptive TATA, initiating methionines and 
polyA signal are indicated on both the CAV-1 Ela/Vaxitas 
insertion and the Glasgow Ela/Vaxitas insertion sequence; 
demonstrating that the Vaxitas insertion consists of a 
copy of the LHT Ela region at the RHT.
30594139
F I G U R E  4.11
Comparison of the Glasgow and Vaxitas 
Right-hand Ends
VAXITAS RHT 
GLASGOU RHT
1 CATCATCAATAATATACAGGACAAAGAGGTGTGGCTTAAATTTGGGTGTTGCAAGGGGCG
1 CATCATCAATAATATACAGGACAAAGAGGTGTGGCTTAAATTTGGGCGTTGCAAGGGGCG
★
61 GGGTCATGGGACGGTCAGGTTCAGGTCACGCCCTGGTCAGGGTGTTCCCACGGGAATGTC
61 GGGTCATGGGACGGTCAGGTTCAGGTCACGCCCTGGTCAGGGTGTTCCCACGGGAATGTC
121 CAGTGACGTCAAAGGCGTGGTTTTACGACAGGGCGAGTTCCGCGGACTTTTGGCCGGCGC
121 CAGTGACGTCAAAGGCGTGGTTTTACGACAGGGCGAGTTCCGCGGACTTTTGGCCGGCGC
181 CCGGGTTTTTGGGCGTT 197
181 CCGGGTTTTTGGGCGTT 197
Matches = 196 Length = 197 Matches/Length = 99.5%
Mismatches = 1 Unmatched = 0
1353 TGACAAGGACGTGCTGTACTTTTTGTGAACTTTCCGGGCCAACCGCCAAAGGGAAACTGC
229 TGACAAGGACGTGCTGTACTTTTTGTGAACTTTCCGGGCCAACCGCCAAAGGGAAACTGC
1413 ACTTAACATTTACCACGCGCCCACATTTTATGACTGTACTTGGCACCACTTCCTCAAACG
289 ACTTAACATTTACCACGCGCCCACAATTTATGACTGTACTTGGCACCACTTCCTCAAACG
*
1473 CCCCGTTATATTCCTTTTCGTTTTCCACACGCCCTACTTTGAGGACTATATAAACGCTGT
349 CCCCGTTATATTCCTTTTCGTTTTCCACACGCCCTACTTTGAGGACTATATAAACGCTGT
TATA E4
1533 GCTTGGCATTTCATCCTCATAGCTCTCCTCTGACAGCCAGCCGTCCGTGAGTACAATGGC
409 GCTTGGCATTTCATCCTCATAGCTCTCCTCTGACAGCCAGCCGTCCGTGAGTACTATGGC
donor splice? *met E4?
1593 AGCTTTAGGAGTGTCTATGGGAGCATGTTTTTGTCTGAGGCTTCACAAGAGTCTAGTGGA
469 AGCTTTAGGAGTGTCTATGGGAGCATGTTTTTGTCTGAGGCTTCACAAGAGTCTAGTGGA
1653 GAGTGTGTGTGCTCAGCTGAGACTTACGAACTTTTTGCCTTCTGAACTCGCCGTGTGGTG
529 GAGTGTGTGTGCTCAACTGAGACTTACGAACTTTTTGCCTTCTGAACTCGCCGTGTGGTG
* donor splice
1713 TTTAGCCTTATTAGGGCTCAGGAAGTGCGTCCGTGTCCTACCTTGCCGCGGCTGTTTCGG
589 TTTAGCCTTATTAGGGCCCAGGAAGTGCGTCCGTGTCCTACCTTGCCGCGGCTGTTTCGG
E4? *
1773 TTTA
649 TTTA
Matches = 420 Mismatches = 4 Unmatched = 0
Length = 424 Matches/length = 99.1 percent
Fig. 4.11 Alignment of the Glasgow and Vaxitas RHT
sequences excluding the Vaxitas insertion. Presumptive 
control signals, i.e. TATA, ATG and possible donor splice 
sites, as inferred by homology to human AdV E4 regions, 
are indicated.
F I G U R E  4.12
Schematic Diagram of the Vaxitas Additional DNA 
In Relation to the Glasgow Right-hand End and Ela Region
GLASGOW CAV-2
Sail
- / / -
Sstll
Hpal I
474bp
Sstll
160bp
-390bp- ->|/81bp\ 171 174bp
Hpal I Hpal I
First 16bp of 
the 81bp 
Glasgow 
HpalI fragment 
conserved
\Last 35bp of 
^he 81 bp 
Glasgow HpalI 
fragment 
conserved
Sail
-//-
Sstll
Hpal I
1598bp
-390bp- Reiterated E1a
Hpal I
Sstll
160bp
|7 | 174bp
Hpal I
VAXITAS CAV-2
-------1---- 1— |---- 1--- Hpal I sites
|<~ 627->| 1891541162 |<-173-> within the
reiterated E1a
Fig. 4.12 Schematic representation of the right-hand 
terminal regions of Glasgow and Vaxitas CAV-2 
demonstrating Sstll and Hpall sites. All fragment sizes 
are indicated in bp.
F I G U R E  4.13
Translation in all Three Reading Frames of the 
Vaxitas Right-Hand End
10 20 30 40 50 60
CATCATCAATAATATACAGGACAAAGAGGTGTGGCTTAAATTTGGGTGTTGCAAGGGGCG 
HisHisGlnEndTyrThrGlyGlnArgGlyValAlaEndlleTrpValLeuGlnGlyAla 
I leileAsnAsnlleGlnAspLysGluValTrpLeuLysPheGlyCysCysLysGlyAr 
SerSerlleileTyrArgThrLysArgCysGlyLeuAsnLeuGlyValAlaArgGlyG
70 80 90 100 110 120
GGGTCATGGGACGGTCAGGTTCAGGTCACGCCCTGGTCAGGGTGTTCCCACGGGAATGTC 
GlySerT rpAspGlyGlnValGlnValThrProT rpSerGlyCysSerHisGlyAsnVal 
gGlyHisGlyThrValArgPheArgSerArgProGlyGlnGlyValProThrGlyMetSe 
lyValMetGlyArgSerGlySerGlyHisAlaLeuValArgValPheProArgGluCysP
130 140 150 160 170 180
CAGTGACGTCAAAGGCGTGGTTTTACGACAGGGCGAGTTCCGCGGACTTTTGGCCGGCGC 
GInEndArgGlnArgArgGlvPheThrThrGlvArgVaiProArgThrPheGlvArgArg 
rSerAspValLysGlyValValLeuArgGlnGlyGluPheArgGlyLeuLeuAlaGlyAl 
roVa UhrSerLysAlaTrpPheTyrAspArgAlaSerSerAlaAspPheT rpProAlaP 
end ITR start reiterated E1a
190 \
CCGGGTTTTTGGGCGT 
ProGlyPheT rpAlaP 
aArgValPheGlyArg 
roGlyPheLeuGlyVa
/200 210 220 230 240
TTATTGATTTTGCGGTTTAGCGGGTGGTGCTTTTACCATGTTTG 
he IleAspPheAIaVaIEndArgVaiVaILeuLeuProCysLeu 
LeuLeuIleLeuArgPheSerGlyTrpCysPheTyrHi sValCy 
ITyrEndPheCysGlyLeuAlaGlvGlvAlaPheThrMetPheA
250 260 270 280 290 300
CGGAAGATTTAGTTGTTTATGGAGCTGGTTTTGGTGCCAGTTCCTCCACGGCTAATGTCA 
ArgLysIleEndLeuPheMetGluLeuValLeuVaIProValProProArgLeuMetSer 
sGlyArgPheSerCysLeuT rpSerT rpPheT rpCysGInPheLeuHi sGlyEndCysGI 
laGluAspLeuValValTyrGlyAlaGlyPheGlyAlaSerSerSerThrAlaAsnValL
310 320 330 340 350 360
AAGTTTATGTCAATATAACAGAAACACTCTGTTCTCTGTTTACAGCACCCCACCCGGTGG 
LysPheMetSerlleEndGlnLysHisSerValLeuCysLeuGlnHisProThrArgTrp 
nSerLeuCysGlnTyrAsnArgAsnThrLeuPheSerValTyrSerThrProProGlyGl 
ysValTyrValAsnlleThrGluThrLeuCysSerLeuPheThrAlaProHisProValV
TATA E1a
370 380 390 400 410 / 420
TTTTTCGCCACGCCTTTGGGTTAATTTTATTTCCCTATACGCGGCCTTAAATTCTCAGTG 
PhePheAlaThrProLeuGlyEndPheTyrPheProIleArgGlyLeuLysPheSerVal 
yPheSerProArgLeuT rpValAsnPhelleSerLeuTyrAlaAlaLeuAsnSerGlnCy 
alPheArgHisAlaPheGlyLeuIleLeuPheProTyrThrArgProEndlleLeuSerA
430 440 450 460 470 480
CAGACGAAAGAGGACTACTCTTGAGTGCGCACGGAGAAGAGTTTTCTCTTCGCTGTGTCT 
GlnThrLysGluAspTyrSerEndValArgThrGluLysSerPheLeuPheAlaValSer 
sArgArgLysArgThrThrLeuGluCysAlaArgArgArgValPheSerSerLeuCysLe 
laAspGluArgGlyLeuLeuLeuSerAlaHisGlyGluGluPheSerLeuArgCysValS
met E1a orf1
490 \500 510 520 530 540
CATATATTTTCTGAAAAATGAAATATACTATTGTGCCGGCGCCGCGCAATCTCCATGATT 
HisIlePheSerGluLysEndAsnlLeLeuLeuCysArgArgArgAlalleSerMetlle 
ulleTyrPheLeuLysAsnGluILeTyrTyrCysAlaGlyAlaAlaGlnSerProEndLe 
erTyrllePheEndLysMetLysTyrThrlleValProAlaProArgAsnLeuHisAspT
550 560 570 580 590 600
ATGTTTTAGAGCTACTGGAAGAGTGGCAGCCGGACTGCCTTGACTGTGAGTATTCTCATG 
MetPheEndSerTyrT rpLysSerGlySerArgThrAlaLeuThrValSerlleLeuMet 
uCysPheArgAlaThrGlyArgValAlaAlaGlyLeuProEndLeuEndValPheSerT r 
yrVa LLeuGluLeuLeuGluGluTrpGlnProAspCysLeuAspCysGluTyrSerHisG
610 620 630 640 650 660
GCAGCCCCTCGCCGCCTACTCTGCACGATCTTTTTGATGTTGAGCTGGAGACTTCTCACA 
AlaAlaProArgArgLeuLeuCysThrllePheLeuMetLeuSerT rpArgLeuLeuThr 
pGlnProLeuAlaAlaTyrSerAlaArgSerPheEndCysEndAlaGlyAspPheSerGl 
LySerProSerProProThrLeuHi sAspLeuPheAspValGluLeuGluThrSerH i sS
670 680 690 700 710 720
GCCCTTTTGTGGGCCTGTGTGATTCCTGTGCGGAGGCTGACACTGATTCGAGTGCGAGCA 
AlaLeuLeuT rpAlaCysValIleProValArgArgLeuThrLeuIleArgValArgAla 
nProPheCysGLyProValEndPheLeuCysGlyGlyEndHi sEndPheGluCysGluHi 
erProPheValGlyLeuCysAspSerCysAlaGluAlaAspThrAspSerSerAlaSerT
730 740 750 760 770 780
CTGAGGGTGATTCTGGGTTTAGTCCTTTATCCACTCCGCCGGTTTCACTATTCCACCGCA 
LeuArgVa11leLeuGlyLeuVaILeuTyrProLeuArgArgPheH i sTyrSerThrAI a 
sEndGlvEndPheTrpVaLEndSerPhelleHi sSerAlaGlyPheThrIleProProHi 
hrGluGlyAspSerGlyPheSerProLeuSerThrProProVaISerLeuPheH i sArgI
790 800 810 820 830 840
TCCCACCTCTCCTGCTAGCATTTCTGACGACATGTTGCTGTGCTTAGAGGAAATGCCCAC 
SerHisLeuSerCysEndHisPheEndArgHisValAlaValLeuArgGlyAsnAlaHis 
sProThrSerProAlaSerIleSerAspAspMetLeuLeuCysLeuGluGluMetProTh 
leProProLeuLeuLeuAlaPheLeuThrThrCysCysCysAlaEndArgLysCysProP
850 860 870 880 890 900
CTTTGATGACGAGGACGAGGTTCGAAGCGCGGCGACCACCTTTGAGCGGTGGGAAAACAT 
LeuEndEndArgGlyArgGlySerLysArgGlyAspHi sLeuEndAlaValGlyLysHis 
rPheAspAspGluAspGluValArgSerAlaAlaThrThrPheGluArgT rpGluAsnlI 
roLeuMetThrArgThrArgPheGluAlaArgArgProProLeuSerGlyGlyLysThrP
910 920 930 940 950 960
TTTGACCCCCATGTGGGTCCTATTTTTGGCTGTTTGCGCTGTGCTTTTTATCAAGAGCAG 
PheAspProHisValGlyProIlePheGlyCysLeuArgCysAlaPheTyrGlnGluGln 
eLeuThrProMetT rpValleuPheLeuAtaValCysAlaValLeuPhelleLysSerAr 
heEndProProCysGlySerTyrPheT rpLeuPheAlaLeuCysPheLeuSerArgAlaG
end orf1
970 980 990 1000 1010 \1020
GATGATAATGCACTTTGTGGGCTTTGCTATCTAAAGGCCCTTGCCGAAGTAAGTTTTAAT 
AspAspAsnAlaLeuCysGlyLeuCysTyrLeuLysAlaLeuAlaGluValSerPheAsn 
gMetlleMetHisPheValGlyPheAlalleEndArgProLeuProLysEndValLeuII 
LyEndEndCysThrLeuT rpAlaLeuLeuSerLysGlyProCysArgSerLysPheEndP
met orf2
1030 1040 1050 1060/ 1070 1080
TTAAATGTTTGGGCAGGTTAAATGTTTGGGCAGGTTAAATGTTTTAGGTGTGTATTGATT 
LeuAsnValTrpAlaGlyEndMetPheGlyGlnValLysCysPheArgCysVaI LeuIle 
eEndMetPheGlyGlnValLysCysLeuGlyArgLeuAsnValLeuGlyValTyrEndPh 
heLysCysLeuGlyArgLeuAsnValTrpAlaGlyEndMetPheEndValCysIleAspP
1090 1100 1110 1120 1130 1140
TTTAATTTTGCTTTTTAGTGCCTTTTGCTATGCCTGTACGTTCAGAACCCGCTTCGGCTG 
PheAsnPheAlaPheEndCysLeuLeuLeuCysLeuTyrValGlnAsnProLeuArgLeu 
eLeuIleLeuLeuPheSerAlaPheCysTyrAlaCysThrPheArgThrArgPheGlyT r 
heEndPheCysPheLeuValProPheAlaMetProValArgSerGluProAlaSerAlaG
1150 1160 1170 1180 1190 1200
GAGCTGAGGAGGAAGATGATGAAGTTATTTTTGTGTCTGCCAAACCTGGGGGCAGAAAGA 
GluLeuArgArgLysMetMetLysLeuPheLeuCysLeuProAsnLeuGlyAlaGluArg 
pSerEndGlyGlyArgEndEndSerTyrPheCysVaICysGInThrT rpGlyGInLysGI 
lyAlaGluGluGluAspAspGluValIlePheValSerAlaLysProGlyGlyArgLysA
1210 1220 1230 1240 1250 1260
GGTCAGCAGCTACTCCCTGTGAGCCAGATGGGGTCAGCAAACGCCCTTGCGTGCCAGAGC 
GlyGlnGlnLeuLeuProValSerGlnMetGlySerAlaAsnAlaLeuAlaCysGlnSer 
uValSerSerTyrSerLeuEndAlaArgTrpGlyGlnGlnThrProLeuArgAlaArgAl 
rgSerAlaAlaThrProCysGluProAspGlyValSerLysArgProCysValProGluP
end orf2
1270 1280 1290 1300 1310/ 1320
CTGAGCAAACAGAACCTTTGGATTTGTCTTTGAAGCCACGCCCGAACTAATCTCCTTGAG 
LeuSerLysGInAsnLeuT rplIeCvsLeuEndSerHi sAlaArgThrAsnLeuLeuGlu 
aEndAlaAsnArgThrPheGlyPheValPheGluAlaThrProGluLeuIleSerLeuSe 
roGluGlnThrGluProLeuAspLeuSerLeuLysProArgProAsnEndSerProEndA 
polyA signal E1a
1330 / 1340 1350 1360 1370 1380
TGACAAGGACGTGCTGTACTTTTTGTG 
EridG I nG I yArgA I aVa I LeuPheVa I 
lAspLysAspValLeuTyrPheLeuEn 
euThrArgThrCysCysThrPheCysG 
revertion to wild-type RHT
CACAAAGCAATAAAGTAATCTTGTTTAACAAGT 
Hi sLysAlalleLysEndSerCysLeuThrSer 
rThrLysGlnEndSerAsnLeuValEndGlnVa 
laGlnSerAsnLysValIleLeuPheAsnLysL 
end reiterated E1a
1390 1400 1410 1420 1430 1440
AACTTTCCGGGCCAACCGCCAAAGGGAAACTGCACTTAACATTTACCACGCGCCCACATT 
AsnPheProGlyGlnProProLysGlyAsnCysThrEndHisLeuProArgAlaH i sile 
dThrPheArgAlaAsnArgGlnArgGluThrAlaLeuAsnlleTyrHisAlaProThrPh 
luLeuSerGlyProThrAlaLysGlyLysLeuHisLeuThrPheThrThrArgProHi sP
1450 1460 1470 1480 1490 1500
TTATGACTGTACTTGGCACCACTTCCTCAAACGCCCCGTTATATTCCTTTTCGTTTTCCA 
LeuEndLeuTyrLeuAlaProLeuProGlnThrProArgTyrlleProPheArgPhePro 
eTyrAspCysThrTrpHi sHi sPheLeuLysArgProVa11lePheLeuPheValPheHi 
heMetThrValLeuGlyThrThrSerSerAsnAlaProLeuTyrSerPheSerPheSerT 
TATA E4
1510 1520 / 1530 1540 1550 1560
CACGCCCTACTTTGAGGACTATATAAACGCTGTGCTTGGCATTTCATCCTCATAGCTCTC 
HisAlaLeuLeuEndGlyLeuTyrLysArgCysAlaT rpHisPhelIeLeuIleAlaLeu 
sThrProTyrPheGluAspTyrlleAsnAlaValLeuGlylleSerSerSerEndLeuSe 
hrArgProThrLeuArgThrlleEndThrLeuCysLeuAlaPheHisProHi sSerSerP
donor splice?
1570 \1580 1590 1600 1610 1620
CTCTGACAGCCAGCCGTCCGTGAGTACAATGGCAGCTTTAGGAGTGTCTATGGGAGCATG 
LeuEndGlnProAlaValArgGluTyrAsnGlySerPheArgSerValTyrGlySerMet 
rSerAspSerGlnProSerValSerThrMetAlaAlaLeuGlyValSerMetGlyAlaCy 
roLeuThrAlaSerArgProEndValGlnTrpGlnLeuEndGluCysLeuTrpGluHi sV
1630 1640 1650 1660 1670 1680
TTTTTGTCTGAGGCTTCACAAGAGTCTAGTGGAGAGTGTGTGTGCTCAGCTGAGACTTAC 
PheLeuSerGluAlaSerGlnGluSerSerGlyGluCysValCysSerAlaGluThrTyr 
sPheCysLeuArgLeuHisLysSerLeuValGluSerValCysAlaGlnLeuArgLeuTh 
alPheValEndGlyPheThrArgValEndTrpArgValCysValLeuSerEndAspLeuA
1690 1700 1710 1720 1730 1740
GAACTTTTTGCCTTCTGAACTCGCCGTGTGGTGTTTAGCCTTATTAGGGCTCAGGAAGTG 
GluLeuPheAlaPheEndThrArgArgVaIValPheSerLeuIleArgAlaGlnGluVal 
rAsnPheLeuProSerGluLeuAlaValTrpCysLeuAlaLeuLeuGlyLeuArgLysCy 
rgThrPheCysLeuLeuAsnSerProCysGlyVaIjEndProTyrEndGlySerGlySerA
1750 1760 1770
CGTCCGTGTCCTACCTTGCCGCGGCTGTTTCGGTTTA 
ArgProCysProThrLeuProArgLeuPheArgPhe 
sValArgValLeuProCysArgGlyCysPheGlyLeu 
laSerValSerTyrLeuAlaAlaAlaValSerVal
Fig. 4.13 Translation in all three reading frames of the 
Vaxitas RHT. The end of the ITR/start of reiterated Ela: 
end of reiterated Ela/revertion to wild-type RHT sequences 
are marked. Presumptive TATA boxes, donor splice sites 
and termination codons are also indicated. Explanation of 
splice site consensus sequences given in figure 4.14.
F I G U R E  4.14
Translation in all Three Reading Frames of the 
Glasgow Right-hand end
10 20 30 40 50 60
CATCATCAATAATATACAGGACAAAGAGGTGTGGCTTAAATTTGGGCGTTGCAAGGGGCG 
HisHisGlnEndTyrThrGlyGlnArgGlyValAlaEndlleTrpAlaLeuGlnGlyAla 
I leileAsnAsnlleGlnAspLysGluValTrpLeuLysPheGlyArgCysLysGlyAr 
SerSerlleileTyrArgThrLysArgCysGlyLeuAsnLeuGlyValAlaArgGlyG
70 80 90 100 110 120
GGGTCATGGGACGGTCAGGTTCAGGTCACGCCCTGGTCAGGGTGTTCCCACGGGAATGTC 
GlySerT rpAspGlyGlnValGlnValThrProT rpSerGlyCysSerHisGlyAsnVaI 
gGlyHisGlyThrValArgPheArgSerArgProGlyGlnGlyValProThPGlyMetSe 
lyValMetGlyArgSerGlySerGlyHi sAlaLeuValArgValPheProArgGluCysP
130 140 150 160 170 180
CAGTGACGTCAAAGGCGTGGTTTTACGACAGGGCGAGTTCCGCGGACTTTTGGCCGGCGC 
GlnEndArgGlnArgArgGlyPheThrThrGlyArgValProArgThrPheGlyArgArg 
rSerAspValLysGlyValValLeuArgGlnGlyGluPheArgGlyLeuLeuAlaGlyAl 
roValThrSerLysAlaT rpPheTyrAspArgAlaSerSerAlaAspPheT rpProAlaP 
end ITR
200 210 220 230 240
GTGCCTATTTGTGGTTTTGTGGTTGACAGGGTGACAAGGACGT 
uCysLeuPheVaiValLeuT rpLeuThrGlyEndGlnGlyArg 
ysAlaTyrleuT rpPheCysGlyEndGInGlyAspLysAspVa 
ValProIleCysGlyPheValValAspArgValThrArgThrC
190 \
CCGGGTTTTTGGGCGTT 
ProGlyPheTrpAlaLe 
aArgValPheGlyArgC 
roGlyPheLeuGlyVal
250 260 270 280 290 300
GCTGTACTTTTTGTGAACTTTCCGGGCCAACCGCCAAAGGGAAACTGCACTTAACATTTA 
AlaValLeuPheValAsnPheProGlyGlnProProLysGlyAsnCysThrEndHisLeu 
iLeuTyrPheLeuEndThrPheArgAlaAsnArgGlnArgGluThrAlaLeuAsnlleTy 
ysCysThrPheCysGluLeuSerGlyProThrAlaLysGlyLysLeuHisLeuThrPheT
310 320 330 340 350 360
CCACGCGCCCACAATTTATGACTGTACTTGGCACCACTTCCTCAAACGCCCCGTTATATT 
ProArgAlaHi sAsnLeuEndLeuTyrLeuAlaProLeuProGlnThrProArgTyrlle 
rH i sAlaProThrlleTyrAspCysThrT rpH i sH i sPheLeuLysArgProValIlePh 
hrThrArgProGlnPheMetThrValLeuGlyThrThrSerSerAsnAlaProLeuTyrS
TATA E4
370 380 390 \ 400 410 420
CCTTTTCGTTTTCCACACGCCCTACTTTGAGGACTATATAAACGCTGTGCTTGGCATTTC 
ProPheArgPheProHisAlaLeuLeuEndGlyLeuTyrLysArgCysAlaTrpHisPhe 
eLeuPheValPheHisThrProTyrPheGluAspTyrlleAsnAlaValLeuGlylleSe 
erPheSerPheSerThrArgProThrLeuArgThrIleEndThrLeuCysLeuAlaPheH
donor splice?
430 440 450 \ 460 470 480
ATCCTCATAGCTCTCCTCTGACAGCCAGCCGTCCGTGAGTACTATGGCAGCTTTAGGAGT 
IleLeuIleAlaLeuLeuEndGlnProAlaValArgGluTyrTyrGlySerPheArgSer 
rSerSerEndLeuSerSerAspSerGlnProSerValSerThrMetAlaAlaLeuGlyVa 
isProHisSerSerProLeuThrAlaSerArgProEndValLeuTrpGlnLeuEndGluC
490 500 510 520 530 540
GTCTATGGGAGCATGTTTTTGTCTGAGGCTTCACAAGAGTCTAGTGGAGAGTGTGTGTGC 
ValTyrGlySerMetPheLeuSerGluAlaSerGlnGItiSerSerGlyGluCysVaiCys 
iSerMetGlyAlaCysPheCysLeuArgLeuHisLysSerLeuValGluSerValCysAl 
ysLeuTrpGluHisValPheVaLEndGlyPheThrArgValEndTrpArgValCysValL
donor splice E4?
550 560 570 580 / 590 600
TCAACTGAGACTTACGAACTTTTTGCCTTCTGAACTCGCCGTGTGGTGTTTAGCCTTATT 
SerThrGluThrTyrGluLeuPheAlaPheEndThrArgArgValValPheSerLeuIle 
aGlnLeuArgLeuThrAsnPheLeuProSerGluLeuAlaValTrpCysLeuAlaLeuLe 
euAsnEndAspLeuArgThrPheCysLeuLeuAsnSerProCysGlyValEndProTyrE
610 620 630 640 650
AGGGCCCAGGAAGTGCGTCCGTGTCCTACCTTGCCGCGGCTGTTTCGGTTTA 
ArgAlaGlnGluValArgProCysProThrLeuProArgLeuPheArgPhe 
uGlyProArgLysCysValArgValLeuProCysArgGlyCysPheGlyLeu 
ndGlyProGlySerAlaSerValSerTyrLeuAlaAlaAlaValSerVal
Fig. 4.14 Translation in all three reading frames of the 
Glasgow CAV-2 right-hand terminal region, encoding the
presumptive E4 promoter. Presumptive TATA marked. All
translational stops are underlined. In addition, possible 
donor splice sites are indicated. The Ad2 E4 donor splice 
site is situated 60bp from the E4 TATA and demonstrates 
the consensus sequence (C/A)(T/A)(G/C)GT(A/G)AG(G/T)
(Rigolet and Galibert, 1984):- the possible donor splice 
of CAV-2 E4 at 452bp shows a 78% similarity to the 
consensus sequence tcCGTGAGT and is situated 57bp from the 
presumptive TATA: the possible donor splice site at 584bp 
shows a 50% similarity to this sequence TGGTgttt but is 
situated 12 0bp from the presumptive TATA. Additionaly,
the second possible donor splice, 120bp from the 
presumptive TATA would involve several ATG codons prior to 
the first splice site, contrary to the human adenovirus E4 
region.
Fig. 4.15 DNA sequence of presumptive Glasgow Ela orfl 
and Vaxitas reiterated Ela orfl transformed to protein. 
Alignment of the two sequences demonstrates the effect 
of the frame shifts and base changes on the presumed 
orfl product of the Vaxitas RHT Ela.
F I G U R E  4.15
Comparison of Open Reading Frame 1 (ORF1) 
of Glasgow Ela (LHT’l and the Vaxitas Reiterated Ela (RHT)
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Fig. 4.16 Organisation of the right-hand terminal of 
Vaxitas CAV-2 as defined by sequence analysis. 
Presumptive TATA boxes and initiating methionine codons 
are indicated.
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F I G U R E  4.16
Schematic Organisation of the Right-hand Terminal
of Vaxitas CAV-2
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F I G U R E  4.17
Sequence Analysis of the 231bp Nobivac CAV-2 Insertion
NOBIVAC
GLASGOW CAV-2 RHT STRAND L
1 CGGCCAAAAGTCCGCGGAA TCGCCCTGTCGTAAAACCACGCCTTTGACGTCACTGGACA 
176 CGGCCAAAAGTCCGCGGAACTCGCCCTGTCGTAAAACCACGCCTTTGACGTCACTGGACA
60 TTCCCGTGGGAACACC TGACCAGGGCGTGACCTGAACCTGACCGTCCCATGACCCCGCC 
116 TTCCCGTGGGAACACCCTGACCAGGGCGTGACCTGAACCTGACCGTCCCATGACCCCGCC
119 CCTTGCAAGACCCAAATTTAAGCCACACCTGTTTGTCCTGTATATTA 165
56 CCTTGCAACGCCCAAATTTAAGCCACACCTCTTTGTCCTGTATATTA 10
* *  *
Hatches = 162 Length = 167 Matches/length = 97.0%
165 AAGTACAGTCATAAAATGTGG CGCGTGGTAAATGTTAAGTGCAAGTTTCCCTTTGGCGG 
329 AAGTACAGTCATAAATTGTGGGCGCGTGGTAAATGTTAAGTGCA GTTTCCCTTTGGCGG
224 TTGGCCCG 231
270 TTGGCCCG 263
Matches = 65 Length = 68 Matches/length = 95.6%
NOBIVAC
VAXITAS RHT STRAND L
1 CGGCCAAAAGTCCGCGGAA TCGCCCTGTCGTAAAACCACGCCTTTGACGTCACTGGACA 
176 CGGCCAAAAGTCCGCGGAACTCGCCCTGTCGTAAAACCACGCCTTTGACGTCACTGGACA
60 TTCCCGTGGGAACACC TGACCAGGGCGTGACCTGAACCTGACCGTCCCATGACCCCGCC 
116 TTCCCGTGGGAACACCCTGACCAGGGCGTGACCTGAACCTGACCGTCCCATGACCCCGCC
119 CCTTGCAAGACCCAAATTTAAGCCACACCTGTTTGTCCTGTATATTA 165
56 CCTTGCAACACCCAAATTTAAGCCACACCTCTTTGTCCTGTATATTA 10
* *
Matches = 163 Length = 167 Matches/length = 97.6%
165 AAGTACAGTCATAAAATGTGG CGCGTGGTAAATGTTAAGTGCAAGTTTCCCTTTGGCGG 
1453 AAGTACAGTCATAAAATGTGGGCGCGTGGTAAATGTTAAGTGCA GTTTCCCTTTGGCGG
* *
224 TTGGCCCG 231
,1394 TTGGCCCG 1387
Matches = 66 Length = 68 Matches/length = 97.1%
NOBIVAC 
CAV-1 ITR
32 AAAACCACGCCTTTGACGTCACTGGACATTCCCGTGGGAA CACC TGACCAGGGCGTGA 
22 AAAAACACCCAATTGACGTCA TGGTCTTTCCCGTGGGAAACGCCCTGAACAGGGTGTGA 
* * ** * * * * * * * *
90 CCTGAACCTGACCGTCCCATGACCCCGCCCCTTGCAAGACCCAA ATTTAAGCCACACCT 
81 CCTTGTCAAAACAATCAGACAAAAACTTTTTTAAAAAAAAACAACATTTAGGCCACACCT 
*** *** ** ** ** *** ***** *** * ** * *
149 GTTTGTCCTGTATATTA 165
141 CTTTGTCCTGTATATTA 157
*
Matches = 96 Length = 137 Matches/length = 70.1%
Fig. 4.17 Additional sequence analysis to the Nobivac 
CAV-2 insertion. Previous similarity to the Vaxitas and 
Glasgow ITRs now extended to include the area of the 
Vaxitas and Glasgow right-hand terminals immediatly prior 
to the E4 promoter.
F I G U R E  4.18
Schematic Representation of the Nobivac 231bp Insertion 
as Compared to the Glasgow and Vaxitas 
Right-hand Termini
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Fig. 4.18 Hpall fragment containing the Nobivac 
additional DNA was sequenced as a single fragment, in both 
orientations, from bpl to bp 231. The numbers above the 
areas of the Nobivac clone which show homology indicate 
the part of the fragment with reference to the whole 231bp 
in the orientation indicated by the sequence given in 
chapter 3. The percentage homology of each region of 
Glasgow (A) and Vaxitas (B) is noted within each block.
Fig. 4.19 Restriction enzyme profile of the Vaxitas 
(V) genome following a single pass in the Mv-l-Lu cell 
line as compared to the genome prior to passage in the 
new cell line. The Glasgow (G) CAV-2 genome is shown 
for comparison.
(A) digestion of the Vaxitas and Glasgow
genomes with; lane 1, PstI; lane 2, Sail; lane 3, 
HpalI; lane 4, EcoRI. Hindlll/EcoRI digested ^  DNA
fragments were used as m.w. markers.
(B) Pattern of fragments produced by
Vaxitas (lane 5) following digestion with PstI prior to
being passed in the Mv-l-Lu cell line. PstI digestion 
of Kavak CAV-2 (lane 1), Epivac CAV-2 (lane 2), Glasgow 
CAV-2 (lane 3) and Nobivac CAV-2 (lane 4) are shown for 
comparison. Hindlll digested \ DNA fragments were used 
as m.w. markers.
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F I G U R E  4.19
Alterations in the Vaxitas Genome Following One Pass 
In the Mv-l-Lu Cell Line
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Plaque Purification of Vaxitas CAV-2
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Fig. 4.20 Comparison of PstI digestion of Vaxitas stock 
from Mv-l-Lu cells (lane 1) and two isolations of Vaxitas 
from plaques (lanes 2 and 3) . The two isolates were 
picked from plaques and amplified to allow for viral DNA 
isolation. The appearance of a heterogeneous stock 
following plaque isolation, displayed by the two isolates 
shown above, is consistent with all plaque isolates 
examined. Hindlll/EcoRI digested \ DNA fragments were used 
as m.w. markers.
D I S C U S S I  O N
The DNA sequence of the Glasgow RHT demonstrates several 
of the conserved regions expected from other AdV sequences 
in the E4 region. A presumptive TATA is situated at bp 395 
with an initiating methionine 70bp downstream which 
initiates an open reading frame until the end of the known 
sequence. The human AdVs, however, contain no ATG before 
the initial donor splice site situated 60bp from the E4 
cap site. The only Glasgow RHT/E4 sequences with a strong 
similarity to this consensus splice site are situated at 
bp 452, 57bp downstream of the presumptive TATA: tcCGTGAGT 
(78% similarity):, and at bp584, 130bp downstream of the 
presumptive E4 TATA: TGGTgttt (50% similarity). S
1
analysis and mRNA mapping will be required to determine 
whether the organisation of the CAV-2 E4 region varies 
from that of Ad2. It may initiate at an ATG prior to the
initial donor splice site (if splice at 584bp), the ATG
may be in a non-coding region (if splice at 452bp) or the
initial CAV-2 donor splice site may have no similarity to
the Ad2 E4 donor splice consensus sequence and is 
situated upstream of the ATG thus again placing the ATG in 
a non-coding region. A summary of the presumptive 
organisation of Glasgow CAV-2 E4 promoter region, as 
defined by sequence analysis, is provided in figure 4.21.
The Hpall analysis of the Sail B and Sstll fragments, 
combined with the sequence data from the RHT of both
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F I G U R E  4.21
Schematic Organisation of the Glasgow CAV-2 
Right-hand Terminus
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Fig. 4.21 Schematic organisation of the right-hand 
terminal region of Glasgow CAV-2 as inferred by DNA 
sequence analysis. It should be noted that the distance
from the end of the ITR to the presumptive TATA is 198bp. 
This is consistent with the spacing of the end of the ITR 
and E4 TATA in Ad2 and Ad5, 194bp. The ITR itself however 
is almost twice the length of that in Ad2, 197bp vs 102bp.
Enhancer binding sites are also indicated based upon
sequence similarity to known consensus sequences. ATF, 
consensus sequence (T/G)(T/A)CGTCA, is thought to have
binding sites at 124bp GACGTCA, 145bp TACaCA and 387bp TGA 
gGAC (upper strand). E4TF1, consensus sequence GGAAGTG, 
is believed to have a binding site at 335bp CACTTCC (upper 
strand) and E4F, consensus sequence identical to ATF but 
only recorded as binding to one site adjacent to E4 TATA's 
(Jones etal, 1988), at bp387 TGAgGAC (upper strand). No 
strong similarity is demonstrated to the consensus 
sequence of NF1, TGGCT(N )AGCCAA except at bp31
3
TGGCT(TAA)Atttgg (64.2%).
Glasgow and Vaxitas, demonstrated that the mode of 
insertion of excess DNA into the Vaxitas genome at the RHT 
was similar to the other vaccine strains. All other 
vaccine strains exhibited insertion of DNA into one, or 
possibly more, Hpall fragments. Vaxitas exhibits the same 
properties the only difference being that the insertion 
itself contained additional Hpall fragments, a possibility 
that cannot be excluded from the other vaccine strains 
until their full sequence, i.e. past the site of 
insertion, can be ascertained.
The striking homology between the Vaxitas/Glasgow RHT and 
the Vaxitas RHT/Glasgow Ela implies that replication error 
of some type has occurred in order to facilitate the 
construction of this aberrant genome. The fact that the 
genomes are not identical is evinced by the single base 
change in the ITR and the 4 base changes in the E4 region 
following the end of the Vaxitas insertion. The base 
changes within these regions do not however affect the 
presumptive control sequences or any presumptive open 
reading frames.
The reiterated Ela within the RHT of Vaxitas also appears 
to retain all the presumptive control sequences 
demonstrated by the Glasgow LHT Ela region (Spibey et al, 
1989). However, numerous base changes and frame shifts 
can be seen to have occurred when the overall sequence is 
compared to Glasgow Ela. The frame shifts in particular 
introduce several additional translational stops within
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both orfl and orf2 (figs.4.13, 4.14 and 4.15). When the 
sequence is transformed to demonstrate the protein 
sequence, the predicted amino acid sequence implies that 
any products of the Vaxitas reiterated Ela should be non­
functional. This is of course based on the assumption 
that the presumptive control sequences are correct. A 
highly conserved region exists in the majority of AdV, 
downstream of the Ela TATA, which is demonstrated 
downstream of the presumptive CAV-2 Ela TATA thus 
supporting this area as the candidate TATA box (fig. 
4.10).
When the presumptive orfs of Glasgow Ela and the Vaxitas 
reiterated Ela are compared it can be seen that the frame 
shifts/base changes cause major alterations in the 
continuity of the orfs. An alignment of orfl from 
Glasgow Ela and orfl from the Vaxitas RHT Ela is 
demonstrated in figure 4.15. An assay was therefore 
required to assess whether the reiterated Ela at the RHT 
of Vaxitas was indeed non-functional or what effect it had 
on the function of E4. Chloramphenicol acetyl transferase 
(CAT) assays should answer both the above questions.
It should be noted that, originally, the dominant Sail B 
fragment within the genome of Vaxitas DNA contained an 
insertion of 2.0kb as opposed to the l.lkb insertion 
examined. Preliminary sequence examination of this 2.0kb 
fragment has indicated that it is of a comparable
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structure to the l.lkb fragment i.e. it also appears to 
consist of a reiterated Ela at the RHT. However, it is 
not yet clear whether the difference in the size of the
insertion is due to two copies of a RHT Ela being present
or whether the 2.0kb reiterated "Ela" in this case also 
includes Elb. Further work will resolve this and the
results may elucidate upon the mechanism by which these 
aberrant genomes arise.
Growth of the Vaxitas strain in the new cell line, Mv-1- 
Lu, was directly comparable to the growth of the wild-type 
Glasgow in MDCK cells and growth of Vaxitas in the former 
NMF cell line. The ability of the new cell line to
support plaque formation was an additional bonus and 
facilitated the plaque purification of the virus which, it 
was hoped, would allow the individual isolation of 
different strains of Vaxitas contained within the 
heterogeneous stock virus.
However, plaque purification techniques require 
amplification of the plaque purified virus before there is 
an adequate supply for a viral DNA preparation. During 
this amplification, facilitated by passage of the plaque 
purified virus through increasing numbers of permissive 
cells, all plaque purified virus reverted to the standard 
heterogeneous mixture and repeated attempts could not 
produce virus on a large enough scale to facilitate DNA 
analysis that yielded one single genomic type without a 
heterogeneous background species.
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The remarkable effect upon the LHT of the Vaxitas genome 
of a single pass in Mv-l-Lu cells is not a unique 
occurrence. Ishiyama et al (1986) described equine AdV 
which was found to contain additional sequences of 100- 
700bp after a single pass in a new cell line. As with 
Vaxitas, the relative amounts of each genome "type" 
present within the heterologous mixture did not appear to 
vary during serial passage. However, the EAdV insertions 
occurred at the LHT not the RHT and insertions of greater 
than 200bp rendered the virus defective for replication 
and/or packaging.
The additional homology now available to the Nobivac 
insertion is in agreement to several other human AdV 
insertions mentioned previously (CH 2, Discussion). The 
Nobivac insertion comprises of a copy of the ITR plus 
adjacent sequences. It is presumed, until the exact 
sequence of the Nobivac ITR can be ascertained, that the 
few base changes that occur between the Nobivac ITR copy 
and the Glasgow/Vaxitas ITRs are due to strain 
differences. However, it is not known whether the Nobivac 
insertion is a direct copy: i.e. does it run from specific 
point within the ITR continuously until the end of the 
area of repeat?
The insertion is divided into two parts; the first 165bp, 
i.e. bases 1 -> 165, are a repeat of the ITR matching
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bases 176 -> 10 of the Glasgow/Vaxitas ITRs; the second 66 
bases, i.e. bases 165 -> 231 (the complete Hpall fragment 
of the Nobivac insertion), are a repeat of the area 
covered by bases 329 -> 2 63 of the Glasgow RHT and the 
corresponding area, bases 1453 -> 1387, of the Vaxitas 
RHT. This is clarified schematically in figure 4.18. Two 
possible structures of the Nobivac RHT are described in 
figure 4.22. The exact site and nature of the Nobivac 
insertion can however only be ascertained by obtaining a 
complete sequence of the Nobivac RHT from the terminus 
until past the site of insertion as has already been 
carried out upon the Vaxitas RHT.
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F I G U R E  4.22
Proposed Structure of the Nobivac Right-hand Terminus
For reference:-
HpalI fragments within the Glasgow RHT
174 8 80 560 170bp
If assume Nobivac is normal until bp329 from the RHT:-
x  Y
174 8 80 <— ><------ >
 ______l_l_____ !--- ------------- >norma I ?
231 bp
Where X+Y=the 231bp Hpall fragment unique to Nobivac. 
Section X of this fragment represents the 66bp homologous 
to bpl387-1453 of the Glasgow RHT (see fig. 19) and 
section Y represents the 165bp homologous to bplO-175 of 
the Glasgow ITR.
(i) The whole area of the genome, until past the 
insertion (X and Y), may be repeated as this would result 
in co-migrating fragments which may not be apparent on an 
acrylamide gel.
231 bp
165
X Y
174 8 80 <— ><-----> 8 80 560
 1— i-----l — i------ 1-------- 1—>normal?
z*
The two 8 and 80bp fragments would co-migrate, the 231bp 
fragment would appear as a distinct band and all other 
fragments would appear as normal unless the "insertion" 
continues past the Hpall site encoded at the terminus of 
the ITR (Y) in which case other fragments may also be 
doubles until the genome presumably reverts to normal.
(ii) If the excess DNA is a straightforward insertion the 
genome would simply contain all normal fragment plus the 
additional Hpall fragment. The genome may then continue 
as normal
174 8 80 231
 1— 1----- 1  >norma I ?
Fig. 4.2-2 Two possible descriptions of the additional 
sequences present at the RHT of the Nobivac genome are 
presented, (i) and (ii). It should be noted that (i) and
(ii) rely on the site of "insertion” being within the 
560bp fragment of wild-type i.e. the first 66bp of this 
fragment have been retained, followed by the copy of the 
ITR as far as the Hpall site of the 231bp fragment. When 
comparing this to the Vaxitas insertion, it seems unlikely 
that the copy of the ITR ends exactly on a Hpall site and, 
as no part of the opposite end of the 560bp fragment is 
present in the sequence, that more than one excess Hpall 
fragment is present within the Nobivac RHT. The evidence 
obtained from analysis of Vaxitas would therefore favour 
version (i) as a copy of the 560bp fragment is apparent 
after Hpall digestion of the Nobivac genome analysed on an 
acrylamide gel.
C H A P T E R  5 
Effect of the Additional DNA on the E4 Region 
of the Vaxitas CAV-2 Genome
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I N T R O D U C T I O N
Expression of the Ela gene facilitates transcription from 
early viral promoters Elb, E2, E3 and E4. In addition, Ela 
gene products are able to activate transcription of the 
mammalian heat shock gene (Nevins, 1982) as well as 
certain cellular genes introduced into cells as 
recombinant DNA molecules by transfection or infection 
(Svensson and Akusjarvi, 1984a). The Ela gene also plays a 
critical role in the ability of an AdV to morphologically 
transform cells in vitro. Ginsberg et al (1987) reported 
that El plays an essential role in the pathogenesis of 
adenovirus pneumonia. The significant sequence
differences between the Glasgow and reiterated Vaxitas 
Ela's, if the Vaxitas reiterated Ela is functional, may be 
an important factor in the ability of Glasgow to replicate 
in the intestine, an unusual site of isolation for a CAV- 
2. The Vaxitas 'normal' left-hand terminal Ela may 
however bear little resemblance to the reiterated Ela at 
the right-hand end of the genome due to mutations in the 
reiterated sequence. If however, the reiterated Ela 
encodes functional protein products then it may be 
considered as closely resembling, if not identical to, the 
Ela present at the left-hand terminus. The differences 
between the Glasgow Ela sequence and Vaxitas reiterated 
Ela sequence may then be considered for their relevance in 
the pathogenicity of the two strains.
The presence of a functional reiterated Ela at the right-
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hand terminus of Vaxitas could have profound effects upon 
the virus both in vivo and in vitro. Presumably excess 
amounts of Ela products would be present in cells soon 
after infection. The effect this would have upon the 
expression of viral genes however is not clear. Initial 
expression of the other early genes may initially be 
enhanced with transcription occurring more quickly after 
infection and perhaps to higher levels due to the excess 
of Ela products. Conversely, it is believed that Ela is 
self-regulatory. It is therefore feasible that the 
regulation of Ela would lead to a premature reduction of 
transcription from the other early genes which may in turn 
lead, via a cascade effect, to reduced production from all 
viral genes.
The effect of the reiterated Ela is likely to be most 
pronounced upon E4. The initiation of expression from 
the reiterated Ela may affect the E4 promoter region. 
Perhaps the presence of the reiterated Ela interferes 
with the E4 promoter to such an extent that it is either 
no longer functional or poorly functional due to the 
increased distance from several known enhancer sequences 
which, by sequence similarity between the CAV-2 RHT and 
the human AdV RHT, lie terminal to the insertion sequence 
and hence greater than 1.2kb from their initial site with 
reference to the E4 promoter.
Alternatively, the initiation of expression from the
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reiterated Ela may lead to the initiation of 
transcription from the E4 promoter by transcripts 
initiating at the reiterated Ela and continuing through 
E4. Thus E4 would be transcribed much earlier in 
infection than is normal and at much higher levels. What 
effect this would have upon viral infection in vitro or in 
vivo is not clear.
An efficient procedure has been developed to measure the 
function and activity of putative promoter sequences. 
Gorman et al (1982) constructed recombinant genomes that 
direct the expression of an enzyme, chloramphenicol 
acetyltransferase (CAT), in mammalian cells. When cells 
were transfected with a recombinant plasmid, e.g. 
pSV2/CAT, consisting of the origin of replication from 
pBR322 coupled to simian virus (SV40) early transcription 
unit and the CAT coding sequences, CAT activity was easily 
detected. Similar recombinants with the SV40 promoter 
removed serve as useful vectors with which to test 
promoter activity. This test is carried out by insertion 
of a putative promoter sequence 3' to the CAT gene; any 
promoter activity from the inserted DNA will result in 
expression of the CAT gene upon transfection into 
mammalian cells. The assay can therefore be used to 
demonstrate both the fact that the promoter is functional 
and the level at which it functions, i.e. a strong or weak 
promoter. There is no endogenous CAT activity present in 
eucaryotic cells.
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CAT assays have been used to examine a range of human AdV 
early promoters e.g. E3 and E4 (Glenn and Ricciardi, 
1985 and 1987: Lillie and Green, 1989). The assay has been 
used to demonstrate the effect of Ela gene products upon 
the function of other AdV early promoters. This was 
achieved by transfecting, e.g., an E3/CAT construct with 
and without Ela. Minimal levels of CAT expression were 
detected from the E3/CAT construct in the absence of Ela. 
However, when the construct was transfected in the 
presence of Ela, high levels of CAT activity were observed 
(Weeks and Jones, 1983). This was again demonstrated for 
the effect of Ela upon the E4 promoter (Lillie and Green, 
1989). CAT assays therefore form a convenient assay which 
can discriminate between a functional and a non-functional 
Ela gene.
Sequence analysis has revealed that the reiterated RHT Ela 
of Vaxitas is situated between the ITR and the presumptive 
E4 promoter. It also suggests that the reiterated Ela is 
non-functional. The Glasgow and Vaxitas RHT Smal/PvuII 
fragments (fig. 3.2, the RHT PvuII site being between the 
two Sstll sites and situated after the end of the 
reiterated Ela in Vaxitas) contain the presumptive E4 
promoter and, in Vaxitas, the reiterated Ela. CAT 
constructs containing these fragments should therefore 
demonstrate whether the CAV-2 E4 will function 
independently of Ela, whether the reiterated Ela promoter 
is functional and, by utilising the Sail B clone of
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Vaxitas containing the reiterated Ela, whether the 
reiterated Ela produces functional products capable of 
transactivation of the E4 promoter. The Glasgow Ela 
clone, EcoRI C, will provide a positive control to 
demonstrate the effect of a functional Ela upon the E4 
promoter.
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M A T E R I A L S  A N D  M E T H O D S
Chloramphenicol Acetyltransferase (CAT) Assay 
Cloning in pCAT12
A pUC12/CAT construct was obtained from Mr M. Riggio
(Department of Veterinary Pathology, University of
Glasgow). The CAT reporter plasmid consisted of an
insertion of the CAT gene into the BamHI/Xbal sites of
pUC12. The vector was cut with Smal, phosphatased, ethanol
precipitated and finally resuspended in TE and stored at - 
o
20 C until required. A second CAT reporter plasmid, 
pSV2, comprising of a pBR322/CAT construct with the CAT 
gene under the control of an SV4 0 promoter was utilised as 
a positive control for transfections and CAT assays 
(courtesy of Mr M. Riggio).
The terminal Sail B clones of Vaxitas and Glasgow were 
then digested with Smal/PvuII, thus providing two blunt 
fragments of 1.5kb and 0.4kb respectively for cloning 
into the pUC12/CAT vector. The viral fragments were 
purified from an agarose gel as previously described and 
ligated to the Smal cut vector. Orientation of the viral 
fragments within the new CAT reporter plasmids were 
checked by restriction enzyme analysis. DNA was then 
prepared by large-scale plasmid preparations through CsCl 
as described previously.
Transfections for CAT assay
Transfections were carried out after the method of Graham
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and Van der Eb (1973). Briefly, Mv-l-Lu cells were split
o
1:15 and allowed to settle at 37 C overnight. Meanwhile,
0.25ml of donor DNA (pCAT12 clones) at a concentration of
80pg/ml in 1/10 TE (O.lmM EDTA, l.OmM Tris pH8.0) was
placed into a sterile bijou and 0.2ml 1/10 TE added.
Next, 0.05ml of 2.5M CaCl was added and the solution
2mixed well. The DNA solution was then added slowly, with 
continuous mixing, to 0.5ml 2xHBS (table 5.1) and 
thoroughly mixed on a bench-top whirlimix. This mixture 
was then left at room temperature for 3 0 minutes.
2
The DNA/calcium phosphate suspension was added to a 75cm
o
flask which was incubated at 37 C overnight to allow 
adsorption. The media containing the DNA precipitate was 
then removed and replaced with fresh media.
Cell Harvest for CAT Assay
Cells were harvested 48 hours after transfection. Cells
were first washed 3x with Dulbecco's PBS (calcium- and
magnesium-free) followed by addition of 1.5ml of harvest
TEN (table 5.1) to the flasks. Cells became rounded and
loose after 5 minutes and were removed by scraping. After
being transferred to a microfuge tube, cells were
collected by centrifugation in a bench-top microfuge for
o
10 minutes at 4 C. The cell pellet was resuspended in
150)il of 250mM Tris pH7.8 buffer and the suspension
o
freeze/thawed 3x at -20 C. Cell debris was pelleted by 
centrifugation for 10 minutes in a bench-top microfuge.
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The cell extract containing the CAT enzyme
o
was stored at -20 C until required.
CAT Assay
The extract from transfected cells was assayed for CAT
enzyme activity as described by Gorman et al (1982) with
slight modifications. Briefly, the enzyme assay was
performed in a final volume of 155jil containing 75pl of
cell extract, 2.5pl of 4 0mM acetyl coenzyme A (sodium
14
salt, Sigma), 2.5pl (0.1 pCi) of C-chloramphenicol
(Amersham) and 75pl tris-HCl (250mM, pH7.8). The mixture
o
was incubated at 37 C for 60 minutes and stopped by the 
addition of 200pl ethyl acetate. CAT enzyme (Sigma), 8 
units, was used as a positive control for the CAT assays. 
Chloramphenicol was extracted from the mixture by three 
treatments with 150pl of ethyl acetate and the 
solvent was evaporated by centrifugation under vacuum.
The chloramphenicol sample was dissolved in 3 0pl of ethyl
acetate and spotted onto a plastic-backed silica thin
layer chromatography plate in 5pl aliquots. The unreacted
chloramphenicol was separated from the lC-acetylated, 3C-
acetylated and the 1C, 3C diacetylated forms by ascending
chromatography in chloroform/methanol (95:5) solvent. The
plate was air dried and subjected to autoradiography at - 
o
70 C overnight.
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T A B L E  5.1 
CAT Assay and Transfection Solutions
2x Hepes Buffered Saline (HBS)
NaCl 1.63g I
HEPES 1.19g V to give
Na HPO .2H 0 0.023g (
2 4 2 \
dH O to 100ml \2 J
adjust pH to 7.1 - 7.25.
TEN
Tris (pH 7.5)
0.5M EDTA
5M NaCl
dH O 
2
to give
280mM 
50mM 
1. 5mM
4 0mM
lmM
150mM
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R E S U L T S
CAT Assay
To assess the effect of the Vaxitas insertion upon the 
function of E4 a combination of virus DNA clones were used 
both singly and in conjunction with others in the 
transfections. The Smal/PvuII/CAT clones of Glasgow and 
Vaxitas were used to monitor the transcription through the 
CAT gene. The Smal/PvuII/CAT clones were transfected as 
follows:-
a) Glasgow Smal/PvuII/CAT clone (pGE4/CAT) alone
b) Glasgow Smal/PvuII/CAT clone (pGE4/CAT) co-transfected 
with the Glasgow El clone (pGEla) which consisted of 
Bluescript containing the EcoRI C fragment
c) Glasgow Smal/PvuII/CAT clone (pGE4/CAT) co-transfected 
with the Vaxitas Sail B clone (pVEla(r))
d) Vaxitas Smal/PvuII/CAT clone (pVE4/CAT) alone
e) Vaxitas Smal/PvuII/CAT clone (pVE4/CAT) co-transfected 
with the Glasgow El clone (pGEla)
The positive control was provided by Mr. M. Riggio, 
University of Glasgow in the form of a pUC12/CAT reporter 
plasmid under the control of the SV40 promoter, pSV2. All 
transfections were performed in the Mv-l-Lu (mink) cell 
line to ensure that the performance of the Ela promoter 
within the Vaxitas insert was not inhibited by cellular 
factors in a cell line non-permissive to Vaxitas.
Figure 5.1 shows the results of the CAT assays, summarised 
in table 5.2. The Glasgow Smal/PvuII/CAT clone, as
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expected, is virtually non-functional when transfected 
without the presence of a functional El. When the Vaxitas 
Smal/PvuII/CAT clone is transfected alone, however, a high 
level of CAT expression can be detected.
The Glasgow E4/CAT reporter plasmid is fully functional 
and the CAT gene is strongly expressed when the 
Smal/PvuII/CAT clone is co-transfected with the EcoRI C 
(El region) clone. Again, CAT expression is demonstrated 
by the Vaxitas Smal/PvulI/CAT construction.
When the Glasgow Smal/PvuII/CAT construction is co­
transfected with the Vaxitas Sail B clone containing the 
reiterated Ela, no CAT expression can be detected.
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Fig. 5.1 (A) CAT assay to demonstrate the effect of
co~transfection with Ela upon the expression of the 
CAV-2 E4 region. Lanes A and F are positive controls, 
using the CAT reporter plasmid pSV2/CAT which consists 
of the CAT gene under the control of the SV4 0 promoter. 
Lanes B (Vaxitas) and E (Glasgow) show the result of 
transfection with the E4 region/CAT constructs alone. 
Lanes C (Vaxitas) and D (Glasgow) demonstrate the 
effect of the same clones co-transfected with the 
Glasgow Ela region.
Transfections of the Glasgow E3 promoter with and 
without Ela, lanes H and G respectively, are also 
demonstrated.
(B) CAT assay to demonstrate the effect of the 
Vaxitas RHT reiterated Ela upon the function of the E4 
promoter of Glasgow CAV-2. Lanes B and C show the 
effect of the Glasgow E4 promoter region transfected 
with (lane C) and without (lane B) the Vaxitas Sail B 
clone containing the reiterated Ela. Lanes A and D 
represent positive controls consisting of A - pSV2/CAT 
and B - CAT enzyme.
F I G U R E  5.1
Activity Of The Vaxitas and Glasgow E4 Promoters 
As Determined by CAT Assay
T A B L E  5.2
CAT Assay Results
pGE4/CAT pVE4/CAT pSV2
pGE4/CAT - nd nd
pVE4/CAT nd + nd
pGElA + + nd
pVElA(r) - nd nd
pSV2 nd nd +
where nd = not tested
+ = positive expression of CAT
= negative expression of CAT
Table 5.2 Summary of results of CAT assays to examine the 
effect of the Vaxitas reiterated E1A upon the function of 
E4. The Glasgow and Vaxitas clones containing the 
presumptive E4 promoters in conjunction with the CAT gene, 
pGE4/CAT (Glasgow) and pVE4/CAT (Vaxitas) were transfected 
into the Mv-l-Lu cell line alone and co-transfected with a 
plasmid containing a functional E1A gene derived from the 
Glasgow CAV-2 genome, pGElA. The Glasgow E4/CAT construct 
was also co-transfected with a plasmid containing the 
Vaxitas RHT reiterated E1A, pVElA(r). The Glasgow E4 
promoter is virtually non-functional in the absence of a 
functional E1A? high levels of CAT expression were however 
obtained in the presence of the Glasgow E1A. The Glasgow 
pGE4/CAT shows no CAT expression in the presence of the 
reiterated E1A of the Vaxitas RHT thus indicating that the 
reiterated E1A encodes no functional products. High 
levels of CAT expression can be detected from the Vaxitas 
E4 clone, pVE4/CAT, both in the presence and in the 
absence of the Glasgow Ela. The Vaxitas E4 promoter 
therefore does not require transactivation by Ela.
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D I S C U S S I O N
The Glasgow E4 promoter is fully functional only in the 
presence of the Glasgow Ela gene. No expression was 
detected either in the absence of Ela or in the presence 
of the Vaxitas RHT reiterated Ela. Therefore, concurring 
with the sequence data, the Vaxitas RHT Ela appears to 
encode no functional products. Expression of the CAT gene 
in the Vaxitas Smal/PvuII/CAT reporter plasmid, in the 
absence of a functional Ela, indicates that, as expected 
from the DNA sequence, the reiterated Ela at the RHT 
contains a functional Ela promoter. Assurance that the 
positive CAT assay result obtained by transfection of the 
Vaxitas E4/CAT reporter plasmid alone is not the result of 
an Mv-l-Lu cellular product with Ela-like activity, comes 
from the negative Glasgow E4/CAT assay results under the 
same circumstances i.e. the Glasgow E4 promoter would also 
be transactivated by the same cellular factor.
The first CAT assay experiment, fig. 5.1(a), described the 
effect of Ela on expression from the the E4 promoter. It 
should be noted that the amount of DNA used in single 
transfections and co-transfections varies. When the 
Glasgow and Vaxitas E4/CAT constructs were transfected 
alone, 20ug of each plasmid was used. However, when the 
experiment involved a co-transfection, i.e. pGE4/CAT + 
pGEla, pVE4/CAT + pGEla, lOug of each plasmid was used. 
Thus the very strong expression of the Vaxitas E4/CAT 
clone compared to the less strong Vaxitas E4/CAT+pGEla co-
150
transfection CAT assay results, is due partly to a
quantitative DNA effect, i.e. half the amount of the CAT
gene is present in the co-transfection, and partly to the 
strength of the Ela promoter.
The Vaxitas E4 promoter appears to be fully functional
both in the presence and in the absence of a functional
Ela. However, further work will be needed to clarify
whether any of the CAT activity detected from the Vaxitas 
E4 promoter during co-transfection with the Glasgow 
functional Ela was due to Ela transactivation or whether 
all CAT activity displayed by this region is due to the 
reiterated Ela promoter. It is likely that, in the co­
transfection, Ela products from the pGEla clone would 
compete, by transactivating the E4 promoter, with 
transcripts running directly from the reiterated Ela 
promoter to express the CAT gene.
The Vaxitas E4 region therefore does not require 
transactivation by Ela. The effect of this in vivo 
however is not clear although it does raise many
interesting questions. Handa and Sharp (1984) reported 
that distal upstream sequences were required for the 
maximum transcription of E4: deletion of sequences between 
-325 and -140 resulted in a 10-fold loss of transcription. 
It is interesting that although the majority of this 
sequence is still present at the right-hand terminus of
Vaxitas, it is now placed more than lOOObp further
151
upstream of the E4 promoter. Presumably therefore, 
"normal" transcription of the Vaxitas E4 promoter is 
reduced compared to transcription of the Glasgow.E4 
promoter.
The effect of the viral DNA binding protein, encoded by 
E2a, upon transcription of Vaxitas E4 also remains unclear 
as yet. Normally E4 transcription is negatively regulated 
in the presence of the viral DNA binding protein 
(Raychaudhuri et al. 1987a). Would this negative control
of E4 expression still function in the presence of an E4 
gene being driven by an Ela promoter? Would the DNA 
binding protein prevent transcription of E4 leading to 
abortive transcripts being formed from the reiterated Ela 
promoter or would E4 continue to be expressed as long as 
the reiterated Ela promoter remained active? Is 
transcription through the E4 region of Vaxitas totally 
dependent upon the reiterated Ela promoter? Does the 
regulation of the left-hand end Ela, in the presence of 
excess Ela products, negatively regulate the reiterated 
Ela promoter at the right-hand terminus thus leading to 
an Ela dependent regulation of transcription from E4?
If the Vaxitas RHT can contain an E4 region which does not 
require transactivation by Ela and yet is presumably 
strongly expressed by way of the Ela promoter, why has the 
AdV genome evolved to contain such a complicated means of 
ensuring the expression of each of its early genes? E4 
has been demonstrated to be essential for the stability of
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late viral nuclear RNA's (Sandler and Ketner, 1989), late 
viral protein synthesis, viral DNA accumulation (Bridge 
and Ketner, 1989) and efficient virus particle assembly 
(Falgout and Ketner, 1987). Functions which are vital to 
the virus and therefore it would seem, should only enhance 
the replicative efficiency of Vaxitas. The effect of 
excess E4 products upon the replication of AdVs has 
however not been reported. It is possible that an 
increased replicative efficiency, in the absence of any 
controlling element, would prove detrimental to the virus. 
It may lead to a highly cytopathic virus which in turn 
leads to cell death before completion of viral replication 
and packaging. The Vaxitas RHT will prove a valuable 
asset in studying the effect of any excess E4 products in 
vitro.
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This study was concerned with the genomic analysis of the 
CAVs in order that the genome organisation could be 
compared to that of the HuAdVs and that the feasibility of 
using the CAVs as viral vectors could be examined.
The general organisation of the genome is now known to be 
similar to that of the human adenoviruses with Ela, hexon, 
E3, fibre and E4 having been positioned at comparable 
sites on the genome of the CAVs (Macartney et alf 1988: 
Spibey and Cavanagh, 1989: Spibey et_al, 1989).
Restriction enzyme analysis of both wild-type and vaccine 
strains and the construction of physical maps of a wild- 
type and vaccine strain of CAV-2 demonstrated the 
distinctiveness of CAV-1 and CAV-2. Both CAV-1 and CAV-2 
demonstrate a low GC content as defined by the number of 
Smal sites (6 Smal sites in CAV-2, 4 in CAV-1) thus 
suggesting that they should be placed in an equivalent of 
group A, highly oncogenic, human adenoviruses. This is in 
agreement with the published data on the oncogenicity of 
the canine adenoviruses (Tsukiyama et_al, 1988).
In addition, it was revealed that all vaccine strains 
examined contained additional DNA near the genome termini. 
This raised the question as to whether the inserted DNA 
could have any relevance to the attenuation of the CAVs. 
It also affected the use of the CAVs as viral vectors. 
The fact that the vaccine strains were competent for 
growth with up to 4kb of stably integrated additional
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DNA, implied that a similar amount of "foreign" DNA could 
be inserted into a "normal" CAV genome with no adverse 
affects upon the replication efficiency of the virus. 
This indicated that the CAVs would be suitable for use as 
viral vectors.
Conversely, however, the same insertions, although 
appearing to be stable, have been demonstrated to undergo 
rapid alterations under certain conditions. When the 
vaccine strain Vaxitas was introduced into an alternative 
cell line the previously dominant species of 33.2kb was 
replaced, in one passage, by a dominant species of 35kb. 
It is not yet known whether this major alteration in the 
size of the genome is due to a further insertion of DNA 
into the genome or whether the new cell line has selected 
for a species which was previously present only as a 
limited background species amongst the very heterogeneous 
species that represents Vaxitas.
The availability of the DNA sequence of the right-hand 
termini of Glasgow and Vaxitas clearly defined the site of 
insertion. The Vaxitas reiterated Ela would seem to have 
"inserted" into the wild-type 80bp Hpall fragment, with 
the initial 16bp and terminal 35bp of the wild-type Hpall 
fragment being retained either side of the reiterated Ela. 
As the initial 16bp conserved sequence forms the end of 
the ITR, it is more likely that the reiteration has 
occurred not by insertion into the right-hand end but by
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replacement, up to bp229, with the initial 1.353bp of the 
left-hand end.
The phenomenon of an adenovirus left-hand terminus present 
at the right-hand end, as in the Vaxitas genome, has been 
reported previously. Brusca and Chinnadurai (1983) 
described Ad2 mutants which contained the left 3% (lllObp) 
of the genome duplicated at the right-hand terminus. 
However, these mutants were observed only after treatment 
with an intercalating agent, Proflavin, which typically 
causes small deletions or insertions (Orgel and Brenner, 
1961). The Ad2 mutants were demonstrated to grow 2- to 4- 
fold slower than their wild-type counterparts. This was 
hypothesised to be due to a retarded replication of the 
mutant viral DNA and/or the increased size of the genome 
causing the virion to be unstable after packaging. In 
addition, the mutants were found to revert to wild-type 
after a relatively low number, 5, of passages in vitro. 
Thus although the type of genome variation is similar, if 
not identical to that of Vaxitas, the effects and 
stability of the reiterated Ela are not. The rate of 
growth and yield of Vaxitas are directly comparable to 
that of wild-type CAV-2 and after multiple passage, >50, 
no reversion to wild-type genome was evident.
The vaccine strains Boostervac (CAV-1), Nobivac (CAV-2) 
and Epivac (CAV-2) appear to differ from Vaxitas in more 
than one respect. Not only are the inserted DNA sequences 
of a different origin (BT1, E2/E3 promoter region: BL2,
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El: N3, ITR/E1: E4, unknown) but neither end of the Hpall 
fragments that appear to encase the inserted sequences 
demonstrate any homology to any known right-hand terminal 
sequences. However, this is probably an indication of the 
similarity in the structure of the right-hand termini 
and not, as previously thought, indicative of differences. 
When the final structure of the Vaxitas right-hand end was 
revealed, it was discovered that the "insertion" contained 
additional Hpall fragments which were not detected on 
acrylamide gels. The initial isolation and sequencing of 
the variant Hpall fragments, 190bp and 600bp, thought to 
constitute the inserted DNA sequences, revealed only that 
they were homologous to the Glasgow Ela region. Only by
sequencing the entire Vaxitas right-hand terminus was it 
shown that the inserted sequence contained additional 
Hpall sites and that reversion to wild-type right-hand 
terminal sequences occurred past the site of insertion. 
Thus, until the DNA sequence of the right-hand end of the 
other vaccine strains can be ascertained, it would be
impossible to determine the exact position or mode of
insertion of the additional DNA. It will also be 
necessary to obtain the DNA sequence of the right-hand 
terminus of a wild-type strain of CAV-1 to enable a
comparison with the right-hand terminus of Boostervac CAV- 
1.
The preliminary investigations into the exact site and 
effect of the 0.4kb deletion in Vaxitas PstI D, and
158
smaller deletions in the same area in the other CAV-2
vaccine strains, have shown that the deletion is placed
within E4, most probably, using an assumed co-linearity
with the human adenovirus E4 region, within the final open
reading frame, orf6 by analogy to the HuAdVs. Huang and
Hearing (1989) reported that deletion mutants of Ad5 E4
varied in their replicative ability dependent upon where
in E4 the deletion occurred. Initially HeLa cells were
infected with 200 particles per cell and assayed for
plaque forming units per ml (pfu/ml). Those genomes with
an intact orf6 and deletions elsewhere, or even the
remainder of the E4 orf's deleted, retained a wild-type
—  +
level of replication. Genomes which were orf6 /orf3
demonstrated a 100-fold drop in yield compared to wild-
- - 4
type, and those which were orf6 /orf3 demonstrated a 10 
5
to 10 -fold drop. When viral DNA accumulation was
examined it was discovered that viruses with deletions in
orf's 1-4 demonstrated normal viral DNA accumulation.
Viruses which also contained deletions or insertions in
orf6 exhibited a lag phase of almost 48hrs before the
onset of viral DNA replication after which the levels of
accumulated viral DNA within the cell were comparable to
—  +
wild-type. Genomes which were orf6 /orf3 accumulated
viral DNA at almost wild-type levels. 0rf6 /orf3 mutants
display dramatically reduced levels of viral late protein
synthesis and virtually fail to switch off host cell
3 5
protein synthesis, resulting in a 10 to 10 -fold decrease 
in final virus yield.
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These results may be of significance when observing the
replicative abilities of the CAV-2 vaccine strains. All
the CAV-2 vaccine strains demonstrate a deletion in PstI
D, now believed to be in the equivalent of the HuAdV E4
orf6. All of the CAV-2 vaccine strains show a much
reduced viral yield compared to wild-type except Vaxitas.
Whereas Nobivac and Epivac exhibit a viral concentration 
6
of 10 pfu/ml, Vaxitas and the wild-type Glasgow
8 9
repeatedly yield 10 to 10 pfu/ml. The loss of 
replicative ability in the Nobivac and Epivac strains can 
perhaps be explained by the presence of a deletion in E4 
orf6. The same deletion however (or a very similar one at 
the same site on the viral genome) does not appear to 
affect the replicative ability of Vaxitas. It is feasible 
that the presence of the reiterated Ela compensates in 
some way for the proposed deletion in orf6, increasing the 
yield of orf3 and the other E4 orf's leading to wild-type 
levels of replication. This would also provide an insight 
into why a genome so much larger than wild-type has been 
selected for, is retained as the dominant species within 
the population and any reversion to a wild-type genome 
(which without the presence of a wild-type virus would not 
be able to undergo recombination/repair of E4) within the 
population is not selected for.
Again, correlation begins to emerge between the function 
of the additional DNA at the genomic termini of the other 
CAV vaccine strains. Perhaps enhancement of E4 in order
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to compensate for deletions in orf6 may again be applied 
to the origin and stability of the additional terminal DNA 
in all the vaccine strains. The five vaccine strains 
examined display additional DNA comprised of the Ela 
promoter (Vaxitas CAV-2), the E2 promoter (Boostervac CAV- 
1, larger species), the ITR and adjacent sequences from 
the right-hand terminal (Nobivac CAV-2), part of Elb. 
(Boostervac CAV-1, smaller species) and a sequence of 
unknown origin (Epivac CAV-2). The duplicated E2 promoter 
present at the right-hand terminal of the larger 
Boostervac species may again, as with Vaxitas, enhance 
transcription through E4. It may even remove the 
requirement of the E4 promoter to be transactivated by Ela 
products as preliminary results indicate that the CAV E2 
promoter does not require transactivation by Ela (N. 
Spibey, personal communication). Nobivac displays 
additional DNA upstream of the E4 promoter which would 
appear to be a direct repeat of part of the ITR (all 
except the initial lObp) and adjacent sequences.
Handa and Sharp (1984) reported that Ad5 mutants with 
deletions in the region -14 0 to -325 upstream of the E4 
promoter displayed a ten-fold decrease in transcription 
through E4. This same region forms part of the duplicated 
ITR and adjacent sequences present at the right-hand 
terminus of Nobivac. Pasananti et al (1987) reported that 
duplication of enhancer sequences is a common method of 
gene amplification in mammalian cells brought about by 
illegitimate recombination events. Perhaps the
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duplication of this known E4 enhancer sequence again 
confers selective advantages to viral genomes with 
deletions in orf6 by amplifying the remaining E4 gene 
products. The smaller of the Boostervac CAV-1 species 
displays an internal part of Elb at its right-hand 
terminus. No promoter function can be associated with 
this sequence. It may be however that the sequence 
contains an enhancer activity or that other additional 
sequences connected to this region exist at the right-hand 
terminus of this viral species, again perhaps acting as an 
E4 enhancer. Epivac CAV-2 contains additional DNA of 
unknown origin at the right-hand terminus. Sequence 
analysis to date implies that the additional DNA may be 
cellular in origin, although as more sequence data becomes 
available for the CAV-2 genome it may reveal a viral 
origin. Further analysis of the Epivac CAV-2 and 
Boostervac CAV-1 (smaller species) right-hand termini will 
be required to assess the extent of the additional DNA and 
whether they do infact contain promoter or enhancer 
sequences.
The different replicative abilities of each strain may 
again be related to the deletion in E4 and to the presence 
of the additional terminal DNA. The relative strength of 
the promoter or enhancer sequences upstream of the E4 
promoter would determine the extent to which these 
additional sequences enhance transcription of the 
remaining functional E4 orf's. Further examination may
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reveal that the replicative abilities of the vaccine 
strains varies according to the strength of any enhancer 
present at the right-hand terminal.
The evidence obtained to support the theory that the 
reiterated Ela of Vaxitas is non-functional again would 
correlate with the above. Ela is believed to be self- 
regulatory and therefore it can be assumed that an excess 
of Ela products very early in infection would be 
detrimental to the expression of all other early genes in 
which Ela plays an essential role. A viral genome 
expressing Ela products at either end simultaneously would 
lead to vastly increased levels of all Ela products very 
early in infection. Premature regulation of Ela 
expression relatively early in expression may lead to 
decreased levels of expression from all other early genes. 
Such a genome would have no selective advantage over a 
wild-type genome and might in fact be almost self- 
destructive, leading perhaps to less transcription through 
the other early Ela dependent genes. However, once the 
replicative error/mutation/recombination which allowed a 
copy of Ela to form at the right-hand terminus had 
occurred (especially in an E4 orf6 mutant) , great 
replicative and therefore selective advantages would be 
conferred upon any genome in which mutations had occurred 
within the reiterated Ela, such that no functional 
proteins were encoded by it, but the promoter remained 
fully functional leading to increased expression of the 
remaining E4 orf's. This perhaps explains to some degree
163
the conservation of the aberrant Vaxitas genome but leads 
to the question of which came first, the E4 deletion or 
the reiterated Ela? Theoretical evidence would imply that 
there is no selective pressure for increased levels of E4 
expression in the absence of an E4 orf6 deletion in which 
case it would be expected that the original 
mutation/replicative error would have been corrected by
recombination with a wild-type genome. The relevance of
the reiterated Ela and deletion in E4 orf6 to the
attenuated form of the virus, if any, is not clear.
However, as the deletion appears to be a consistent part 
of CAV-2 attenuated vaccine strain genome it is likely 
that E4 plays some role in the attenuated state which is 
as yet unknown. The origin of the original CAV strains 
used for the attenuation of each vaccine is not known. It 
is feasible that only one attenuated strain, containing 
the deletion, was obtained from a common source by each 
vaccine company for utilisation as a vaccine. Subsequent 
differences in cell lines and production methods may have 
then given rise to the individual terminal DNA sequences. 
Ginsberg et al (1987) reported that deletions in E3 led to 
viral latency in vivo which may confer additional 
advantages to an attenuated vaccine strain but this 
function has not been reported for E4 deletion mutants. 
Paradoxically, the same group also reported that sequence 
alterations in the Ad5 El region led to increased 
pneumonia in cotton rats. Any correlation between these 
findings and the Vaxitas aberrant right-hand terminal Ela
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will be investigated as the DNA sequence of the left-hand 
terminal becomes available.
Liu et al (1988) described a vaccine strain of CAV-1 (CCL 
- Connaught Laboratories Ltd.) which, following eight 
passes in DK-N (dog kidney) cells, led to the production 
of 3-4kb deletions at the right-hand terminus. These 
aberrant genomes were not viable and were isolated only 
from plaques containing full length genomes in addition to 
the aberrant genomes. This does indicate however that 
replicative errors do occur in the CAVs genome under 
certain conditions and, it would seem, with higher 
frequency in certain cell lines. It is also interesting 
to note that the aberrant genome described by Liu et al 
involved deletions at the right-hand terminus. No 
aberrant genomes were described with large deletions at 
the left-hand terminus. The right-hand end would 
therefore, for some unknown reason, seem to be more prone 
to replication errors than the left-hand end. This is in 
agreement with the vaccine strains described in this study 
where, although both termini exhibit additional DNA 
sequences, the largest "insertion" in the terminal 
sequences was always demonstrated at the right-hand end.
In addition, Liu et al (1988) described viable isolates 
with aberrant genomes from the CCL CAV-1 vaccine strain. 
The genome length of the viable isolates was found to be 
480bp shorter than wild-type CAV-1. Liu et al speculate 
that this deletion, 83-91m.u., is situated in E3 and is
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directly involved in the attenuation of the virus, by 
which they concluded that E3 is responsible for virulence. 
The vaccine strain was found to still display the 480bp 
deletion following passage in dogs. This assumption is 
not supported by the data produced by Ginsberg et al 
(1987) who found that deletions in E3 led to latency and 
may be related to increased viral pathogenicity. It may 
be, however, that the CAVs are more widely diverged from 
the human adenoviruses than is presently believed.
However, their assumption that the deletion is based in E3 
was solely due to the fact that Tsukiyama et al (1988) 
reported that the left-hand terminal region of the canine 
adenoviruses demonstrated transforming ability; presumed 
due to the presence of Ela at the LHT; and that by 
alignment of the CAV-1 genome with the human adenoviruses, 
the deletion occurs in E3. No analysis of the CAV-1 
vaccine strain genome was carried out to confirm this 
speculative position of the deletion.
Analysis of the E3 region of CAV-2 shows that the E3 
region of CAV-2 is much smaller than that described for 
the HuAdVs thus placing the organisation of the right end 
of the genome out of alignment with the HuAdVs although 
all regions are conserved i.e. E3->, fibre->, <-E4 (M.
Macdonald, University of Glasgow, personal communication). 
Perhaps the function of E3 in the CAVs is altered somewhat 
from that of the HuAdVs, hence the requirement for a
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smaller E3 region. If the function has indeed altered in 
some way, the findings of Ginsberg et al (1987), that E3 
deletions led to latency in Ad5 infections, may not be 
applicable to the canine adenoviruses.
The deletion displayed near the right-hand terminal of the 
Boostervac CAV-1 vaccine strain genome appears to be 
situated at the same position on the CAV-1 genome as that 
described by Liu et al and by alignment to the Glasgow and 
Vaxitas genomes would appear to be situated in E3.
The fact that the deletion described by Liu et al was 
retained by the CAV-1 vaccine strain following several 
passages through animals is presumably due to the fact 
that no wild-type CAV-1 was available in vivo for 
recombination/repair. Perhaps selective advantages may be 
conferred upon attenuated strains with the ability for 
latency. Preliminary results indicate that in the CAV-2 
vaccine strains described in this work, the additional DNA 
sequences/deletions are also stable following passage 
through dogs (Dr. N. Spibey, personal communication) .
No explanation has been found to explain the varying cell 
specificity of the CAV-2 strains. The wild-type Glasgow 
used throughout this study was isolated from the faeces of 
a pup, an unusual site of isolation for a CAV-2 and 
indicating enteric replication. Vaxitas appears to be 
unable to replicate in all the canine cell lines examined 
and most probably is blocked at the stage of entry into
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the cell as no intracellular viral DNA has been detected 
following infection of canine cells with Vaxitas. This 
would imply that the Vaxitas fibre has a role to play in 
this cell specificity.
Two differences have been described between the short 3' 
region of the fibre genes of Glasgow and Vaxitas examined 
to date which may or may not be involved in this altered 
cell specificity. However, analysis of the complete fibre 
genes of Glasgow, Vaxitas and a wild-type respiratory CAV- 
2 will be required to determine the extent of any 
alterations. It is not yet known whether the Glasgow 
isolates aptitude for enteric infection/replication is
associated with cell attachment or replicative ability 
once within the enteric cells. The essential role of El 
in the pathogenesis of adenovirus pneumonia may also have 
a part to play. Ginsberg et al (1987) reported that no 
viral pneumonia could be detected in the absence of the 
Elb 55kD protein. Perhaps a comparison of this gene in
Glasgow (as an enteric isolate), Vaxitas (as an attenuated 
vaccine strain) and a wild-type respiratory CAV-2 would 
reveal significant differences relating this gene product 
to pneumonia, perhaps altered in some way to lead to
enteric replication and even to attenuation. Preliminary 
investigations reveal that the Elb 21kD region of Glasgow 
contains several point mutations when compared to CAV-1. 
No data is available as yet on the Elb 55kD regions of
Glasgow CAV-2 and the wild-type CAV-1.
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The relevance of these findings to the vaccination 
efficiency of the CAV vaccines can only be determined by a 
detailed analysis of the antibody titres of dogs examined 
before and after vaccination with each vaccine strain.
This would require a vast number of samples for each
vaccine in order that valid statistical results could be 
obtained. Preliminary investigations, however, into the 
efficiency of Vaxitas have implied that the vaccine is
acting as a killed vaccine, as was expected by the 
inability of the virus to gain entry into canine cells. 
Details of the preliminary investigation are presented in 
table 1.
Of a random sample of 30 dogs three exhibited high Ab 
levels at time of vaccination and were therefore
discounted on the basis that high levels of maternal
antibody were still present or that the pups had been
exposed to wild-type CAV-2 infection. Fourteen either
failed to respond to the first inoculation or raised. Ab 
levels of <200 (12 raised Ab levels of <100). When the 
criteria is taken that an antibody titre of <200 
constitutes minimal protection to the animal then 46.7% of 
the dogs inoculated failed to give an adequate response to 
the vaccination. Nobivac CAV-2 however, which is fully 
competent for growth in dog cells, elicits an antibody
response of >2000 in >95% of pups (Intervet, unpublished 
results)
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Table 1:- Explanatory Notes
*
1st = i.e. after 1st vaccination, taken at time of second
vaccination (usually 4 weeks after initial 
vaccination)
*
2nd = two weeks after 2nd vaccination 
*
3rd = taken at time of 3rd vaccination, usually 1 year
after initial vaccination
*
4th = taken two weeks after 3rd vaccination
where:- + = <200
++ = <1024 
+++ = >1024 but <4000 
++++ = >4000
= no response or, if titre prior to 
initial vaccination not known, titre 
of 16 or less 
0 = not known
# = initial levels probably due to 
maternal antibody but could be due 
to infection 
? = most likely due to infection 
following "vaccination"
! - sample 33 is noted due to the remarkable change in Ab
levels. On day of initial vaccination, titre was <32.
Six weeks later titre had risen to 5813, three weeks
after which it again became <32.
Notes:-
Dog 26 demonstrated good maternal Ab protection which is not 
demonstrated in the table above. At age 6 weeks the pup 
exhibited an Ab level of 2048; at 7 weeks this had dropped 
to 734? on the day of vaccination, the Ab titre was 16 which 
had risen to 734 when the pup was tested four weeks later. 
Thus although at a young age good Ab protection against CAV 
existed, which lowered as the pup became older, the pup did 
not respond well to vaccination with Vaxitas CAV-2. 
Unfortunately, further blood tests on this pup were not 
available.
It is notable that dogs 24 and 25, showing classic Ab levels 
indicative of wild-type infection, are from the same litter.
T A B L E  1
Anitbodv Titre Against CAV-2 in P u p s  Before and After 
Vaccination with Vaxitas CAV-2
Dog/
Sample
Titre Prior to 
1st Vaccination 
and age in weeks
Immunological Response 
After Each Vaccination
1st* 2nd* 3rd* 4th*i i i
1 0, 10W 16 + ++++
2 16, 12w - - +
3 16, lOw ++ ++ +++ +++
4 0, llw 90 ++ ++
5 0, 8w 64 +
6 16, 12w +++ ++
7 16, 13w +++ ++ ++
? 8 0, 8w 16 ++ ++++
9 0, 8w 64 ++ + +
10 0, lOw 24 - - .
11 16, 12w +++ ++
# 12 734, 9w - ++++ +++
13 0, 12w 4096 ++
14 16, lOw - +
15 64, 8w - +++ +
# 16 5813, 12w 0 11620
17 16, llw +++ +
18 16, llw ++ ++ ++
19 <16, 12w ++++ +++
20 48, 9w - - ++
21 <16, lOw +++ ++++
22 <16, 16w +++ ++
23 <16, 9w ++++ ++
# 24 16384, 12 w ++++ +++
# 25 11620, 12w +++ ++++
26 16, 12w ++
27 <16, 9w + + + ++
28 367, 13w - ++ +++
29 32, llw ++ ++
30 512, 17w - - -
31 <32, lOw +
32 16, 12w ++ ++
! 33 <32, 9w ++++ 16
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Several models can be used to explain the presence of a 
copy of the left end of an adenovirus genome at the right 
end. Two types of replication are believed to be involved 
in the adenovirus replicative cycle. Type I replication 
is characterised by, after initiation, replication 
proceeding in a continuous fashion along a template strand 
to the opposite end of the genome and, in the process, 
displacing the parental strand whose 5' terminus was at 
the origin. Type II involves the replication of the 
displaced parental strand, from type I replication, and 
can take three forms. Either type II replication might 
initiate at the 3' end of the displaced single-stranded 
molecule or it could begin with the formation of a 
panhandle structure formed by hybridisation of the ITRs, 
generating a double-stranded origin of replication. 
Alternatively, recent results suggest that the single 
stranded parental DNA may form a circular structure, using 
the homology between the ITR's, and undergo replication to 
the double stranded form as a circular molecule (Graham et 
al, 1989). Circular replication may also be involved 
during type I replication by utilising strand displacement 
mechanisms.
If the displaced parental strand of type I replication 
breaks before type II replication can begin, then the 
ssDNA would lack an ITR and could not form a panhandle 
structure. The DNA could however, fold back onto itself 
at a region of partial homology and continue synthesis 
using the 5' half of the same molecule as a template.
171
Normal type II replication would then generate a double­
stranded genome with right-hand terminal sequences missing 
and duplicated left-hand terminal sequences.
This model, when applied to the Vaxitas genome, would 
require that the displaced parental 1-strand from a "wild- 
type" genome lacked the final 238bp of the right-hand 
terminus. The end of this ssDNA would then hybridise to 
sequences to the right of position 1352 at the left end of 
the same strand. Replication beginning at the 3' end 
would proceed to the 5'end of the left end region which 
would serve as a template for the new right-hand terminal. 
This possible mechanism for the occurrence of a reiterated 
Ela at the right-hand terminus is represented 
schematically in figure I. However, the sequences in the 
areas described above demonstrate only 3 0% homology among 
the first 40bp.
It is also feasible that strand displacement may occur, 
figure II, where a partial ssDNA copy with the polymerase 
still attached becomes displaced from the original 
parental strand. ITR homology may enable the displaced 
partially formed ssDNA/polymerase to attach to another 
parental strand, although not necessarily the same one, 
and by formation of stem loops, which by bulk alone may 
result in the non-replication of certain small regions, 
re—initiate reolication. This method may be feasible for 
both the Vaxitas genome type and the Nobivac genome.
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A final mechanism by which aberrant genome termini may 
arise could be due to physical interference of the type 
two replication of a ssDNA strand either by a second ssDNA 
strand or by template switching to the 3' end of the 
growing chain during circular replication. This may cause 
the polymerase to change strands thus completing the type 
II genome with a second Ela region. This mechanism, 
represented in figure III, is dependent upon the fact that 
during type I replication of the adenovirus genome, no 
strand is preferentially replicated and thus either strand 
can be present as a displaced parental ssDNA.
The origin of the additional DNA sequences at the left- 
hand terminus of the vaccine strains, with Vaxitas again 
displaying the largest variation in size from wild-type 
left-hand terminus, has yet to be determined. It is 
possible that the additional left-hand terminal sequences 
have no relationship to the additional right-hand terminal 
sequences although it is more likely that they are 
related. Haj-ahmad and Graham (1986a) described the 
isolation of Ad5 mutants during the construction of E1/E3 
deletion mutants. The mutants, thought to arise during 
multiple passage of Ad5 in vitro, contained two copies of 
the ITR at the left-end of the genome. During replication 
the extra terminal segment, i.e. additional copy of the 
ITR, was found to be copied again at the right-hand 
terminus. Thus prior to replication the genome consisted 
of two ITRs at the left end and one at the right end;
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F I G U R E  I
Possible Model For Rearrangement of Genome Termini
Type I replication results in a broken ssDNA parental strand
Panhandle
structure
formed
Replication initiates 
at 3’ end and uses  
the 3 ’ 1TR and adjacent 
sequences as a template  
for the missing 5 ’ end
Ficr. I Possible mechanism by which ssDNA strand breakage 
may be responsible for the reiteration of the left-hand 
terminus ITR/Ela region at the right-hand terminus. Full 
explanation given in text.
F I G U R E  II
Possible Model Bv Which The Aberrant Genome Termini 
Of The Vaccine Strains May Arise
Replication
ITR Ela  
or E4
Strand displacem ent or breakage leading to short ssDNA 
with polymerase still attached
Short ssDNA/polymerase hybridise to ITR region of 
another strand and forms secondary, possible loop, structure
e -g- Nobivac CAV-2
first lObp of ITR 
not repeated ^
e -g- Vaxitas CAV-2
„ E4 region
replication continues
^Ela region
replication continues
E4
330bp deletion from
''normal'' r ight-hand term inal
Fig. II Possible mechanism by which a displaced 
daughter strand, of type I or n  replication,- with 
attached polymerase (indicated as P) may be involved in 
the formation of a reiterated Ela at the right-hand 
terminus.
F I G U R E III
Alternative Mechanism for the Production of 
Aberrant Genome Termini During Adenovirus Replication
B
Fig. Ill A model for replication/aberrant replication 
from circular molecules. (A) Synthesis has initiated and 
proceeded all the way round the circular genome, by either 
strand displacement of by using a ssDNA template, reaching 
the junction region and termination near the 57 pTP-
blocked end of the newly made strand, 
panhandle. Annealing of newly made 
template switching as the 37 end of 
progresses down the 7 right7 ITR, 
terminus similar in structure to the ends of 
If the sequences at the 37 end of the newly
(B) Generation of a 
ITR sequences, or 
the growing chain 
generates a duplex 
viral DNA. 
synthesised
Q ui emu. are incomplete they can be repaired using the 
sequences as a template. Model adapted from Graham et 
(1989) .
5 7
al
after replication two ITRs were present at both ends.
This may be related to the insertions at both ends of the 
CAV vaccine strain genome. It may be that, when the left- 
hand additional DNA sequences are analysed, they reveal 
strong homology to the additional DNA sequences at the
right-hand end. The left end of the Vaxitas genome may
exhibit two copies of Ela: Nobivac left end may exhibit 
two ITRs, one with adjacent E4 sequences and one
(internal) with adjacent Ela sequences etc. However,
unlike the Ad5 embedded ITRs, the CAVs do not display 
additional sequences of identical sizes at each end. The 
additional right-hand terminal DNA has always been larger 
than the size of any additional left-hand terminal DNA 
sequences. The appearance of the larger Vaxitas genome, 
following passage in the new mink cell line Mv-l-Lu, may 
indicate that the enlarged right-hand terminus has been 
duplicated at the left end. Restriction enzyme and 
sequence analysis will be required to solve this puzzle 
and may in turn clarify the original mechanism by which 
the aberrant genomes arose.
Salewski et al (1989) described mutants of Adl2 with
enhanced replicative abilities which correlated with 
insertions of various lengths, consisting of adenoviral 
sequences, at the right end of the viral genome. The 
mutants demonstrated additional sequences of 180-560bp at 
the right termini following either prolonged passage in 
Vero cells or transfection with Adl2 DNA into Vero cells.
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The replicative ability of these mutants in Vero cells
exceeded their replication levels in HeLa cells, the
normal Adl2 replicative host in vitro, whereas the
activity of wild-type virus in HeLa cells exceeded that in
1 2
Vero cells by 10 -10 . In addition, the mutants grew in 
primary African green monkey cells which are totally non- 
permissive for wild-type Adl2. The additional DNA
sequences at the right-hand termini of the mutants were 
found to consist of either the left-hand terminal and 
adjacent sequences or a repeat of the right-hand terminal 
and adjacent sequences. Part of the right-hand terminal 
ITR was always retained outwith the additional sequences, 
i.e. 4-llbp of the "original" right-hand terminus still
formed the extreme end of the genome. Thus the additional 
DNA sequences had inserted into the ITR. Continued 
passage in Vero cells favoured the accumulation of
insertions in this part of the viral genome. However, all 
the replication mutants examined also demonstrated an 
identical 69bp deletion in the first exon of Ela. 
Recombinants containing the additional DNA sequences but 
not the Ela deletion behaved like wild-type virus in Vero 
cells; those with the deletion but no additional DNA at 
the genome terminus replicated as well as the mutants
containing both the deletion and the insertion in Vero 
cells. This evidence implied that the enhanced growth 
potential was due to the deletion in Ela. The deletion 
in Ela was found to be placed at such a site as to render 
the mutants transformation defective but fully active in
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induction of both viral and cellular genes. No mention 
was made of the effect of the Ela deletion upon those 
mutants capable of replicating in African green monkey 
cells. Perhaps then, further examination may reveal that 
the CAV vaccine strains deviate from the wild-type CAV Ela 
sequence, a deviation which has not as yet been detected. 
The presence of the additional DNA at the left-hand end of 
the vaccine genomes may be masking any deletion in El when 
the genomic termini are examined by restriction enzyme 
analysis i.e. the increase in size of fragments near the 
left-hand terminus hides the presence of a nearby 
deletion. Further * restriction enzyme analysis and 
sequence data will resolve whether or not there is in fact 
a deletion in the El region of the CAV vaccine strains.
The isolation of the Boostervac CAV-1 vaccine strain has 
provided a naturally occurring E3 deletion mutant which 
appears to undergo normal viral replication, albeit at 
reduced levels. The virus remains competent for growth in 
canine cells and exhibits an attenuated phenotype. Thus 
Boostervac has provided not only a deletion mutant for the 
construction of viral vectors but a virus which can be 
used to study further the effect of E3 deletions when the 
virus is introduced into its natural host, a facility not 
amenable to investigation for ethical reasons in the human 
adenoviruses. The question of latency induced by E3 
deletions can be investigated and any correlation between 
E3 and pathogenicity examined.
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The construction of a right-hand terminal clone of Vaxitas 
has effectively created a plasmid which appears to express 
all E4 products, except those of the distal open reading 
frame, the equivalent of orf6 in the HuAdVs, controlled by 
the Ela promoter and which does not require 
transactivation by, or the presence of, a functional copy 
of Ela. Use of this plasmid will allow a detailed
investigation into the function of E4 proteins. In
»
addition, were this plasmid to be introduced into a cell 
line in which it could be stably maintained it would 
provide an invaluable asset in the creation and
maintenance of E4 deletion mutants for use as viral 
vectors. The attenuation of the CAV-2 vaccine strains may 
or may not be related to the deletion present in E4 and 
the additional DNA at the genomic termini. Evidence 
suggests, however, that were these attenuated strains 
altered to be E4 and a desired protein coding region, 
e.g. the herpes simplex virus thymidine kinase gene or the 
rabies virus glycoprotein gene, inserted into the former 
E4 region, in the presence of the Vaxitas right-hand
terminal clone, replication in vitro would be at wild-
type levels. Evidence also suggests that when the isolated 
E4 recombinant CAV were grown in the absence of E4 
products, replication would be much reduced compared to 
that of wild-type virus, a facility which may be 
advantageous when the virus is used for vaccination. The 
recombinant viruses, however, wonid retain the ability to 
replicate and, one would hope, their attenuated phenotype.
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Inoculation into the host species of the recombinant 
viruses can now be used to correlate the information 
gained in vitro to that operating in vivo.
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A P P E N D I X  I 
Preliminary Investigation of the Area of the Vaxitas Genome 
Containing the Deletion in PstD
179
I N T R O D U C T I O N
Construction of a physical map of the Vaxitas genome 
revealed, when compared to wild-type CAV-2, that a 
deletion of approximately 0.4kb had occurred in the 
fragment PstD resulting in the loss of a Kpnl site. By 
comparison to the organisation of the human AdV genomes, 
this deletion should occur in either the fibre gene or in 
E4.
The fibre of adenoviruses is responsible for the 
attachment of the virion to cellular receptors and is
therefore of major importance in the initiation of 
infection. Similarly, the fibre structure/composition
must help to define the cell specificity of any given
strain of AdV and hence, perhaps, plays a role in the
pathogenesis of the virus. If the deletion has occurred 
in the fibre gene, it may help to explain why Vaxitas is 
non-permissive for growth in the MDCK cell line and yet is 
permissive in the mink cell lines Mv-l-Lu and NMF which do 
not support the replication of wild-type CAV-2. It would 
also reflect upon the function of Vaxitas as a viable live 
vaccine. If the virus strain cannot gain entry to dog 
cells which normally facilitate the replication of CAV-2, 
then how can it do so in vivo? The dog however consists 
of many cell types which are not available in vitro. It 
may be that Vaxitas is capable of replication in dog cells 
other than the MDCK cell line.
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Alternatively, the deletion could be situated within E4. 
It has been reported that E4 deletion mutants are
defective for viral DNA accumulation, late protein 
synthesis and fail to inhibit host cell protein synthesis 
(Falgout and Ketner, 1987). The deletion mutants are also 
defective in the accumulation of late viral mRNA due to 
the absence of an E4 product which normally stabilises 
late viral mRNA's (Sandler and Ketner, 1989) .
DNA sequencing and the analysis of E4 RNAs have
identified several open reading frames (orfs) in this 
region (Freyer et al, 1984; Sandler and Ketner, 1989; 
figure A). Three protein products encoded by E4 have been 
identified immunologically and include a 34kD protein from 
orf6, an llkD protein from orf3 and a 19.5kD protein from 
orf6/7 (Sandler and Ketner, 1989 and references therein). 
The 34kD protein of orf6 has been shown to be physically 
associated with the 55kD protein encoded by Elb and the 
complex is thought to be involved in the transport of late 
viral messages from the nucleus to the cytoplasm of
infected cells. The functions of the llkD and the 19.5kD
proteins are unknown as yet although the llkD protein is 
known to be associated with the nuclear matrix. It has 
also been demonstrated that an unidentified E4 product 
acts, in conjunction with Ela gene products, in the 
transactivation of the E2 promoter. The E4 gene product 
is believed to stabilise the binding of cellular 
transcription factors, induced by Ela products, to the E2
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promoter (J. Nevins, Guest Speaker, MRC Institute of 
Virology, University of Glasgow, September, 1989). A 
number of other polypeptides have been associated with E4 
but they have not as yet been assigned to specific orf's 
(Huang and Hearing, 1989).
Bridge and Ketner (1989) have revealed that of the six 
E4 open reading frames of Ad2 two were interchangeable, 
orf 3 and orf 6, i.e. the presence of either would 
complement for the loss of the other. Deletion mutants of 
Ad5 E4 demonstrated that the orf6 product provides full E4 
function with the products of orf's 1, 2 and 4
contributing very minor functions. Orf6/7 does not appear 
to contribute to E4 function (Huang and Hearing, 1989). 
Bridge and Ketner (1989) also revealed that only viral 
genomes with deletions in both orf 6 and orf 3 were 
defective for late protein synthesis and also for plaque 
formation. It should be noted that while the Vaxitas 
strain of CAV-2 was grown in the original NMF (normal mink 
fibroblast) cell line it was not possible to obtain 
plaques for the isolation of individual genome types: a
facility which may be associated with the deletion in 
PstD.
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F I G U R E  A
Open Reading Frames Within Ad5 E4
E4 polyA 
[3000
E4 TATA
tj-j —r
2000
i
1000 0 bp
~ r  
9590 100 m.u.
orf4 orf 3 orf2 orf1
— orf3/4—
orf6
— orf6/7---
<-> <  >
97bp 882bp
< >
276bp
Fig. A Schematic organisation of the open reading frames 
of region E4 (Adapted from Bridge and Ketner, 1989) .
R E S U L T S
DNA Sequence
Figure B represents the sequencing strategy used thus far 
to ascertain the DNA sequence, of both Glasgow and Vaxitas 
CAV-2, from the Sail site towards the right-hand terminus 
i.e. towards the region containing the 0.4kb deletion in 
Vaxitas Sail B. The sequences were obtained by the use of 
commercially available and synthesised primers to the
bluescript clones of Glasgow and Vaxitas Sail B as
indicated. The DNA sequences obtained are shown, in
direct alignment, in figure C.
Three base changes and a single base deletion can be seen 
to occur between the Vaxitas and Glasgow genomes in the
448bp sequence. The sequence data has not yet reached the
site of the 0.4kb deletion. The area sequenced thus far
however appears, from sequence similarity to the human
adenovirus genome, to encode the end of fibre/ end of E4,
thus placing the deletion within an E4 coding region. 
This is demonstrated more clearly in figures D and E.
Figures D and E demonstrate the translation, in all three 
reading frames, of the above sequences. Both orientations 
are shown. Presumptive control signals are shown in the 
appropriate figures.
The effect of the base changes between the two sequences 
can now be seen. Two of the base changes affect fibre and
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one affects E4. The initial base change (27bp from the 
Sail site)? C in Vaxitas, T in Glasgow; produces a 
termination codon in one reading frame of the Glasgow 
fibre gene but not in Vaxitas. The second, at 62bp from 
the Sail site, a T in Vaxitas and a C in Glasgow leads to 
simple amino acid changes between the two. The effect of 
the translational stop in the Glasgow fibre gene, not 
present in the Vaxitas fibre gene, is unknown until splice 
patterns and coding regions can be established.
The single base deletion 178bp from the Sail site appears 
to have no effect upon either genome. The base deletion: 
AAA-AAAA in Vaxitas, AAAgAAAA in Glasgow: is situated
between the presumptive fibre polyA addition signal and 
site thus not affecting transcription of either fibre or 
E4.
Analysis of DNA Sequence Data.
No similarity could be detected between the DNA sequences 
obtained from this region of Vaxitas or Glasgow and any 
other adenovirus DNA sequences of the fibre/E4 region.
Figure F demonstrates the only similarity found between 
any of the predicted protein products from the 3'end of 
the Glasgow and Vaxitas E4 and fibre genes. Both viral 
predicted E4 regions show a 40.3% similarity to the 3' end 
of the human Ad2 E4 protein coding region. No significant 
similarity could be demonstrated against any of the
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reading frames from the proposed fibre gene.
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F I G U R E  B
Sequencing Strategy for the Region Containing the Vaxitas 
0.4Kb Deletion Within the Sail B Fragment
Glasgow genome
Sail
Vaxitas genome
Sail
Sail B clones in bluescriot 
Sail
/////////'
Kpnl Kpnl PstI
/////////'
V
Sail
-x-
Kpnl PstI
Smal
— J-////////////////
-******* * r-//////
Smal
T3
Sal A
Commercial Primers
T3 - 5' ATTAACCCTCACTAAAG 3'
Synthesised Primers
Sal A - 5' AGCTTTATTTTTCATAC 3'
Fig. B Sequencing strategy for the region containing the 
0.4kh deletion of Vaxitas CAV-2. Site of deletion, as yet 
not precisely defined, marked as — x— . Site of Vaxitas 
insertions marked as — ****— . The Sail and Smal sites 
mark the insertion points of the terminal Sail B fragments 
of both viruses into Bluescript.
F I G U R E  G
DNA Sequence of the Vaxitas and Glasgow Regions 
from the Unique Sail Site Towards the Right-hand Terminus
VAXITAS
GLASGOU
T3- ->
1 GTCGACGGTGCCCCCAGCAGAAGTATCGACTGCATGCTAATTATTAACAAACCAAAAGGC
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
1 GTCGACGGTGCCCCCAGCAGAAGTATTGACTGCATGCTAATTATTAACAAACCAAAAGGC
Sal I site *
61 GTTGCACTTACACCTTACCTTTAGGTTTTTAAACTTTAACAGACTAAGCGGAGGTACCCT
I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I
61 GCTGCACTTACACCTTACCTTTAGGTTTTTAAACTTTAACAGACTAAGCGGAGGTACCCT 
*
121 GTTTAAAACTGATGTCTTAACCTTTACCTATGTAGGCGAAAATCAATAAAACAAAAA AA
111111111111111111111111111111111111II1111111111111111111 ii
121 GTTTAAAACTGATGTCTTAACCTTTACCTATGTAGGCGAAAATCAATAAAACAAAAAGAA
*
Sal A Primer >
181 ATAAGTTTAAAGCTTTATTTTTCATACACGCGAGCGGTAAGGCTGCCGCCTTCAGGAAAA
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I II I I I I I I I I I I I I I I I I
181 ATAAGTTTAAAGCTTT ATTTTTCAT ACACGCGAGCGGTAAGGCTGCCGCCTTCAGGAAAA 
241 GTTACTCTGTAAACAGTTCTTTCACAACAGCACAAAACATAGGTATTAGTTAACAGTTCA
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l  III
241 GTTACTCTGTAAACAGTTCTTTCACAACAGCACAAAACATAGGTATTAGTTAACAGATCA
★
301 TTTGGGCTATAATAATATACATTTTCTTGGGTGGCAAAGCAAGGGTCGGTAATCTCAACA
II I I I I I I I I II I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I
301 TTTGGGCTATAATAATATACATTTTCTTGGGTGGCAAAGCAAGGGTCGGTAATCTCAACA 
361 AAACATCACTGGAATGCAAGAATAGTCCAGCAGGTGGGTTCAATCTAAAAATGAAGAACG
I I I I II I II I I I I I I I I I I I  I I I I I I I I  I I I I I I I I II I II I I I I II I I I I I I II I I I I I
361 AAACATCACTGGAATGCAAGAATAGTCCAGCAGGTGGGTTCAATCT AAAAATGAAGAACG 
421 CGTTGAGGTTCATAAGCAACAGGTTTTG
l l l l l l l l l l l l l l l l  l l l l l l l l l l l l
421 CGTTGAGGTTCATAAGCAACAGGTTTTG
Matches = 444
Length = 448
Mismatches = 3 Unmatched = 1
Matches/length = 99.1 percent
F I G U R E  D
Translation of Vaxitas DNA from the Region Shown in
Ficrure C
a) .5'-3' Upper Strand:- Region encoding the end of fibre
10 20 30 40 50 60
GTCGACGGTGCCCCCAGCAGAAGTATCGACTGCATGCTAATTATTAACAAACCAAAAGGC 
ValAspGlyAlaProSerArgSerlleAspCysMetLeuIleileAsnLysProLysGly 
SerThrValProProAlaGluValSerThrAlaCysEndLeuLeuThrAsnGlnLysAl 
ArgArgCysProGlnGlnLysTyrArgLeuHisAlaAsnTyrEndGlnThrLysArgA
70 80 90 100 110 120
GTTGCACTTACACCTTACCTTTAGGTTTTTAAACTTTAACAGACTAAGCGGAGGTACCCT 
ValAlaLeuThrProTyrLeuEndVatPheLysLeuEndGlnThrLysArgArgTyrPro 
aLeuHisLeuHisLeuThrPheArgPheLeuAsnPheAsnArgLeuSerGlyGlyThrLe 
rgCysThrTyrThrLeuProLeuGlyPheEndThrLeuThrAspEndAlaGluValProC
polyA signal fibre
130 140 150 160 / 170 180
GTTTAAAACTGATGTCTTAACCTTTACCTATGTAGGCGAAAATCAATAAAACCAGAAAAA 
ValEndAsnEndCysLeuAsnLeuTyrLeuCysArgArgLysSerIleLysProGluLys 
uPheLysThrAspValLeuThrPheThrTyrValGlyGluAsnGlnEndAsnGlnLysLy 
ysLeuLysLeuMetSerEndProLeuProMetEndAlaLysIleAsnLysThrArgLysL 
polyA site fibre
/ 190 200 210 220 230 240
AATAAGTTTAAAAGCTTTATTTTTCATACACGCGAGCGGTAAGGCTGCCGCCTTCAGGAA 
AsnLysPheLysSerPhellePheHisThrArgGluArgEndGlyCysArgLeuGlnGlu 
sileSerLeuLysAlaLeuPhePhelleHisAlaSerGlyLysAlaAlaAlaPheArgLy 
ysEndValEndLysLeuTyrPheSerTyrThrArgAlaVaIArgLeuProProSerGlyL
250 . 260 270 280 290 300
AAGTTACTCTGTAAACAGTTCTTTCACAACAGCACAAAACATAGGTATTAGTTAACAGTT 
LysLeuLeuCysLysGlnPhePheHi sAsnSerThrLysHisArgTyrEndLeuThrVaI 
sSerTyrSerValAsnSerSerPheThrThrAlaGlnAsnlleGlylleSerEndGlnPh 
ysValThrLeuEndThrValLeuSerGlnGlnHisLysThrEndValLeuValAsnSerS
310 320 330 340 350 360
CATTTGGGCTATAATAATATACATTTTCTTGGGTGGCAAAGCAAGGGTCGGTAATCTCAA 
HisLeuGlyTyrAsnAsnlleHisPheLeuGlyT rpGlnSerLysGlyArgEndSerGln 
elleTrpAlallei leileTyrllePheLeuGlyGlyLysAlaArgValGlyAsnLeuAs 
erPheGlyLeuEndEndTyrThrPheSerT rpValAlaLysGInGlySerValIleSerT
370 380 390 400 410 420
CAAAACCATCAACTGGAATGCAAGAATAGTCCAGCACGGTGGGTTCAATCTAAAAATGAA 
GlnAsnHisGlnLeuGluCysLysAsnSerProAlaArgT rpValGlnSerLysAsnGlu 
nLysThrlleAsnTrpAsnAlaArglleValGlnHisGlyGlyPheAsnLeuLysMetLy 
hrLysProSerThrGlyMetGlnGluEndSerSerThrValGlySerlleEndLysEndA
430 440 450
GAAACGCGTTGAGGTTCATAAGCAACAGGTTTTG 
GluThrArgEndGlySerEndAlaThrGlyPhe 
sLysArgValGluValHisLysGlnGlnValLeu 
rgAsnAlaLeuArgPhelleSerAsnArgPhe
b) 5'-3' Lower Strand:- Region encoding the end of E4
10 20 30 40 50 60
CAAAACCTGTTGCTTATGAACCTCAACGCGTTTCTTCATTTTTAGATTGAACCCACCGTG 
GlnAsnLeuLeuLeuMetAsnLeuAsnAlaPheLeuHi sPheEndlleGluProThrVal 
LysThrCysCysLeuEndThrSerThrArgPhePhellePheArgLeuAsnProProCy 
LysProValAlaTyrGluProGlnArgValSerSerPheLeuAspEndThrHi sArgA
70 80 90 100 110 120
CTGGACTATTCTTGCATTCCAGTTGATGGTTTTGTTGAGATTACCGACCCTTGCTTTGCC 
LeuAspTvrSerCysIleProValAspGlyPheValGlu!leThrAspProCysPheAla 
sT rpThrlleLeuAlaPheGlnLeuMetValLeuLeuArgLeuProThrLeuAlaLeuPr 
laGlyLeuPheLeuHisSerSerEndTrpPheCysEndAspTyrArgProLeuLeuCysH
130 140 150 160 170 180
ACCCAAGAAAATGTATATTATTATAGCCCAAATGAACTGTTAACTAATACCTATGTTTTG 
ThrGlnGluAsnValTyrTyrTyrSerProAsnGluLeuLeuThrAsnThrTyrValLeu 
oProLysLysMetTyrllei leileAlaGlnMetAsnCysEndLeuIleProMetPheCy 
i sProArgLysCysIleLeuLeuEndProLysEndThrValAsnEndTyrLeuCysPheV
190 200 210 220 230 240
TGCTGTTGTGAAAGAACTGTTTACAGAGTAACTTTTCCTGAAGGCGGCAGCCTTACCGCT 
CysCysCysGluArgThrVaITvrArgVaIThrPheProGIuGlyGlySerLeuThrAI a 
sAlaValValLysGluLeuPheThrGluEndLeuPheLeuLysAlaAlaAlaLeuProLe 
alLeuLeuEndLysAsnCysLeuGlnSerAsnPheSerEndArgArgGlnProTyrArgS 
polyA signal E4 polyA site E4
250 \ 260 270 / 280 290 300
CGCGTGTATGAAAAATAAAGCTTTTAAACTTATTTTTTTCTGGTTTTATTGATTTTCGCC 
ArgVaITyrGluLysEndSerPheEndThrTyrPhePheLeuVaILeuLeuIlePheAla 
uAlaCysMetLysAsnLysAlaPheLysLeuIlePhePheT rpPheTyrEndPheSerPr 
erArgValEndLys!leLysLeuLeuAsnLeuPhePheSerGlyPhelleAspPheArgL
310 320 330 340 350 360
TACATAGGTAAAGGTTAAGACATCAGTTTTAAACAGGGTACCTCCGCTTAGTCTGTTAAA 
TyrIleGlyLysGlyEndAspIleSerPheLysGlnGlyThrSerAlaEndSerValLys 
oThrEndValLysVaILysThrSerVaILeuAsnArgVaiProProLeuSerLeuLeuLy 
euHi sArgEndArgLeuArgHi sGlnPheEndThrGlyTyrLeuArgLeuValCysEndS
370 380 390 400 410 420
GTTTAAAAACCTAAAGGTAAGGTGTAAGTGCAACGCCTTTTGGTTTGTTAATAATTAGCA 
ValEndLysProLysGlyLysValEndValGlnArgLeuLeuValCysEndEndLeuAla 
sPheLysAsnLeuLysValArgCysLysCysAsnAlaPheT rpPheValAsnAsnEndHi 
erLeuLysThrEndArgEndGlyValSerAlaThrProPheGlyLeuLeuIleileSerM
430 440 450
TGCAGTCGATACTTCTGCTGGGGGCACCGTCGAC 
CysSerArgTyrPheCysT rpGlyHi sArgArg 
sAlaValAspThrSerAlaGlyGlyThrValAsp 
etGlnSerlleLeuLeuLeuGlyAlaProSer
Fig. D Translation in all three reading frames of the 
Vaxitas DNA sequence on both strands. Presumptive polyA 
signals and sites are indicated. All translational stops 
prior to these are underlined. The three base changes 
between the above sequence and the Glasgow A sequence of 
the same region are underlined. Underlined region of E4 
reading frame 1 is discussed in fig. F.
F I G U R E  E
Translation of Glasgow DNA from the Region Shown in
Figure C
a) 5'-3' Upper Strand:- Region encoding the end of fibre 
10 20 30 40 50 60
GTCGACGGTGCCCCCAGCAGAAGTATTGACTGCATGCTAATTATTAACAAACCAAAAGGC 
ValAspGlyAlaProSerArgSerlleAspCysMetLeuIleileAsnLysProLysGly 
SerThrValProProAlaGluValLeuThrAlaCysEndLeuLeuThrAsnGlnLysAl 
ArgArgCysProGlnGlnLysTyrEndLeuHisAlaAsnTyrEndGlnThrLysArgA
70 80 90 100 110 120
GCTGCACTTACACCTTACCTTTAGGTTTTTAAACTTTAACAGACTAAGCGGAGGTACCCT 
AlaAlaLeuThrProTyrLeuEndValPheLysLeuEndGlnThrLysArgArgTyrPro 
aLeuHisLeuHisLeuThrPheArgPheLeuAsnPheAsnArgLeuSerGlyGlyThrLe 
rgCysThrTyrThrLeuProLeuGlyPheEndThrLeuThrAspEndAlaGluVaIProC
polyA signal fibre
130 140 150 160 / 170 180
GTTTAAAACTGATGTCTTAACCTTTACCTATGTAGGCGAAAATCAATAAAACCAGAAAAG 
ValEndAsnEndCysLeuAsnLeuTyrLeuCysArqArqLvsSerlleLysProGluLys 
uPheLysThrAspValLeuThrPheThrTyrValGlyGluAsnGlnEndAsnGlnLysAr 
ysLeuLysLeuMetSerEndProLeuProMetEndAIaLys11eAsnLysThrArgLysG 
polyA site fibre
/ 190 200 210 220 230 240
AAATAAGTTTAAAAGCTTTATTTTTCATACACGCGAGCGGTAAGGCTGCCGCCTTCAGGA 
LysEndValEndLysLeuTyrPheSerTyrThrArgAlaValArgLeuProProSerGly 
gAsnLysPheLysSerPhellePheH i sThrArgGluArgEndGlyCysArgLeuGInGl 
lulleSerLeuLysAlaLeuPhePhelleHisAlaSerGlyLysAlaAlaAlaPheArgL
250 260 270 280 290 300
AAAGTTACTCTGTAAACAGTTCTTTCACAACAGCACAAAACATAGGTATTAGTTAACAGA 
LysValThrLeuEndThrValLeuSerGlnGlnHisLysThrEndValLeuValAsnArg 
uLysLeuLeuCysLysGInPhePheH i sAsnSerThrLysH i sArgTyrEndLeuThrAs 
ysSerTyrSerValAsnSerSerPheThrThrAlaGlnAsnlleGlylleSerEndGlnl
310 320 330 340 350 360
TCATTTGGGCTATAATAATATACATTTTCTTGGGTGGCAAAGCAAGGGTCGGTAATCTCA 
SerPheGlyLeuEndEndTyrThrPheSerT rpValAlaLysGlnGlySerValIleSer 
pH i sLeuGlyTyrAsnAsnlleH i sPheLeuGlyT rpGInSerLysGlyArgEndSerGI 
leileTrpAlallei leileTyrllePheLeuGlyGlyLysAlaArgValGlyAsnLeuA
370 380 390 400 410 420
ACAAAACCATCAACTGGAATGCAAGAATAGTCCAGCACGGTGGGTTCAATCTAAAAATGA 
ThrLysProSerThrGlyMetGlnGluEndSerSerThrValGlySerlleEndLysEnd 
nGInAsnH i sGInLeuGluCysLysAsnSerProAlaArgT rpVaIGInSerLysAsnGI 
snLysThrlleAsnTrpAsnAlaArglleValGlnHi sGlyGlyPheAsnLeuLysMetL
430 440 450
AGAAACGCGTTGAGGTTCATAAGCAACAGGTTTTG 
ArgAsnAlaLeuArgPhelleSerAsnArgPhe 
uGluThrArgEndGlySerEndAlaThrGlyPhe 
ysLysArgValGluValHisLysGlnGlnValLeu
b) 5'-3' Lower Strand:- Region encoding the end of E4
10 20 30 40 50 60
CAAAACCTGTTGCTTATGAACCTCAACGCGTTTCTTCATTTTTAGATTGAACCCACCGTG 
GlnAsnLeuLeuLeuMetAsnLeuAsnAlaPheLeuHi sPheEndl leGluProThrVal 
LysThrCysCysLeuEndThrSerThrArgPhePhellePheArgLeuAsnProProCy 
LysProValAlaTyrGluProGlnArgValSerSerPheLeuAspEndThrHi sArgA
70 80 90 100 110 120
CTGGACTATTCTTGCATTCCAGTTGATGGTTTTGTTGAGATTACCGACCCTTGCTTTGCC 
LeuAspTyrSerCysIleProValAspGlyPheValGlu!leThrAspProCysPheAla 
sT rpThrlLeLeuAlaPheGlnLeuMetValLeuLeuArgLeuProThrLeuAlaLeuPr 
laGlyLeuPheLeuH i sSerSerEndTrpPheCysEndAspTyrArgProLeuLeuCysH
130 140 150 160 170 180
ACCCAAGAAAATGTATATTATTATAGCCCAAATGATCTGTTAACTAATACCTATGTTTTG 
ThrGlnGluAsnValTyrTyrTyrSerProAsnAspLeuLeuThrAsnThrTyrValLeu 
oProtysLysMetTyrI lei leileAlaGlnMetlleCysEndLeuIleProMetPheCy 
i sProArgLysCysIleLeuLeuEndProLysEndSerValAsnEndTyrLeuCysPheV
190 200 210 220 230 240
TGCTGTTGTGAAAGAACTGTTTACAGAGTAACTTTTCCTGAAGGCGGCAGCCTTACCGCT 
CysCysCysGluArgThrValTyrArgValThrPheProGluGlyGlySerLeuThrAla 
sAlaValValLysGluLeuPheThrGluEndLeuPheLeuLysAlaAlaAlaLeuProLe 
a ILeuLeuEndLysAsnCysLeuGInSerAsnPheSerEndArgArgGInProTyrArgS 
polyA signal E4 polyA site E4
250 \ 260 270/ 280 290 300
CGCGTGTATGAAAAATAAAGCTTTTAAACTTATTTCTTTTCTGGTTTTATTGATTTTCGC 
ArgValTyrGluLysEndSerPheEndThrTyrPhePheSerGlyPhelleAspPheArg 
uAIaCysMetLysAsnLysAIaPheLysLeuIIeSerPheLeuVaILeuLeuIlePheAl 
erArgValEndLys!IeLysLeuLeuAsnLeuPheLeuPheTrpPheTyrEndPheSerP
310 320 330 340 350 360
CTACATAGGTAAAGGTTAAGACATCAGTTTTAAACAGGGTACCTCCGCTTAGTCTGTTAA 
LeuHi sArgEndArgLeuArgH i sGlnPheEndThrGlyTyrLeuArgLeuValCysEnd 
aTyrlleGlyLysGlyEndAspIleSerPheLysGlnGlyThrSerAlaEndSerValLy 
roThrEndValLysValLysThrSerValLeuAsnArgValProProLeuSerLeuLeuL
370 380 390 400 410 420
AGTTTAAAAACCTAAAGGTAAGGTGTAAGTGCAGCGCCTTTTGGTTTGTTAATAATTAGC 
SerLeuLysThrEndArgEndGlyValSerAlaAlaProPheGlyLeuLeuIleileSer 
sValEndLysProLysGlyLysValEndValGlnArgLeuLeuValCysEndEndLeuAl 
ysPheLysAsnLeuLysValArgCysLysCysSerAlaPheT rpPheValAsnAsnEndH
430 440 450
ATGCAGTCAATACTTCTGCTGGGGGCACCGTCGAC 
MetGlnSerlleLeuLeuLeuGlyAlaProSer 
aCysSerGlnTyrPheCysT rpGlyHi sArgArg 
i sAlaValAsnThrSerAlaGlyGlyThrValAsp
Fig. E Translation in all three reading frames of both 
strands of the Glasgow DNA sequence encoding the presumed 
end of E4 and fibre. Presumptive polyA signals and sites 
are indicated and all transcription termination signals 
prior to these are underlined. The base changes and 
single additional base in this sequence compared to the 
Vaxitas sequence of the same area are underlined. 
Underlined region of E4 RF1 is discussed in fig. F.
F I G U R E  F
Sequence Analysis of Open Reading Frames from the Presumed
End of The E4 Region.
Ad2 E4 
Glasgow E4
949 GlyGluPhelleAsnlleThrAspGluArgLeuAlaArgGlnGluThrValT rpAsnlle
30 Gly PheValGluIleThrAspProCysPheAlaThrGlnGluAsnValTyrTyrTyr
* * * * * * * * * * *
969 ThrProLysAsnMetSerVaiThrHi sAspMetMetLeuPheLysAlaSerArgGlyGlu
49 SerPro AsnAspLeuLeuThrAsnThrTyrValLeuCysCysCys Glu
* * * * * * * * * * * * * * *
989 ArgThrValTyrSerValCysT rpGluGlyGlyGlyArgLeuAsnThrArgValLeuEnd
65 ArgThrValTyrArgValThrPheProGluGlyGlySerLeuThrAlaArgValTyrGlu
* * * * * * * *  * *
1009 ValEnd 1010
85 LysEnd 86
Matches = 25 Length = 62 Matches/length = 40.3 percent
Ad2 E4 
Vaxitas E4
949 GlyGluPhelleAsnlleThrAspGluArgLeuAlaArgGlnGluThrValTrpAsnlle
30 Gly PheValGluIleThrAspProCysPheAlaThrGlnGluAsnValTyrTyrTyr
*  * *  *  *  *  *  *  *  *  *
969 ThrProLysAsnMetSerVaIThrHisAspMetMetLeuPheLysAlaSerArgGlyGlu
49 SerPro AsnGluLeuLeuThrAsnThrTyrValLeuCysCysCys Glu
*  *  * * * *  * * * * * * * * *
989 ArgThrValTyrSerValCysT rpGluGlyGlyGlyArgLeuAsnThrArgValLeuEnd
65 ArgThrValTyrArgVaiThrPheProGluGlyGlySerLeuThrAlaArgValTyrGlu
* * * *  * *  *  *  * *
1009 ValEnd 1010
85 LysEnd 86
Matches = 25 Length = 62 Matches/length = 40.3 percent
Fig. F Computer analysis of the similarity between the 
predicted 3' end of the Vaxitas and Glasgow E4 regions and 
the comparable region of Ad2. Each region of the CAV genes 
demonstrating similarity is underlined in figs. D and E.
D I S C U S S I O N
The complete sequence of the human adenovirus type 2 
genome is available (Ginsberg, 1984). The end of the Ad2 
E4 region contains a termination codon 97bp upstream of 
the polyadenylation signal. The polyadenylation site for 
E4 is shared, on the opposite strand, as the 
polyadenylation site for fibre.
Consistent with Ad2, both strains of CAV-2 appear to
demonstrate polyA sites which serve for both E4 and fibre.
A termination codon is apparent 95bp upstream of the
proposed E4 polyA signal in reading frame three, although
this is preceded by termination codons in all three
reading frames. Further analysis will be required to
confirm that the proposed polyA signals and sites are
indeed those for fibre and E4 and, using mRNA analysis and
S mapping, the extent of any similarity between the 
1
organisation of the canine adenovirus fibre/E4 regions and 
those of the human adenovirus genomes.
Two base changes can be detected when the 3' end of the 
Glasgow fibre gene is compared to the same region of the 
Vaxitas genome. One base change introduces a 
translational stop in one reading frame of Glasgow: 
Vaxitas - Arg, Glasgow - End: and an amino acid change in 
another: Vaxitas - Ser, Glasgow - Leu. The second base
change introduces an amino acid change in one reading 
frame only: Vaxitas - Val, Glasgow - Ala. The
186
significance of these differences cannot be ascertained 
until the coding regions and splice sites, if any, of the 
fibre gene can be determined. The human adenovirus type 2 
fibre gene contains no splice sites between the initiation 
codon and the termination codon. Slight differences 
between the fibre genes of Glasgow and Vaxitas could 
result in the different binding capacities to various cell 
types and hence may determine to some degree the 
pathogenicity of the virus to certain cells.
By alignment with the Ad2 genome, it would appear that the
0.4kb deletion, present in the Vaxitas E4 region, is
situated in the equivalent of Ad2 E4 orf6 (fig. A). This
presumption is supported by the evidence of Bridge and
Ketner (1989) who reported that the presence of a 
functional orf3 or an orf6 could compensate for the loss 
of the other. The absence of both orf3 and orf6 results 
in a 160-fold reduction in late protein synthesis, whereas 
a functional orf3 and/or a functional orf6 results in 
normal late protein synthesis and accumulation. Their 
results indicate that the viral phenotype would remain 
wild-type as long as one of these two orf's was fully 
functional and would display no loss of replicating 
ability.
Huang and Hearing (1989) revealed however, that the 
product of orf6 is more efficient in the regulation of 
viral late protein synthesis, shutoff of host cell protein 
synthesis, the production of infectious virus and the
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augmentation of viral DNA replication than is the product 
of orf3. Therefore the assumption is, that although normal 
phenotype may be retained by mutants defective in orf6, 
due to compensation by orf3, they are not as efficient in 
the above functions as genomes encoding both orf's.
When the above data is applied to the Vaxitas genome it 
may provide an insight as to the selection and retention 
of mutant genomes encoding a reiterated Ela at the right- 
hand terminus. The reiterated Ela effectively increases 
the levels of expression of all E4 orf's including orf3. 
It may be possible that increased amounts of the orf3 
product are advantageous in the absence of orf6, 
complementing for the loss of orf6 to an even greater 
degree. The genome containing the reiterated Ela may 
therefor display greater selective/replicative advantages 
over an E4 orf6 mutant which does not contain the 
reiterated functional Ela promoter at the right-hand 
terminus to drive the E4 promoter at greatly increased 
levels.
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